

AUTHOR INDEX

- Abbasi, F., 159, 280, 495
Abdella, N., 638
Abian, J., 1118
Abudula, R., 1378
Abuin, A., 1322
Acampora, C., 1243
Ackermans, M. T., 886
Adachi, M., 1113
Adams, M. J., 1399
Adeli, K., 228
Agbaje, O. F., 1349
Ågren, Å., 1496
Ahn, J., 607
Ahrén, B., 624, 1355
Aizawa, T., 949
Akanuma, H., 583
Akirav, E. M., 1558
Alberca, I., 666
Albrecht, C., 17
Al Daghri, N., 430
Alderson, N. L., 969
Alemzadeh, R., 441
Aljada, A., 330
Alllick, G., 886
Allison, G., 495
Alm, R., 1436
Almeida, M., 666
Alméras, N., 310
Alonso-Vale, M. I. C., 500
AlRimawy, H., 209
Alsaeid, M., 638
Al-Sheikh, N., 638
Alshingiti, A., 727
Alstrup, K. K., 1158
Altena, T. S., 749
Amani, Z., 165
Amico, M. C., 1274
Anan, F., 777, 1359
Andersen, O., 1565
Andersen, U. B., 1565
Ando, F., 135
Andreotti, S., 500
Angelini, G. D., 1315
Angelini, V., 1081
Angelopoulos, T. J., 193
Anhê, G. F., 500
Antonacci, E., 995
Aoki, Y., 868
Aparicio, M., 614
Apolone, G., 435
Aquino, K. A., 215
Arai, H., 977
Arai, K., 28
Araki, A., 353
Araújo-Vilar, D., 1462
Arcelus, R., 1512
Arch, J. R. S., 1322
Arii, K., 297
Arima, H., 977
Arinami, T., 182
Arnesen, H., 1574
Arosio, M., 740
Asahi, T., 733
Aso, Y., 693, 1152
Asztalos, B. F., 1255
Au, C. S., 228
Awata, T., 1548
Azevedo, J. L., Jr., 284
Badiou, S., 989
Bai, H., 423
Bailey, C. J., 252
Baker, A. J., 964
Bannister, P., 545
Bar, R. S., 1454
Barakat, H. A., 1, 247
Barash, V., 836
Barbara, A., 532
Barmada, M. M., 303, 458
Barnard, R. J., 377
Barnett, A. H., 430
Baron, J. A., 578
Baron, M. A., 1331
Barone, G., 563
Barthe, N., 614
Basu, R., 1467
Batista, M. C., 1255
Batta, A. K., 556, 927
Baumgartner, M., 809
Bausserman, L., 193
Bazargan, M., 1166
Beck-Peccoz, P., 740
Bedno, S., 340
Belfort, R., 1233
Benavente, M., 1045
Ben-Ezra, V., 348
Berenson, G. S., 1184
Berg, G., 1013
Bergeron, J., 310
Berglund, G., 1436
Bergman, R. N., 1202
Berneis, K., 483
Bernini, F., 153
Bernstein, E. L., 790
Berria, R., 1233
Bertie, J., 545
Best, K., 37
Bilbie, C., 193
Bilecen, S., 1197
Bilz, S., 918
Binnert, C., 4
Bisschop, P. H., 886
Bistrian, B. R., 273
Blair, S. N., 1066
Blanche, P. J., 483
Blanco, P. G., 273
Blanco-Vaca, F., 1512
Bo, M., 984
Bodenlenz, M., 1484
Bodvarsdóttir, T., 441
Boerwinkle, E., 1184
Bogardus, C., 904
Bollati, A., 563
Bollheimer, L. C., 1443
Bolineni, J., 927
Bonfanti, C., 563
Booth, S. L., 215
Borges-Silva, C. d. N., 500
Borgiani, P., 995
Born, J., 894, 1449
Boston, R. C., 1202
Bottini, E., 995
Bottini, N., 995
Bouchard, C., 108, 1192
Braun, C., 799
Bravo-Vera, R., 358
Brem, A. S., 811
Breu, J., 790
Brites, F., 1262
Brock, B., 1158
Broderick, T. L., 1391
Brodsky, I. G., 340
Brousseau, M. E., 1255
Brown, M. D., 673
Brown, W. V., 1296
Browne, P. O., 11
Browning, L. M., 899
Buettner, R., 1443
Buisson, A., 782
Bujo, H., 1095
Bullock, M., 1552
Burattin, A., 563
Burgo, R. M., 666
Buse, M. G., 165
Byun, S. Y., 1527
Byun, Y., 1007
Cabezas, M. C., 49, 1197
Cabezas-Cerrato, J., 1462
Cai, R. Y., 236
Calabrese, P. A., 1016
Calabresi, L., 153
Caldiz, C. I., 382
Camacho, R. C., 1290
Campbell, K. L., 1107
Camps, J., 95
Canavan, B., 790
Canavesi, M., 153
Cano, B., 1045
Capasso, A. M., 1081
Cappiello, V., 740
Carey, A. L., 1492
Carhart, R. L., 284
Carmines, P. K., 868
Caselli, A., 222
Cassader, M., 984
Cassis, C., 388
Casti, A., 1140
Castro, C., 594
Castro, J., 1262
Cattin, L., 1126
Cefalu, W., 1331
Cha, B. Y., 142
Chan, K. W., 955
Chan, O., 1558
Chang, S. A., 142

AUTHOR INDEX

- Abbasi, F., 159, 280, 495
Abdella, N., 638
Abian, J., 1118
Abudula, R., 1378
Abuin, A., 1322
Acampora, C., 1243
Ackermans, M. T., 886
Adachi, M., 1113
Adams, M. J., 1399
Adeli, K., 228
Agbaje, O. F., 1349
Ågren, Å., 1496
Ahn, J., 607
Ahrén, B., 624, 1355
Aizawa, T., 949
Akanuma, H., 583
Akirav, E. M., 1558
Alberca, I., 666
Albrecht, C., 17
Al Daghri, N., 430
Alderson, N. L., 969
Alemzadeh, R., 441
Aljada, A., 330
Alllick, G., 886
Allison, G., 495
Alm, R., 1436
Almeida, M., 666
Alméras, N., 310
Alonso-Vale, M. I. C., 500
AlRimawy, H., 209
Alsaeid, M., 638
Al-Sheikh, N., 638
Alshingiti, A., 727
Alstrup, K. K., 1158
Altena, T. S., 749
Amani, Z., 165
Amico, M. C., 1274
Anan, F., 777, 1359
Andersen, O., 1565
Andersen, U. B., 1565
Ando, F., 135
Andreotti, S., 500
Angelini, G. D., 1315
Angelini, V., 1081
Angelopoulos, T. J., 193
Anhê, G. F., 500
Antonacci, E., 995
Aoki, Y., 868
Aparicio, M., 614
Apolone, G., 435
Aquino, K. A., 215
Arai, H., 977
Arai, K., 28
Araki, A., 353
Araújo-Vilar, D., 1462
Arcelus, R., 1512
Arch, J. R. S., 1322
Arii, K., 297
Arima, H., 977
Arinami, T., 182
Arnesen, H., 1574
Arosio, M., 740
Asahi, T., 733
Aso, Y., 693, 1152
Asztalos, B. F., 1255
Au, C. S., 228
Awata, T., 1548
Azevedo, J. L., Jr., 284
Badiou, S., 989
Bai, H., 423
Bailey, C. J., 252
Baker, A. J., 964
Bannister, P., 545
Bar, R. S., 1454
Barakat, H. A., 1, 247
Barash, V., 836
Barbara, A., 532
Barmada, M. M., 303, 458
Barnard, R. J., 377
Barnett, A. H., 430
Baron, J. A., 578
Baron, M. A., 1331
Barone, G., 563
Barthe, N., 614
Basu, R., 1467
Batista, M. C., 1255
Batta, A. K., 556, 927
Baumgartner, M., 809
Bausserman, L., 193
Bazargan, M., 1166
Beck-Peccoz, P., 740
Bedno, S., 340
Belfort, R., 1233
Benavente, M., 1045
Ben-Ezra, V., 348
Berenson, G. S., 1184
Berg, G., 1013
Bergeron, J., 310
Berglund, G., 1436
Bergman, R. N., 1202
Berneis, K., 483
Bernini, F., 153
Bernstein, E. L., 790
Berria, R., 1233
Bertie, J., 545
Best, K., 37
Bilbie, C., 193
Bilecen, S., 1197
Bilz, S., 918
Binnert, C., 4
Bisschop, P. H., 886
Bistrian, B. R., 273
Blair, S. N., 1066
Blanche, P. J., 483
Blanco, P. G., 273
Blanco-Vaca, F., 1512
Bo, M., 984
Bodenlenz, M., 1484
Bodvarsdóttir, T., 441
Boerwinkle, E., 1184
Bogardus, C., 904
Bollati, A., 563
Bollheimer, L. C., 1443
Bolineni, J., 927
Bonfanti, C., 563
Booth, S. L., 215
Borges-Silva, C. d. N., 500
Borgiani, P., 995
Born, J., 894, 1449
Boston, R. C., 1202
Bottini, E., 995
Bottini, N., 995
Bouchard, C., 108, 1192
Braun, C., 799
Bravo-Vera, R., 358
Brem, A. S., 811
Breu, J., 790
Brites, F., 1262
Brock, B., 1158
Broderick, T. L., 1391
Brodsky, I. G., 340
Brousseau, M. E., 1255
Brown, M. D., 673
Brown, W. V., 1296
Browne, P. O., 11
Browning, L. M., 899
Buettner, R., 1443
Buisson, A., 782
Bujo, H., 1095
Bullock, M., 1552
Burattin, A., 563
Burgo, R. M., 666
Buse, M. G., 165
Byun, S. Y., 1527
Byun, Y., 1007
Cabezas, M. C., 49, 1197
Cabezas-Cerrato, J., 1462
Cai, R. Y., 236
Calabrese, P. A., 1016
Calabresi, L., 153
Caldiz, C. I., 382
Camacho, R. C., 1290
Campbell, K. L., 1107
Camps, J., 95
Canavan, B., 790
Canavesi, M., 153
Cano, B., 1045
Capasso, A. M., 1081
Cappiello, V., 740
Carey, A. L., 1492
Carhart, R. L., 284
Carmines, P. K., 868
Caselli, A., 222
Cassader, M., 984
Cassis, C., 388
Casti, A., 1140
Castro, C., 594
Castro, J., 1262
Cattin, L., 1126
Cefalu, W., 1331
Cha, B. Y., 142
Chan, K. W., 955
Chan, O., 1558
Chang, S. A., 142

- Chassereau, C. N., 969
 Chassin, L. J., 1484
 Chatterjee, V. K. K., 11
 Chauveau, P., 614
 Chen, W., 1184
 Cheng, C., 1107
 Cheng, J., 772, 1500
 Cherrington, A. D., 933
 Chetty, R., 430
 Chevalier, S., 388
 Chiappe De Cingolani, G. E., 382
 Chiba, H., 942
 Chinkes, D. L., 128
 Chiodera, P., 1140
 Choi, J. H., 1284
 Choi, S. M., 1054, 1538
 Choi, Y. O., 269
 Chong, T., 228
 Chopra, I. J., 538, 1101
 Christian, B., 247
 Christ-Roberts, C. Y., 1233
 Chu, C. A., 933
 Chu, C.-H., 1136
 Chu, J. W., 159
 Church, T. S., 1066
 Chuyen, N. V., 1517
 Cipolla-Neto, J., 500
 Cittadini, A., 1081
 Clapham, J. C., 1322
 Clàra, J., 1118
 Clark, T. A., 1145
 Clement, S., 54
 Cochran, C. S., 1202
 Cochran, E., 513
 Coggan, A. R., 875
 Coghlan, M. P., 1322
 Cohan, P., 1101
 Coiro, V., 1140
 Collins, J. N., 1121
 Considine, R. V., 138
 Cooper, D. A., 454
 Corcoran, S. L., 1322
 Corica, F., 435
 Corrales, J. J., 666
 Cossi, S., 1016
 Cotter, J., 454
 Coudray, C., 660
 Cozzi, R., 563
 Crawford, L., 578
 Cubero, J. M., 1512
 Cui, H., 942
 Cuomo, V., 1522
 Cuzzolaro, M., 435
 Ćwikowska, J., 66
 Daido, H., 89
 Dalgaard, M., 77
 Damcott, C. M., 303, 458
 Dandona, P., 54, 330
 Darwin, C., 1101
 Das, A. M., 809
 Date, Y., 84
 Davidson, M. B., 1166
 Davis, J., 247
 De Bruin, T. W. A., 187
 Deeg, M. A., 138
 De Faria, E. C., 858
 DeGeitere, C., 1262
 De Jaegere, P. P. T., 49
 De Jong, S. A., 318
 Delannoy, P., 532
 De La Puerta Vásquez, R., 59
 De Marco, D., 1243
 De Martinis, M., 1016
 De Michele, M., 1243
 Dengel, D. R., 397
 Denis, B. G., 532
 Dennis, E. M., 720
 Denny, J. C., 1290
 De Oya, M., 1045
 Depaoli, A. M., 513
 De Ruijter-Heijstek, F. C., 187
 DeRuisseau, L. R., 1417
 De Souza, J. B., 1048
 Després, J.-P., 108, 310
 Devaraj, S., 236
 Dhillon, K. S., 1101
 Dhindsa, S., 330
 Diffenderfer, M. R., 1255
 Di Minno, G., 852
 DiSilvestro, R. A., 37
 Doi, T., 977
 Dolnikowski, G. G., 215, 520, 1255
 Donahue, E. P., 933
 Donahue, O. M., 749, 1365
 Doy, M., 42
 Drouin, R., 1027
 Duckworth, W. C., 1037
 Dwivedi, M., 1336
 Economides, P. A., 222
 Edel, A. L., 1145
 Eid, H. M. A., 1574
 Elased, K. M., 1048
 Elbert, A., 1013
 Elliott, J. I., 17
 Endert, E., 886
 Endo, K., 182
 Erichsen, L., 1349
 Erkelens, D. W., 187
 Erkkilä, A. T., 215
 Esmatjes, E., 1118
 Evans, S. A., 727
 Ezaki, O., 942
 Falkner, B. E., 1107
 Fan, Q., 1473
 Farmer, B., 933
 Fawcett, J., 1037
 Febbraio, M. A., 1492
 Fee, H., 755
 Fehm, H. L., 894, 1449
 Feillet-Coudray, C., 660
 Feingold, E., 303, 458
 Felton, C. V., 571
 Fenicchia, L. M., 284
 Fernandez, M. L., 823
 Fernández-Pérez, C., 1411
 Ferrante, E., 740
 Ferré, N., 95
 Ferrell, R. E., 303, 458
 Ferrer-Martínez, A., 1032
 Field, A., 430
 Fields, D. A., 875
 Fiestras-Janeiro, G., 1462
 Finardi, L., 1140
 Fineberg, N. S., 138
 Flakoll, P., 933
 Flatt, P. R., 252
 Fledelius, C., 441
 Flores, L., 1118
 Flurkey, K., 799
 Flyvbjerg, A., 1565
 Fonseca, V. A., 1331
 Fontaine, R. N., 465
 Ford, G. C., 340
 Fowler, B., 809
 Francescato, M. P., 1126
 Franceschini, G., 153
 Franks, P. W., 11
 Freaney, R., 1251
 Fredrikson, G. N., 1436
 Fruchart, J.-C., 1262
 Fujimoto, M., 1532
 Fujino, T., 123
 Fujisawa, Y., 600
 Fukaya, M., 977
 Fukushima, M., 831
 Fukushima, S., 42
 Fukuzawa, Y., 260
 Funabiki, K., 842
 Furman, M., 340
 Fusi, S., 1126
 Gaillard, T., 414, 1552
 Gais, S., 894
 Galli, P., 1140
 Gannon, M. C., 241, 1399
 Garcés, C., 1045
 García-Berrocal, B., 666
 García-Estevez, D. A., 1462
 Garrow, T. A., 594
 Garvey, W. T., 1296
 Gault, V. A., 252
 Geat, M., 1126
 Gebb, M., 1355
 Gee, M. K., 1121
 Geluk, C. A., 49
 Gemelli, F., 744
 Gemma, S., 37
 Genovese, D. J., 1202
 Gentile, A., 620
 Gerich, J., 1208
 Gerich, J. E., 1331
 German, B., 236
 Ghanim, H., 330
 Giavoli, C., 740
 Gibney, J., 1251
 Gil, A., 1045
 Girman, P., 655
 Giustina, A., 563
 Gloria-Bottini, F., 995

- Glueck, C. J., 465
 Gobal, F., 174
 Godstrand, I. F., 571
 Goel, D. P., 1145
 Gohda, T., 842, 1473
 Goldner, W. S., 1454
 Goldspink, P., 340
 Gomez, J. E., 638
 Gómez Foix, A. M., 1032
 Gomez-Sánchez, C. E., 89
 González, A. I., 1013
 González-Buitrago, J. M., 666
 González-Sánchez, J. L., 1411
 Gorden, P., 513
 Gordon, P., 193
 Goto, Y., 550
 Gougeon, R., 388
 Goulding, A., 1372
 Gouller, A., 358
 Goyke, E., 1060
 Gozansky, W. S., 348
 Gragnoli, C., 959
 Grassi, V., 1016
 Graunke, D. M., 799
 Gray, R., 545
 Green, B. D., 252
 Green, J. S., 1192
 Greer, B., 252
 Gregersen, S., 73
 Grinspoon, S., 790
 Grossi, E., 435
 Gruppo, R., 465
 Grusak, M. A., 215
 Guardasole, V., 1081
 Gumaar, K. A., 1048
 Guo, ZK., 794
 Gushiken, N., 1113
 Gustavson, S. M., 933
- Haas, M. J., 174, 766, 1342
 Habener, J. F., 959
 Hada, T., 772, 1500
 Hagberg, J. M., 673
 Hägg, E., 1496
 Haggan, W. E., 614
 Hagiwara, S., 842
 Hahn, J. R., 1527
 Halkes, C. J. M., 49, 1197
 Hallman, D. M., 1184
 Hallschmid, M., 1449
 Hamaguchi, H., 182
 Hamido, M. S. M., 209
 Hamman, R. F., 303, 458
 Hamsten, A., 852
 Han, H. S., 1007
 Han, M., 607, 1284
 Han, Y.-Q., 22, 912
 Hanada, T., 84
 Hancock, J. C., 760
 Hanif, W., 430
 Hansen, B. R., 1565
 Hara, M., 777, 1359
 Hara, T., 260
 Harding, A.-H., 11
- Hardy, M. P., 811
 Harlan, D. M., 403
 Harper, A. J., 1322
 Harriott, P., 252
 Hashimoto, K., 297
 Hashimoto, N., 1095
 Hashimoto-Tamaoki, T., 1500
 Hashizume, K., 949
 Hatayama, T., 644
 Hattemer, A., 620
 Haugaard, S. B., 1565
 Hauner, H., 632
 Hawe, E., 852
 Hayakawa, N., 550
 Hayashi, T., 650, 1532
 Hayashi, Y., 84
 Hayden, J., 280
 Haynes, W. G., 1454
 Hedblad, B., 1436
 Heinemann, L., 1227
 Heise, T., 1227
 Heled, Y., 836
 Heller, S., 1227
 Henderson, K. K., 140, 1021
 Henriksen, E. J., 101, 1215
 Henrotte, J. G., 660
 Hermansen, K., 73, 77, 1158, 1378, 1522
 Hermayer, K. L., 969
 Herron, K. L., 823
 Heshka, S., 1503
 Heyliger, C. E., 1145
 Heymsfield, S. B., 1503
 Hickner, R., 247
 Higa, N., 733
 Higashino, H., 1544
 Higgins, C. F., 17
 Higgins, M., 942
 Higurashi, M., 1095
 Hilesmaa, V., 1433
 Hirano, T., 526, 589, 1113
 Hirose, H., 879
 Hirshberg, B., 403
 Hjerkinn, E. M., 1574
 Ho, S.-C., 1136
 Hoffer, L. J., 1480
 Holder, J. C., 1322
 Holiman, D. A., 140, 1021
 Holmes, A. G., 1492
 Holst, J. J., 73, 77, 624
 Honda, A., 42
 Horani, M. H., 174, 1342
 Horikoshi, S., 842
 Horio, T., 710
 Horton, E. S., 222
 Hoshikawa, T., 1223
 Hosoda, K., 650, 1532
 Hovorka, R., 1349, 1484
 Hsia, S., 1331
 Hsia, S. H., 1166
 Hsu, S.-P., 1136
 Huang, M. H., 1177
 Hubold, C., 1449
 Hulver, M. W., 1
 Humphries, S. E., 852
- Hung, N. T. K., 1517
 Hunter, R. J., 964
 Hunter, S. J., 1296
 Hutchison, A. K., 1391
 Hyodo, T., 1113
- Iannuzzi, A., 1243
 Ichiyanagi, K., 583
 Idei, T., 476
 Iguchi, T., 476
 Ikeda, H., 260
 Ikeda, M., 831
 Ikeda, Y., 297
 Ikeyiri, A., 1113
 Ikenaga, H., 868
 Imamura, S., 550
 Inaba, M., 1548
 Inokuchi, T., 772, 1500
 Inoue, G., 650, 1532
 Inoue, Y., 260
 Inouye, K., 1558
 Inukai, K., 1548
 Inukai, T., 693, 1152
 Iovine, C., 620
 Irwin, N., 252
 Isaia, G., 984
 Ishida, H., 488
 Ishii, N., 868
 Ishikawa, T., 260
 Ishimi, Y., 942
 Ishiwata, Y., 550
 Ishizuka, T., 89
 Isomura, Y., 89
 Itabe, H., 423
 Itagaki, E., 488
 Ito, T., 842
 Itoh, H., 716
 Itoh, M., 550
 Itoh, Y., 550
 Itokawa, M., 476
 Iversen, J., 1565
 Izawa, T., 1424
- Jackson, C. L., 760
 Jafari, M., 687
 Jahoor, F., 1087
 Jalbert, S. M., 215
 James, F. D., 1290
 James, R. W., 153
 James-Krake, M., 749
 Jang, Y. J., 269
 Jankowski, C. M., 348
 Janowska, J., 1268
 Jansen, H., 187
 Jebb, S. A., 899
 Jen, K.-L. C., 782
 Jenkins, A. J., 969, 1296
 Jensen, M. D., 1467
 Jeong, S., 607, 1284
 Jeppesen, P. B., 73, 1378
 Jeremy, J. Y., 760, 1315
 Jia, D., 405
 Jialal, I., 236
 Jing, T.-Y., 324

- Johnston, D., 545
 Johnston, D. G., 17
 Jolly, M., 545
 Jones, L. M., 1372
 Jordan, K., 241
 Jornayvaz, F. R., 847
 Jotti, G. S., 1140
 Joven, J., 95
 Juhan-Vague, I., 852
 Jung, T. S., 1527
- Ka, T., 772, 1500
 Kaaja, R., 1433
 Kai, Y., 644
 Kajimura, N., 84
 Kajiya, F., 335
 Kakizawa, H., 550
 Kanaley, J. A., 284
 Kanatsuka, A., 1095
 Kaneko, S., 842
 Kang, S. K., 142
 Kangawa, K., 84, 710
 Kaplow, J., 1552
 Karasová, L., 469
 Kasa-Vubu, J. Z., 507
 Kashyap, S., 1233
 Katagiri, T., 476
 Katahira, H., 488
 Katakura, M., 949
 Katayama, S., 1548
 Kato, K., 260
 Kato, T., 550
 Kato, Y., 1395
 Katsilambros, N., 222
 Katsuta, H., 488
 Kauffman, R. F., 1121
 Kaul, N., 236
 Kawagoe, Y., 1382
 Kawaguchi, A., 589
 Kawaguchi, M., 1395
 Kawakami, M., 1517
 Kawamura, M., 476
 Kawano, Y., 710
 Kawasaki, T., 583
 Kazumi, T., 589
 Keller, B. T., 927
 Keller, U., 918
 Kelley, D. E., 1331
 Kern, W., 894, 1449
 Khaodhiar, L., 222
 Kim, B. H., 1284
 Kim, C., 269
 Kim, D. R., 1527
 Kim, D.-H., 863
 Kim, H. S., 142
 Kim, J., 1284
 Kim, K. S., 1054, 1538
 Kim, M., 607, 1284
 Kim, S. H., 1007
 Kim, S. R., 142
 Kim, S. Y., 1007
 Kim, T. W., 607
 Kimoto, S., 716
- Kimura, K., 335
 King, L. P., 969
 Kiniwa, M., 680
 Kinnick, T. R., 1215
 Kishida, M., 448
 Kitabchi, A. E., 117
 Kitagawa, H., 1095
 Klaude, M., 1076
 Klein, R. L., 969, 1296
 Klein, S., 875
 Knowler, W. C., 904
 Knudsen, P., 520
 Ko, S. Y., 142
 Koba, S., 476
 Kobayashi, M., 842
 Kobayashi, Y., 1544
 Kogure, A., 1223
 Kohno, H., 710
 Koide, H., 1382
 Kolterman, O., 1227
 Komatsu, M., 949
 Kondo, K., 1517
 Kooistra, T., 852
 Korczynska, J., 1060
 Koshinaka, K., 22, 912
 Kosutic, G., 54
 Koutkia, P., 790
 Koyama, Y., 1290
 Koza, R. A., 799
 Kozak, L. P., 799
 Kraenzlin, M., 918
 Krauss, R. M., 483
 Krebs, J. D., 899
 Kreisman, S. H., 388
 Kruer, M. C., 1037
 Kubota, M., 912
 Kuk, J. L., 1066
 Kukowski, J., 340
 Kulaputana, O., 673
 Kumagai, K., 423
 Kumagai, S., 644
 Kumar, S., 430
 Kumon, Y., 297
 Kurihara, S., 1548
 Kurokawa, T., 260
 Kuroki, M., 1517
 Kurose, T., 831
 Kurtz, T. A., 138
 Kushner, H., 1107
 Kushwaha, R. S., 817
 Kusunoki, M., 260
 Kwon, H. J., 1007
 Kwon, H. S., 142
- Laakso, J., 1072
 Laaksonen, R., 1072
 La Belle, M., 483
 Lacy, D. B., 1290
 Lagasse, M., 278
 Lailerd, N., 101
 Laivuori, H., 1433
 Lamendola, C., 159, 280, 495
 Lamont-Fava, S., 1255
 Landauer, H. C., 1443
- Langer, I., 918
 Langzam, L., 836
 Latif, S. A., 811
 Latini, R. A., 744
 Lavoie, C., 1027
 Layden, J. D., 203, 1131
 Le, N.-A., 1296
 Leary, E. T., 159
 Leclerc, D., 594
 Lee, C. C., 507
 Lee, H., 607, 1284
 Lee, J. G., 269
 Lee, K. H., 1527
 Lee, K. W., 142
 Lee, W. C., 142
 Lee, Y.-H., 1136
 Lee, Y. N., 1527
 Leem, C. H., 269
 Legge, M., 1372
 Lehtimäki, T., 1072
 Leiter, E. H., 799
 Lemieux, S., 310
 Leon, A. S., 108, 1192
 Levenson, C. W., 727
 Levy-Marchal, C., 904
 Li, H., 927
 Li, R.-S., 600
 Licenziati, M. R., 1243
 Lichtenstein, A. H., 215, 520
 Lima, F. B., 500
 Lin, S.-Y., 922
 Lin, Y., 1309
 Lindgärde, F., 1355
 Ling, P.-R., 273
 Lister, C. A., 1322
 Liu, R., 423
 Liu, Y., 140, 1021
 Ljungquist, K., 790
 Llano, A., 1322
 Locher, M., 165
 Lofgren, I. E., 823
 Lok, K. H., 1296
 Lorenz, H., 1002
 Lottenberg, A. M., 858
 Luan, J., 11
 Lucarelli, P., 995
 Lücke, T., 809
 Lundman, P., 852
 Lupattelli, G., 744
 Lussier-Cacan, S., 594
 Luthra, K., 1336
 Luzio, S. D., 1349
 Lyberg, T., 1574
 Lyons, T. J., 969, 1296
- McBrinn, Y., 1251
 McCance, D. R., 755
 McConaughay, M. M., 247
 McCormick, M. P., 318
 McCowen, K. C., 273
 McCoy, K., 37
 MacDonald, K. G., 1
 Macé, K., 1032
 McEneny, J., 755

- McHenry, M. B., 1296
 McKenna, T. J., 1251
 McKenzie, J. A., 673
 McLaughlin, T., 159, 280, 495
 McMillan, J. M., 165
 McNeill, G., 1309
 McSorley, P. T., 755
 McTernan, P. G., 430
 Madsbad, S., 1565
 Maffei, M. L., 1140
 Maggs, D., 1227
 Magotti, M. G., 1140
 Mai, T. T. T., 1517
 Maïmoun, L., 989
 Makita, Y., 842, 1473
 Malkova, D., 203, 1131
 Mandarino, L. J., 1233
 Manetta, J., 989
 Mannarino, E., 744
 Mannucci, E., 435
 Mar, M.-H., 594
 Marchesi, S., 744
 Marchesini, G., 435
 Marengoni, A., 1016
 Margaglione, M., 852
 Marie, P. J., 532
 Marklund, S. L., 1496
 Marotta, M., 1032
 Marsh, J. B., 1255
 Marshall, J. A., 303, 458
 Martínez-Domínguez, E., 59
 Martinez-Larrad, M. T., 1411
 Martini, W. Z., 128
 Maruyama, M., 488
 Massicotte, D., 1027
 Masulli, M., 1522
 Masuzaki, H., 650, 1532
 Matarazzo, M., 1081
 Mather, J. F., 278
 Matsuda, T., 1382
 Matsumoto, T., 550
 Matsumoto, Y., 448
 Matsuo, K., 977
 Matsuo, N., 650
 Matsutomo, R., 1152
 Matsuura, K., 448
 Matsuura, M., 977
 Matsuura, N., 680
 Matsuura, T., 831
 Matsuzaki, Y., 42
 Matthews, S. G., 1558
 Mattioli, F., 1274
 Mawatari, S., 123
 Mayer, M. C., 1243
 Maykel, J. A., 273
 Mazur, A., 660
 Meijer, A. J., 886
 Meijer, G. W., 1309
 Melchionda, N., 435
 Memoli, A., 1274
 Menzinger Von Preussenthal, G., 959
 Merl, V., 894, 1449
 Merville, P., 614
 Metso, S., 1072
 Meyer, C., 1208
 Meyerovitch, J., 836
 Michno, A., 66
 Mikhailidis, D. P., 1315
 Miles, M., 193
 Milla, C., 1467
 Miller, A. L., 760
 Miller, C. S., 284
 Milot, M., 1027
 Mimura, Y., 448
 Minami, C., 716
 Miralles, J. M., 666
 Misra, A., 1336
 Mizuno, A., 875
 Mochizuki, S., 335
 Moffett, S. P., 303, 458
 Mohamed-Ali, V., 852
 Mohammed, B. S., 875
 Mohanty, P., 330
 Mook, S., 1197
 Moon, Y.-S., 863
 Mooney, M. H., 252
 Mooradian, A. D., 174, 766, 1342
 Moore, G. B., 1322
 Mooser, V., 4
 Morais, J. A., 388
 Moran, A., 1467
 Moran, D. S., 836
 Moran, S. A., 513
 Morange, P. E., 852
 Morgan, T. M., 578
 Morita, H., 89
 Moriwaki, Y., 772, 1500
 Morra, F., 984
 Morris, D. J., 811
 Morrison, A. D., 1322
 Morrison, J. A., 465
 Morton, R. E., 858
 Moussa, M. A. A., 638
 Moyna, N., 193
 Muller, A., 1274
 Mune, T., 89
 Murakami, K., 123
 Murakami, T., 526
 Muraoka, S., 1532
 Murayama, S., 1113
 Murphy, G. J., 1322
 Murray, B., 1251
 Nadeau, A., 310
 Nadler, J. L., 290
 Nagamatsu, S., 488
 Nagano, M., 644
 Nagasaki, M., 912
 Nagata, M., 550
 Nair, K. S., 340
 Nakagawa, M., 1359
 Nakagawa, Y., 476
 Nakagawa, Y., 600
 Nakai, Y., 831
 Nakamichi, Y., 488
 Nakamoto, H., 335
 Nakamura, H., 879
 Nakamura, T., 260
 Nakamura, T., 1382
 Nakanishi, K., 1305
 Nakanishi, T., 600
 Nakao, K., 650, 1532
 Nakatani, T., 942
 Nakaya, Y., 260
 Nakazato, M., 84
 Nam, E.-C., 1007
 Nam, K.-H., 607
 Napoli, R., 1081
 Nasr, I. S., 209
 Nawata, K., 1395
 Nawata, T., 1359
 Neal, D., 933
 Nestler, J. E., 1331
 Ngo, T. H., 377
 Nichaman, M. Z., 1066
 Nicol, C. J., 1284
 Niino, N., 135
 Nikkilä, M., 1072
 Nilsson, J., 1436
 Nilsson, J.-Å., 1436
 Nimmo, M. A., 203, 1131
 Nishikai, K., 879
 Nishiki, M., 1395
 Nishioka, F., 526
 Nishizawa, M., 933
 Noacco, C., 1126
 Nogalska, A., 1060
 Norberg, M., 1496
 Norisada, N., 1532
 Nowotny, P., 1174
 Nunes, V. S., 858
 Nuttall, F. Q., 241, 1399
 Oda, N., 550
 Ogasawara, J., 1424
 Ogasawara, Y., 335
 Ogata, N., 583
 Ogawa, H., 1382
 Ogawa, H., 260
 Ogawa, T., 879
 Ogawa, Y., 650
 Ogawa, Z., 868
 Ogura, T., 448
 Oh, G. T., 607, 1284
 Oh, H. H., 1054
 Ohanna, F., 989
 O'Harte, F. P. M., 252
 Ohata, H., 28
 Ohkubo, T., 1548
 Ohkuwa, T., 716
 Ohmori, K., 680
 Ohmori, R., 1517
 Ohsawa, I., 22
 Ohzeki, T., 600
 Okabayashi, N., 260
 O'Keefe, M. P., 1215
 Ollero, M., 273

- Olsson, T., 624
 Olszanecka-Glinianowicz, M., 1268
 Oltmanns, K. M., 894, 1449
 Ono, Y., 550
 Onuma, S., 1305
 Ooie, T., 777, 1359
 O'Rahilly, S., 11
 Oral, E. A., 513
 Ordix, F., Jr., 782
 Ordoñez-Llanos, J., 1512
 Orfao, A., 666
 Orini, S., 1016
 Orsi, E., 740
 Ørskov, H., 1565
 Ortega, E., 1512
 Osaki, F., 297
 Osei, K., 414, 1552
 Oshida, Y., 22, 912
 Oshiro, Y., 733, 1405
 Ota, K., 297
 Otagiri, A., 28
 Otake, K., 260
 Otani, M., 405
 Otsuka, F., 448
 Otsuki, M., 405
 Overton, J. M., 727, 1417
 Owens, D. R., 1349
 Ozawa, S., 488
- Pacak, K., 1202
 Pacini, G., 624
 Pacioni, D., 620
 Päävä, H., 1072
 Palou, A., 1411
 Pan, H.-J., 799
 Pan, L., 927
 Pandey, R. M., 1336
 Panesar, N. S., 955
 Papaioannou, G. I., 278
 Paris, F., 989
 Park, C. S., 269
 Park, J.-J., 673
 Park, J.-Y., 673
 Parnau, J., 1032
 Parsons, A. D., 1417
 Patel, V. B., 964
 Patten, N., 513
 Patterson, N. B., 403
 Pearce, N. J., 1322
 Pelikánová, T., 469, 655
 Pellizzon, M., 782
 Penczek, R. R., 1290
 Peres, S. B., 500
 Pérez, A., 1512
 Perez, F. R., 1215
 Pérez-Cerdá, C., 809
 Péronnet, F., 1027
 Pescatello, L., 193
 Peters, A., 894, 1449
 Peters, J. C., 454
 Peterson, J. W., 215
 Petro, A. E., 454
 Peuler, J. D., 147
 Phares, D. A., 673
- Phelps, L. E., 147
 Phillips, D. I. W., 720
 Phillips, G. B., 324
 Piché, M.-È., 310
 Pieber, T. R., 1484
 Pierce, G. N., 1145
 Pinkernell, B. H., 324
 Pirro, M., 744
 Playfair, J. H. L., 1048
 Plokker, T. W. M., 49
 Ploutz-Snyder, L. L., 284
 Poiesi, C., 563
 Poli, L., 984
 Poretsky, L., 358
 Pories, W. J., 1
 Porretti, S., 740
 Potaux, L., 614
 Pratipanawatr, T., 1233
 Pratipanawatr, W., 1233
 Pratley, R. E., 904
 Preedy, V. R., 964
 Premkumar, A., 513
 Privette, J., 247
 Proenza, A. M., 1411
 Puech, A.-M., 989
 Pulkki, P., 1433
 Purkayastha, D., 1331
 Putz, D. M., 1454
- Qiu, W., 228
 Quintão, E. C. R., 858
- Rabbani, A., 687
 Rademacher, T. W., 1048
 Ramis, J. M., 1411
 Rankin, S. E., 1121
 Rankinen, T., 108, 1192
 Rao, D. C., 108, 1192
 Rask, E., 624
 Rasmussen, B. M., 77
 Raspo, S., 984
 Raszeja-Specht, A., 66
 Rayssiguier, Y., 660
 Reaven, G. M., 159, 280, 495
 Reaven, P. D., 280
 Rector, R. S., 140, 1021
 Refai, T. M. K., 638
 Reifsnnyder, P. C., 799
 Reynolds, J., 513
 Reynolds, T. H., IV, 397
 Rhinesmith, S., 414
 Riccardi, G., 620, 1522
 Riddell, M. C., 1558
 Riu, F., 95
 Rivellese, A. A., 620, 1522
 Rizk, M. M., 209
 Rizzo, M., 483
 Robert, G., 1027
 Roberts, C. K., 377
 Robinson, S., 545
 Rodela, S., 1118
 Rodriguez, R., 817
 Rodriguez-Espinosa, J., 1512
 Röhrlig, K., 632
- Rolandsson, O., 1496
 Rolfsen, S. E. D., 1378
 Romanelli, L., 1274
 Romijn, J. A., 886
 Ronchi, C. L., 740
 Rooyackers, O. E., 1076
 Roscini, A. R., 744
 Ross, R., 1066
 Rossi, M., 989
 Rother, K. I., 403
 Roxbee-Dox, L., 1322
 Rozen, R., 594
 Rudrum, M., 1309
 Ruiz-Gutiérrez, V., 59
 Ruokonen, I., 1072
 Russo, V., 1243
 Rutkowski, B., 1060
 Ryu, H. J., 269
- Saavedra-González, Á., 1462
 Saccà, L., 1081
 Saengsirisuwann, V., 101
 Saito, T., 777, 1359
 Saito, I., 879
 Saito, K., 123
 Saito, Y., 1095
 Sakai, T., 583
 Sakakibara, F., 260
 Sakane, N., 335
 Saku, K., 423
 Sakurai, T., 1424
 Saleh, O., 1
 Salehi, M., 358
 Salen, G., 42, 556, 927
 Salvatore, V., 1243
 Sampson, S. R., 836
 Sánchez Perona, J., 59
 Sander, S., 809
 Sarnak, M. J., 1255
 Saruta, T., 868, 879
 Sasaki, H., 644
 Sasaki, H., 977
 Sasamoto, K., 353
 Sasse, M., 809
 Sato, Y., 22, 912
 Sato, Y., 949
 Sauerwein, H. P., 886
 Savini, G., 1274
 Scarponi, A. M., 744
 Schaefer, E. J., 520, 1255
 Schaller, H. C., 1484
 Schaupp, L. A., 1484
 Scheaffer, S. E., 348
 Scholl, S., 809
 Schöllerich, J., 1443
 Schreier, L., 1013
 Schultes, B., 894, 1449
 Schuster, D., 414, 1552
 Schwahn, B. C., 594
 Schweimer, J., 1443
 Sebring, N., 513
 Seino, Y., 831
 Seip, R. L., 193

- Sekizuka, K., 1382
 Seljeflot, I., 1574
 Selz, R., 847
 Semler, A. J., 1296
 Serrano-Ríos, M., 1411
 Shalev, A., 403
 Shames, D. M., 483
 Shang, Q., 927
 Shangraw, R. E., 1087
 Shan, Y., 836
 Shapiro, Y., 836
 Sharman, M., 823
 Sheets, K. A., 247
 Shefer, S., 42, 927
 Sheikh, A., 358
 Sheu, W.-H. H., 922
 Shibasaki, T., 28
 Shigematsu, S., 1359
 Shiina, K., 842
 Shike, T., 1473
 Shimabukuro, M., 733, 1405
 Shimajiri, Y., 1405
 Shimokata, H., 135
 Shin, C., 607
 Shin, S. U., 1538
 Shirabe, S., 353
 Shukla, N., 1315
 Siepi, D., 744
 Sierksma, A., 1309
 Simon-Vermot, L., 17
 Sinzinger, H., 744
 Sirtori, C. R., 153
 Sivitz, W. L., 1454
 Skarulis, M. C., 513
 Skibová, J., 469
 Skibowska, A., 66
 Skinner, J. S., 108, 1192
 Sloniger, J. A., 101
 Smith, B. K., 749, 1365
 Smith, K. L., 465
 Smith, S. A., 1322
 Smith, T. P., 1251
 Söderberg, S., 624
 Soga, T., 28
 Sohmiya, M., 1395
 Soliman, A. T., 209
 Son, H. S., 142
 Son, H.-Y., 142
 Song, D.-K., 863
 Song, Y.-H., 607
 Sonntag, M., 1177
 Souness, G. W., 811
 Sparks, C., 222
 Sparks, J. D., 228
 Sposito, A. C., 858
 Sprangers, F., 886
 Srinivasan, S. R., 1184
 Stanforth, P. R., 1192
 Stefan, N., 904
 Stelmanska, E., 1060
 Stentz, F. B., 117
 Stevenson, J. C., 571
 Still, J. G., 54
 Stoeckli, R., 918
 Stoll, D., 4
 Stoller, A., 578
 St-Onge, M.-P., 1503
 Striffler, J. S., 290
 Strobel, S., 1227
 Stroop, D., 465
 Stumvoll, M., 904
 Stupar, G., 1126
 Sturek, M. S., 140, 1021
 Sturis, J., 441
 Sucunza, N., 1512
 Suehiro, T., 297
 Suga, S.-i., 710
 Suga, T., 868
 Suliman, A. M., 1251
 Sultan, C., 989
 Sumner, A. E., 1202
 Sun, G. Y., 749, 1021, 1365
 Supiano, M. A., 397, 507
 Surwit, R. S., 454
 Surwit, S. J., 454
 Sutherland, W. H. F., 318
 Suwa, M., 644
 Suzara, D., 340
 Suzuki, A., 550
 Suzuki, H., 831
 Swaim, W. R., 1399
 Swierczynski, J., 1060
 Syddall, H. E., 720
 Syed, T., 330
 Szolkiewicz, M., 1060
 Szutowicz, A., 66
 Taira, T., 1113
 Takahashi, K., 1095
 Takahashi, N., 777, 1359
 Takahashi, S., 772, 1500
 Takahashi, Y., 1382
 Takahashi-Yasuno, A., 650
 Takakura, Y., 1223
 Takami, R., 89
 Takano, T., 423
 Takasu, N., 733, 1405
 Takata, N., 1548
 Takaya, J., 1544
 Takebayashi, K., 693, 1152
 Takeda, E., 977
 Takeda, N., 89
 Takei, M., 1424
 Taketani, Y., 977
 Takizawa, M., 488
 Taman, K. H., 209
 Tanaka, N., 42
 Tanaka, T., 488
 Taniguchi, A., 831
 Tanimoto, M., 842, 1473
 Tappy, L., 4, 847
 Tapsell, L., 1522
 Taskinen, M.-R., 520
 Tataranni, P. A., 904
 Taylor, C. M., 1322
 Taylor, J. A., 140
 Tervonen, R., 1072
 Theintz, G. E., 847
 Thomas, T. R., 140, 749, 1021, 1365
 Thompson, C. S., 1315
 Thompson, P. D., 193, 278
 Thomsen, C., 77
 Thorpe, S. R., 969
 Thu, N. N., 1517
 Thunblad, L., 1076
 Tikkkanen, M. J., 1433
 Tilly-Kiesi, M., 520
 Tint, G. S., 556, 927
 Tischler, M. E., 1215
 Tobe, K., 448
 Toda, H., 1223
 Togashi, K., 108
 Tohma, T., 1405
 Tokudome, T., 710
 Tokuyama, Y., 1095
 Tomino, Y., 842, 1473
 Toshinai, K., 84
 Tosulkao, C., 101
 Toth, D., 578
 Tous, M., 95
 Trautwein, E. A., 1309
 Tremblay, A., 310
 Tremblay, A. J., 310
 Tremoli, E., 852
 Tripathy, D., 330
 Troll, S., 1443
 Tsai, L.-P., 1136
 Tsai, P.-J., 1136
 Tsongalis, G. J., 193
 Tsui, B. T., 1037
 Tsukada, T., 84
 Tsutsumi, K., 260
 Tsutsumi, Z., 772, 1500
 Tsuzura, S., 297
 Tulipano, G., 563
 Tura, A., 624
 Turazzi, S., 563
 Turini, M., 1032
 Ueda, H., 1424
 Ugarte, M., 809
 Um, S. J., 1007
 Umekawa, T., 1223
 Urano, Y., 1424
 Usami, M., 831
 Uusitupa, M., 1522
 Vaccaro, O., 1522
 Valabhji, J., 17
 Valle, D., 563
 Valsamakis, G., 430
 Van Beek, A. P., 187
 Vandenberg, J. F., 817
 Vandenberg, J. L., 817
 Van der Wielen, R. P. J., 1309
 Van Harleben, V., 632
 Van Herle, A., 1101
 Vaudo, G., 744
 Vega, G. L., 1202
 Vega-López, S., 236
 Venkatesan, S., 545
 Verona, J., 1262

- Vesali, R. F., 1076
 Vessby, B., 1522
 Veves, A., 222
 Viana, A. Y. I., 912
 Vierhapper, H., 1174
 Vikram, N. K., 1336
 Vilella, E., 95
 Villa, B., 153
 Visich, P., 193
 Viturro, E., 1045
 Vlasáková, Z., 469
 Volek, J. S., 823
 Volpi, J. R., 1140
 Von Mach, M.-A., 918
 Vranic, M., 1558
 Wagner, A., 228
 Wagner, J. D., 1121
 Wakabayashi, S., 1152
 Waldhäusl, W., 1174
 Walgren, J. L., 165
 Wang, M. H., 1177
 Wang, P., 465
 Wang, X., 942
 Wang, Y., 1227
 Wang, Y.-Y., 922
 Ward, A. M. V., 720
 Wareham, N. J., 11
 Warfield, R. K. N., 147
 Wargent, E., 1322
 Wasserman, D. H., 1290
 Watanabe, H., 583
 Watanabe, M., 1548
 Watanabe, M., 1532
 Watanabe, R. M., 1202
 Watanabe, T., 476
 Watt, M. J., 1492
 Wegge, J. K., 377
 Weinstock, R. S., 284
 Weiss, E. P., 673
 Welshons, W. V., 140
 Welty, F. K., 520, 1255
 Wendel, U., 594
 Werner, J., 1076
 Weverling, G. J., 886
 Weyer, C., 904, 1227
 Whelan, A. P., 318
 Widén, I., 1355
 Wikinski, R., 1013, 1262
 Wilinska, M. E., 1484
 Williams, M. J. A., 318
 Williams, P. T., 700
 Wilmore, J. H., 108, 1192
 Witchel, H. J., 760
 Woerle, H. J., 1208
 Wohl, P., 655
 Wolf, F. I., 660
 Wolfe, R. R., 128
 Won, J. Y., 1007
 Wong, N. C. W., 174, 766, 1342
 Wong, N. L. M., 1177
 Wood, P. J., 720
 Wrede, C. E., 1443
 Wu, J., 942
 Wuolijoki, E., 1072
 Wutzke, K. D., 1002
 Xiao, J., 1378
 Xu, G., 42, 927
 Yagui, K., 1095
 Yamada, H., 680
 Yamada, K., 942
 Yamada, Y., 135
 Yamada, Y., 831
 Yamaguchi, S., 488
 Yamakawa, M., 1405
 Yamakawa-Kobayashi, K., 182
 Yamakita, N., 89
 Yamamoto, A., 680
 Yamamoto, A., 772, 1500
 Yamamoto, K., 550
 Yamamoto, M., 405
 Yamamoto, T., 716
 Yamamoto, T., 772, 1500
 Yamamoto, Y., 879
 Yamanouchi, T., 353, 583
 Yamato, F., 1544
 Yamazaki, Y., 716
 Yanagawa, T., 353
 Yanagi, H., 182
 Yang, H. S., 1054, 1538
 Yang, S.-P., 1136
 Yang, Y., 933
 Yasuda, A., 680
 Yasuda, K., 89
 Yates, J. W., 1322
 Yeo, K.-T. J., 578
 Ylikorkala, O., 1433
 Yoneda, F., 1532
 Yoo, S. J., 1007
 Yoo, S. J., 142
 Yoon, K. H., 142
 Yoon, M., 607, 1284
 Yoon, Y., 1054, 1538
 Yoshida, R., 716
 Yoshida, S., 1095
 Yoshida, T., 42
 Yoshida, T., 335, 1223
 Yoshida, Y., 1095
 Yoshihara, F., 710
 Yoshimasa, Y., 650
 Yoshimatsu, H., 777, 1359
 Yoshimoto, K., 488
 Yoshino, G., 589, 1113
 Yoshioka, K., 1223
 Young, I. S., 755
 Young, J. R., 513
 Yu, C.-H., 1136
 Yu, YX., 182
 Yudkin, J. S., 852
 Yufu, K., 1359
 Zahorska-Markiewicz, B., 1268
 Zaratin, A. C. M., 858
 Zarra, E., 1081
 Zeisel, S. H., 594
 Zhang, B., 423
 Zhang, L., 1121
 Zheng, D., 1296
 Zhou, L., 794
 Zhu, S., 1503
 Zoeller, R., 193
 Zou, B., 644
 Zuo, C. S., 222
 Zurkowski, Z., 1268

SUBJECT INDEX

- AA, *see* Amino acids
ABCA1 gene
expression of leukocyte, associated with fasting glucose concentration in normoglycemic men, 17-21
serum HDL-C or apo A-I levels associated with polymorphism of, in Japanese school-age children, 182-186
Abdominal adipose tissue (AT)
exercise effects on, *see* Abdominal adipose tissue, exercise effects on
in lipodystrophic HIV-infected subjects, 1567
and metabolic risk in non-obese premenopausal women, 1066-1071
in obese NIDDM subjects, bezafibrate effects on, 408
Abdominal adipose tissue (AT), exercise effects on
on body composition, MS and, in PM women on or not on ERT, 1192-1196
in older hypertensive subjects, 399
Abdominal aorta of obese children, preclinical changes in, 1243-1246
Acanthosis nigricans in PCOS, 366
ACAT (acyl-coenzyme A:cholesterol acyltransferase), role of
cholesterol absorption and activity of hepatic, in lipemic response to HF/HC diet, 817-822
ACE, *see* Angiotensin-converting enzyme inhibitors
Acetyl-coenzyme A (CoA), platelet, ATPCL role in metabolism and function of, in DM, 66-72
Acetyl-coenzyme A (CoA) carboxylase mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
 α_1 (alpha₁)-Acid glycoprotein (AGP) in inflammation of chronic disease, 901, 902
Acid phosphatase locus 1 (ACP1) polymorphism, interaction between adenosine deaminase and, in NIDDM, 995-1001
Acidemia, late-onset propionic, fatal outcome and, 809-810
Acipimox, effects of, on plasma NEFAs during exercise at cold temperature, 1131-1135
ACP1 (acid phosphatase locus 1) polymorphism, interaction between adenosine deaminase and, in NIDDM, 995-1001
ACT (α_1 -antichymotrypsin) in inflammation of chronic disease, 901, 902
ACTH, *see* Adrenocorticotropin hormone
Activated CD4⁺ (and CD8⁺) T lymphocytes, emergence of growth factor receptors in, 117-122
Acute effects
of nicotine on serum glucose, insulin, GH, and cortisol, 578-582
of wine drinking, *see* Acute effects of wine drinking
Acute effects of wine drinking
absence of red wine drinking, on vascular reactivity, 1081-1086
of red and white wine drinking on circulating inflammation-sensitive molecules in men with CAD, 318-323
Acute insulin-induced hypoglycemia, effects of normoglycemic hyperinsulinemia and, on glucose retinal uptake and ocular metabolism, 1274-1283
Acute regulatory protein mRNA (messenger ribonucleic acid), low temperature blocking stimulatory effects of hCG on
testosterone production but not on cAMP production in tumor cells, 955-958
Acute spinal cord injury (SCI), circulating leptin as marker of fat mass in, 989-994
Acyl-coenzyme A:cholesterol acyltransferase (ACAT), role of
cholesterol absorption and activity of hepatic, in lipemic response to HF/HC diet, 817-822
ADA (adenosine deaminase), interaction between ACP1 polymorphism and, in NIDDM, 995-1001
Adaptability of AT to fasting, pinealectomy effects on, 500-506
Adaptive thermogenesis, resistance to obesity and, 1417-1423
Adenosine deaminase (ADA), ACP1 polymorphism interaction with, in NIDDM, 995-1001
Adenosine monophosphate (AMP)
HF diet effects on protein kinase activated by, 914
see also cAMP
Adenosine triphosphate-citrate lyase (ATPCL), role of, in platelet acetyl-CoA metabolism and function in DM, 66-72
Adenosine triphosphate-citrate lyase (ATPCL) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
Adhesion molecules, *see* Circulating cell adhesion molecules; Intercellular adhesion molecule-1; Vascular cell adhesion molecule
Adipocyte(s)
hypertension with IR and GLUT₄ of, 382-387
restricted diet effects on, 30
see also Adipocytokines; Preadipocytes; Resistin
Adipocyte precursor cells, *see* Preadipocytes
Adipocyte-secreted factor, *see* Resistin
Adipocytokines, serum, effects of moderate weight loss and orlistat or sibutramine on waist circumference and, in obese women, 430-434
Adipogenic properties of PPFS-410, 1532-1537
Adiponectin
CRP and, *see* Adiponectin, CRP and ethnic differences in levels of, 1-3
G276T polymorphism of, in Japanese NIDDM subjects with incipient nephropathy, 1223-1226
NEFAs regulating, 790-793
in obesity, *see* Adiponectin in obesity
plasma, *see* Plasma adiponectin
Pro12Ala PPAR γ 2 polymorphism associated with concentrations of, in young Japanese men, 1548-1551
serum, *see* Serum adiponectin
Adiponectin, CRP and
IR and, in postpubertal Asian Indian adolescents, 1336-1341
in obesity, NIDDM, and monodrug therapy, 1454-1461
Adiponectin, effects of moderate weight loss by obese women on by insulin-resistant obese women, 280-283
with sibutramine or orlistat therapy, 432
Adiponectin in obesity
CRP, NIDDM, monodrug therapy and, 1454-1461
see also Adiponectin, effects of moderate weight loss by obese women on
Adipose tissue (AT)
abdominal, *see* Abdominal adipose tissue
diet and, *see* Adipose tissue, diet and distribution, *see* Adipose tissue distribution
exercise effects on, *see* Adipose tissue, exercise effects on in hyperinsulinemic young men, whole-body protein synthesis and, 389
in IGT first-degree relatives of African American NIDDM subjects, 1553
isotretinoin effects on, 5
in LBW Pima Indians with normal glucose tolerance, 906
in lipodystrophic HIV-infected subjects, 1567
MHN-01 effects on, 980, 981
in non-obese subjects, *see* Adipose tissue in non-obese subjects

- Adipose tissue (AT) (Continued)**
- in obesity, *see* Adipose tissue in obesity
 - in overweight women, 1269
 - pinealectomy effects on adaptability of, to fasting, 500-506
 - in SCI men with MS, 1373, 1374
 - serum adiponectin association with, in young men, 590, 591
 - in severe lipodystrophy, effects of leptin replacement therapy on, 514
 - in Vietnamese children, apo E polymorphism and, 1519
 - see also* Fat mass and entries beginning with element: Adipose tissue (AT), diet and
 - correlation between food intake, serum leptin and, in sixth-month period following kidney transplantation, 614-619
 - effects of LF versus HF diet and caloric intake on, in obese NIDDM subjects, 455
 - relationship between alcohol intake, exercise and, to HDL-C levels, 700-709
 - restricted diet effects on glucocorticoid receptor and PPAR γ signaling in, 28-36
 - Adipose tissue (AT), exercise effects on
 - apo E genotype changes and, 195, 198, 199
 - effects of moderate exercise and soy isoflavone on bone loss and accumulation of, in postmenopausal subjects, 942-948
 - relationship between exercise, alcohol intake, and AT to HDL-C levels, 700-709
 - Adipose tissue (AT) distribution
 - Pro12Ala polymorphism of PPAR γ 2 effects on, in Korean women, 1538-1543
 - see also* Subcutaneous adipose tissue; Total adipose tissue; Visceral adipose tissue; White adipose tissue
 - Adipose tissue (AT) in non-obese subjects
 - liver, in non-obese premenopausal women, metabolic risk and, 1066-1071
 - as predictor of fibrinogen level in non-obese men, 984-988
 - Adipose tissue (AT) in obese NIDDM subjects
 - effects of LF versus HF diet and caloric intake on, 455
 - total, bezafibrate effects on, 407
 - Adipose tissue (AT) in obesity
 - obese adolescents, 864
 - obese women, 1269
 - see also* Adipose tissue in obese NIDDM subjects; Obesity; Omental adipose tissue, subcutaneous and, in obese subjects
 - Adipsin mRNA (messenger ribonucleic acid), CL316,243 effects on, in diabetes, 804
 - Adjustable silicone gastric banding (ASGB), RYBG and, for morbid obesity, changes in BMC after, 918-921
 - ADMA, *see* Asymmetric dimethylarginine
 - Adolescents
 - IDDM Kuwaiti, cardiovascular disease risk factors associated with serum sialic acid in, 638-643
 - postpubertal Asian Indian, adiponectin, CRP, and IR in, 1336-1341
 - see also* Adolescents, obese
 - Adolescents, obese
 - Japanese male adolescents, 448-453
 - serum TNF- α levels and components of MS in, 863-867
 - ADR, *see entries beginning with terms:* Adrenergic receptor
 - Adrenal androgens, cortisol and, in obese PCOS women, 361
 - Adrenal (ovarian) hypothesis of PCOS, 360, 361
 - Adrenal insufficiency, hypoglycemia effects on plasma PTH levels in, 1251-1254
 - Adrenaline, *see* Epinephrine
 - β (beta)-Adrenergic blockers in CAD, 319
 - β (beta)-Adrenergic receptor (ADR), racial differences in density of, in subcutaneous and omental AT from obese women, 247-251
 - β_2 (beta₂)-Adrenergic receptor (ADR), interaction of β_3 -ADR Trp64Arg and Arg16Gly polymorphisms with, serum lipid profile and, 1184-1191
 - β_3 (beta₃)-Adrenergic receptor (ADR), Trp64Arg polymorphism of association of increased leptin levels with, but not with - 3826A→G polymorphism of UCP-1 gene in Spanish subjects, 1411-1416
 - in GDM Taiwanese women, 1136-1139
 - interaction of Arg16Gly β_2 -ADR polymorphism with, serum lipid profile and, 1184-1191
 - Adrenocortical disorders, plasma cortisol in, in 89-94
 - Adrenocorticotropin hormone (ACTH; corticotropin)
 - circulating, and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis, 209-214
 - nighttime and daytime differences in counterregulation of hypoglycemia and, 895
 - plasma, *see* Plasma adrenocorticotropin hormone
 - ADSF (adipocyte-secreted factor), *see* Resistin
 - Adult cystic fibrosis (CF) with impaired glucose tolerance, insulin regulating kinetics of NEFAs in, 1467-1472
 - Advanced non-insulin-dependent diabetes mellitus (NIDDM) nephropathy, resting metabolic rate in, 1395-1398
 - Adverse reactions to Pancreatic Tonic, 1170
 - Aerobic capacity, *see* VO_{2max} during exercise
 - Aerobic exercise, effects of low-fat, high-fiber diet and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
 - African Americans, *see* Race and ethnicity
 - 1.5-AG (1,5-anhidroglucitol) in NIDDM, microalbuminuria and, 354
 - Age
 - of acromegalic subjects, 565
 - adiponectin and, *see* Age, adiponectin and
 - β_2 -ADR Arg16Gly polymorphism and, 1184, 1185
 - of at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 2
 - of CAD men, *see* Age of CAD men
 - carotid atherosclerosis, vascular dementia and, 477
 - of children with glycoprotein PC-1 K121Q polymorphism, 467
 - of chronic renal disease subjects, 1256
 - of CT subjects, 557
 - CV disease risk factors and, *see* Age, CV disease risk factors and diet and, *see* Age, diet and
 - of DM subjects, *see* Age of DM subjects
 - of Ecuadorian Amazon Shuar women, 1356
 - effects of, on HbA_{1c}, 1497
 - and effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism, 305, 306
 - and erythrocyte membrane lipid composition, 574
 - exercise and, *see* Age, exercise and
 - gestational, *see* Gestational age
 - of HD subjects, 1014
 - of HL-deficient subjects, 522
 - of hypercholesterolemic subjects, *see* Age of hypercholesterolemic subjects
 - of hypogonadal men, 1175
 - of IGT subjects, *see* Age of IGT subjects
 - of insulin-resistant subjects, *see* Age of insulin-resistant subjects and isotretinoin effects on insulin sensitivity and plasma TGs, 5
 - of Japanese subjects, *see* Age of Japanese subjects
 - of kidney transplantation recipients, 615

- Age (Continued)**
- of LBW Pima Indians with normal glucose tolerance, 906
 - leptin levels and, 1412-1414
 - of lipodystrophic subjects, *see* Age of lipodystrophic subjects of MS subjects
 - of non-obese subjects, *see* Age of non-obese subjects
 - of normoglycemic men, and *ABCA1* expression-fasting glucose relationship, 19
 - of obese subjects, *see* Age of obese subjects
 - and pioglitazone effects on carotid artery IMT and stiffness in NIDDM nephropathy, 1383
 - and plasma LDL clearance, 484
 - and plasma vitamin K transport, 216
 - of PM women, *see* Age of PM women
 - and PPAR γ 2 Pro12Ala polymorphism on AT distribution in Korean women, 1539
 - and pregnancy, *see* Age, pregnancy and
 - of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
 - of premenopausal women, sex steroids and plasma Lp and, 189
 - and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1450
 - of primary hyperthyroidism subjects, 1102
 - ω -3 PUFA effects and, *see* Age, ω -3 PUFA effects and smoking effects and, *see* Age, and effects of smoking and uncoupling protein-3 polymorphism-body composition association, 460
 - and WPG effects on normal or mildly elevated plasma cholesterol, 1311
 - see also specific age groups; for example:* Adolescents, Children
 - Age, adiponectin and**
 - adiponectin levels, ethnic differences and, 2
 - C-reactive protein and, in obese NIDDM subjects, 1456
 - and NEFAs regulation by, 791 - Age, CV disease risk factors and**
 - diet and, 1437
 - of hypothyroidic subjects, 278 - Age, diet and**
 - acute effects of red wine drinking and food intake on vascular reactivity and, 1082
 - and PP TG response to different nutrients, 621
 - PPAR γ Pro12Ala polymorphism effects on dietary fat-physical activity association with fasting insulin level, 13, 14
 - red and white wine drinking effects on circulating inflammation-sensitive molecules, 319
 - see also* Age, wine drinking and - Age, and effects of ω -3 PUFAs with exercise**
 - on HDL and LDL subfractions, 750
 - on PP lipemia, 1366 - Age, and effects of smoking**
 - acute effects of nicotine, 579
 - on intravascular remodeling of HDL particles, 860 - Age, exercise and**
 - cholesterol efflux in soccer players and, 1263
 - effects of apo E genotype changes on $V_{O_{max}}$ and, 195, 198, 199
 - insulin concentration and CHO requirement in IDDM during moderate exercise, 1127
 - OC effects on glucoregulatory responses to exercise and, 350
 - by overweight nondiabetic subjects, 1236
 - and plasma nitrate/nitrite assessment during OGTT, 675
 - and PPAR γ Pro12Ala polymorphism effects on dietary fat-physical activity association with fasting insulin level, 13, 14
 - ω -3 PUFAs and, *see* Age, and effects of ω -3 PUFAs with exercise

Age, exercise and (Continued)

 - see also* Age, resistance exercise effects and
 - Age, pregnancy and**
 - GDM Taiwanese women with β_3 -ADR Trp64Arg polymorphism, 1137
 - leucine turnover and, 546
 - and preeclampsia, 1434 - Age, ω -3 PUFA effects and**
 - anti-inflammatory effects of ω -3 PUFAs alone or combined with all-rac α -tocopherol, 237
 - see also* Age, and effects of ω -3 PUFAs with exercise - Age, resistance exercise effects and**
 - in NIDDM women, 285
 - in older hypertensive subjects, 399 - Age, wine drinking and**
 - acute effects of red wine drinking and food intake on vascular reactivity and, 1082
 - red and white wine drinking effects on circulating inflammation-sensitive molecules, 319 - Age of CAD men**
 - red and white wine drinking effects on circulating inflammation-sensitive molecules and, 319
 - risk factors for myocardial infarction and, 325, 326
 - serum HDL-C, oxidized LDLs and, 424-426 - Age of DM subjects**
 - of GDM Taiwanese women with β_3 -ADR Trp64Arg polymorphism, 1137
 - and relation between plasma VEGF, ET-1 concentration, and glycemic control, 551
 - see also* Age of IDDM subjects; Age of NIDDM subjects - Age of hypercholesterolemic subjects**
 - of hypercholesterolemic women, simvastatin effects and, 745
 - of mildly hypercholesterolemic subjects, 1073
 - serum LPL concentration and, 527, 528 - Age of IDDM subjects**
 - energy substrate oxidation and, 656
 - and glycemic control effects on F₂ isoprostane level at IDDM onset, 1119
 - and insulin concentration and CHO requirement during moderate exercise, 1127
 - of Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 - oxidation of glycated and nonglycated LDLs and, 970 - Age of IGT subjects**
 - of IGT first-degree relatives of African American NIDDM subjects, 415
 - of non-obese IGT subjects, 625, 1553 - Age of insulin-resistant obese subjects**
 - with IGT or normal FPG, 1096
 - of insulin-resistant obese Japanese men, 651, 652
 - of insulin-resistant obese women, and moderate weight loss effects on plasma adiponectin, 281 - Age of insulin-resistant subjects, 1109**
 - fatty acid TG content and VAT accumulation and, 311, 312
 - with LVH, 778, 779
 - with NIDDM, cardiovascular autonomic dysfunction, microalbuminuria and, 1360
 - and relationship between BMI, beta-cell function, and IR, 1463
 - serum GPI-PLD and, 139
 - see also* Age of insulin-resistant obese subjects - Age of Japanese men**
 - 1562C→T MMP-9 gene polymorphism association with BMD and, 136

- Age of Japanese men (*Continued*)
 Pro12Ala PPAR γ 2 polymorphism and adiponectin concentrations in young men, 1549
- Age of Japanese NIDDM subjects
 with incipient nephropathy, 1224
 insulin secretion and sensitivity and, 832
- Age of Japanese subjects
 with beta-cell dysfunction, 950-952
 of Japanese men, *see* Age of Japanese men
 with NIDDM, *see* Age of Japanese NIDDM subjects
 and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
- Age of lipodystrophic subjects
 with HIV infection, 1567
 with severe lipodystrophy, 514
- Age of MS subjects
 with CHD, 853
 with CRH, 722
 with liver cirrhosis, 923, 924
 with SCI, 1373
- Age of NIDDM subjects
 alcohol effects on PP lipemia and, 78
 and association of corrected QT intervals with carotid artery IMT, 1153, 1155
 and in at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224
 bezafibrate effects on lipids and glucose metabolism in NIDDM and, 411
 glyburide and nateglinide effects on NIDDM and, 1332
 HbA_{1c}-RBC membrane lipid composition correlation and, 124
 with IGT, 646
 and insulin therapy effects on serum high-sensitive CRP, 694, 697
 of Japanese subjects, *see* Age of Japanese NIDDM subjects
 metformin effects on risk factors for CV disease and, 160
 with microalbuminuria, *see* Age of NIDDM subjects with microalbuminuria
 NIDDM women, and resistance exercise effects on glycemic control, 285
 obese, *see* Age of obese NIDDM subjects
 overweight subjects, exercise effects in, 1236
 with retinopathy, 585, 586
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- Age of NIDDM subjects with microalbuminuria
 and cardiovascular autonomic dysfunction, and IR, 1360
 glycemic control and, 354
- Age of non-obese subjects
 non-obese men, AT as level fibrinogen level and, 985, 986
 of non-obese premenopausal women, 1068
 and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting, 1450
- Age of obese NIDDM subjects
 adiponectin, C-reactive protein and, 1456
 bezafibrate effects on lipids and glucose metabolism and, 411
- Age of obese subjects
 adolescents, 864
 children, 1244
 Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055
 proliferation and differentiation of adipocyte precursor cells and, 633, 634
- Age of obese subjects (*Continued*)
 and relationship between BMI, beta-cell function, and insulin resistance, 1463
 and smoking-ADMA-obesity relationship, 1575
 women, *see* Age of obese women
see also Age of insulin-resistant obese subjects; Age of obese NIDDM subjects
- Age of obese women
 with IR, and moderate weight loss effects on plasma adiponectin, 281
 with NIDDM, bezafibrate effects on lipids and glucose metabolism and, 411
 PM women, fluvastatin effects on endothelial function and, 735 and serum TNF soluble receptors, TNF- β , and NO, 1269
- Age of PM women
 hypercholesterolemic women, simvastatin effects and, 745
 insulin sensitivity and, 508
 obese, and fluvastatin effects on endothelial function, 735
 sex steroids, plasma Lp and, 189
- Aging subjects, *see* Older subjects
- AGP (α_1 -acid glycoprotein) in inflammation of chronic disease, 901, 902
- Agricultural lifestyle, effects of traditional versus, on leptin in Ecuadorian Amazon Shuar women, 1355-1358
- AICAR (5-aminoimidazole-4-carboxamide-1- β -D-ribonucleoside), glucose transport in SM stimulated by, 514
- Akt1/protein kinase β α (Akt1/PK β α), insulin regulation of hepatic apo B production independently of mass or activity of, 228-236
- Alanine (Ala)
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
see also Alanine aminotransferase; Pro12Ala polymorphism of PPAR γ ; Pro12Ala polymorphism of PPAR γ
- Alanine aminotransferase (ALT)
 in dyslipidemic CRF subjects on HD, 1116
 in hyperuricemic Japanese male adolescents, 450
 in liver cirrhosis with IR, 923
 in obese subjects, *see* Alanine aminotransferase in obese subjects plasma, NO-1886 effects on, in STZ-DM, 261
 WPG effects on, 1312
- Alanine aminotransferase (ALT) in obese subjects
 in hyperuricemic Japanese male adolescents, 450
 Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
- Albumin
 in chronic renal disease, 1256
 and IR in liver cirrhosis, 923
 in Korean women, AT distribution and, 1541
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 plasma, and HHcy in disabled hospitalized older subjects, 1018
 serum, *see* Serum albumin
 in 6-month period following kidney transplantation recipients, 617
see also Albuminuria
- Albuminuria
 in IDDM, oxidation of glycated and nonglycated LDLs and, 970
 in NIDDM, corrected QT intervals association with carotid artery IMT and, 1155
 in NIDDM nephropathy, pioglitazone effects on, 1382-1386
 in NIDDM retinopathy, 586
see also Microalbuminuria; Proteinuria
- Alcohol
 bile, in CTX, treatment effects on, 558, 559

Alcohol (Continued)

differential effects of glucose and, on ROS generation and intranuclear nuclear factor- κ B in mononuclear cells, 330-334
see also Alcohol intake

Alcohol intake

atherosclerosis and, *see* Alcohol intake, atherosclerosis and by disabled hospitalized older subjects, HHcy and, 1018
drinking and, *see* Drinking
effects of, on risk for metabolic syndrome, 1506-1508
IR and, 722
in mild hypercholesterolemia, 1073, 1311
by NIDDM subjects, *see* Alcohol intake by NIDDM subjects
normal plasma cholesterol and, 1311
relationship of exercise, adiposity and, to HDL-C levels, 700-709
Alcohol intake, atherosclerosis and
carotid atherosclerosis, vascular dementia and, 477
by normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia, 51

Alcohol intake by NIDDM subjects

effects of, on PP lipemia and PP incretin levels, 77-83
by IGT NIDDM subjects, as risk factor for CHD, 646

Alkaline phosphatase (ALP)

in PM women, simvastatin effects on BMD and, 745, 746
in primary hyperthyroidism, 1102
in severe lipodystrophy, leptin replacement therapy effects on, 516
SR effects on, in MC3T3-E1 osteogenic cells, bone matrix mineralization and, 533

in STZ-DM, effects of oral vanadate with tea extract on, 1148

ALP, *see* Alkaline phosphatase

Alpha_1 (α_1 -acid glycoprotein (AGP) in inflammation of chronic disease, 901, 902

Alpha_1 (α_1 -antichymotrypsin (ACT) in inflammation of chronic disease, 901, 902

7Alpha (α)-hydroxylase, cholesterol, effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932

17alpha (α)-hydroxylase/17,20-lyase deficiency, mutant CYP17 genes in, 1527-1531

3n3 Alpha (α)-linolenic acid in MS, 312

Alpha-lipoprotein, *see* High-density lipoprotein

Alpha-lipoprotein-cholesterol, *see* High-density lipoprotein-cholesterol

Alpha-tocopherol, *see* α -Tocopherol

ALT, *see* Alanine aminotransferase

Alveolar macrophages, effects of caffeine on, via its effects on synthesis of cAMP and prostaglandin, 687-692

Amazon Shuar women, Ecuadorian, effects of agricultural versus traditional lifestyle on, 1355-1358

Amenorrhea, sex steroids and plasma Lp in, 189

Amino acids (AA)

plasma concentrations of, and whole-body protein synthesis in hyperinsulinemic young men, 388-396
see also specific amino acids

5-Aminimidazole-4-carboxamide-1- β -D-ribonucleoside (AICAR), glucose transport stimulated in SM stimulated by, 514

bis(ω -Aminophenoxy)ethane-N,N,N',N' tetraacetic acetoxymethyl ester (dimethyl-BAPTA/AM), effects of, on IR and spontaneous hypertension, high-fat diet and, 269-272

4-Aminopyridine (4AP), effects of, on delayed vasorelaxation by troglitazone, 147-152

Aminoterminal propeptide type 1 collagen in adrenal insufficiency, 1252

Aminotransferase, *see* Alanine aminotransferase; Aspartate aminotransferase

AMP, *see* Adenosine monophosphate

Amyloid A, serum, aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380

Androgen(s)

aging NIDDM men with partial deficiency of, glycemic control and, 666-672

role of, in estrogen-deficient state, 187-192

see also Androgen(s) in PCOS; Androgenicity

Androgen(s) in PCOS

adrenal, 361

in obese PCOS women, antiandrogenic therapy of, 366, 370 ovarian, 360, 361

Androgenicity, independent association of obesity and, with insulin sensitivity in postmenopausal women, 507-512

Androstenedione

in premenopausal women, plasma Lp and, 189, 190
see also Androstenedione in PM women

Androstenedione in PM women

obese, insulin sensitivity and, 508-509 plasma Lp and, 189, 190

Androsterone glucuronide in PCOS, 366

Angiotensin-converting enzyme (ACE) inhibitors

in CAD, 319

in NIDDM, effects of, on microalbuminuria, 354

Anglo subjects, *see* Race and ethnicity

1,5-Anhidroglucitol (1,5-AG) in NIDDM, microalbuminuria and, 354

Antiandrogenic therapy of PCOS in obese women, 366, 370

α_1 (α_1 -) α -Antichymotrypsin (ACT) in inflammation of chronic disease, 901, 902

Antidiabetic medications, *see* Glycemic control of DM

Antigen, tPA- and PAI-, in NIDDM, 224

Antihyperglycemic effects, *see* Glycemic control of DM

Anti-inflammatory effects of ω -3 polyunsaturated fatty acids alone or combined with *all-rac* α -tocopherol, 236-240

Aorta

abdominal, preclinical changes in, in obese children, 1243-1246 effects of micromolar copper concentrations on endothelium-dependent relaxation of, in DM, 1315-1321

4-AP (4-aminopyridine), effects of, on delayed vasorelaxation by troglitazone, 147-152

Apo(s), *see specific apolipoproteins*

Apolipoprotein A-1 (apo A-1)

ABCA1 gene and, *see* Apolipoprotein A-1, *ABCA1* gene and carotid atherosclerosis, vascular dementia and, 477

in chronic kidney disease with obesity and MS, 1255-1261

in dyslipidemic CRF subjects on HD, 1114

in erythrocyte membrane, 574

exercise and, *see* Apolipoprotein A-1, exercise and fat mass in acute SCI subjects, 991

in FCHL, ω -3 PUFA effects on, 154

in hepatoma cells, *see* HepG2 cells, apo A-1 and

in hypercholesterolemia, serum LPL concentration and, 528

in IDDM, *see* Apolipoprotein A-1 in IDDM

in IR, serum GPI-PLD and, 139

plasma, *see* Plasma apolipoprotein A-1

in PM women, *see* Apolipoprotein A-1 in PM women

in premenopausal women, sex steroids and, 189

serum, in CAD men, 425

serum adiponectin and, in young men, 590

smoking effects on, 859, 860

Apolipoprotein A-1 (apo A-1), *ABCA1* gene and

ABCA1 expression relation with fasting glucose in normoglycemic men, 19

- Apolipoprotein A-1 (apo A-1), *ABCA1* gene and (*Continued*)
ABCA1 polymorphism in Japanese school-age children, 182-186
 Apolipoprotein A-1 (apo A-1), exercise and
 apo E polymorphism- $\dot{V}O_{2\max}$ association and, 111-113
 endurance exercise, 196, 198-200
 in soccer players, 1264
 Apolipoprotein A-1 (apo A-1) in IDDM
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 plasma apo C-3 polymorphisms and, 1299
 Apolipoprotein A-1 (apo A-1) in PM women
 obese women, fluvastatin effects on, 736
 and sex steroids, 189
 Apolipoprotein A-2 (apo A-2)
 erythrocyte membrane, 574
 in FCHL, ω -3 PUFA effects in, 154
 in obese PM women, fluvastatin effects on, 736
 serum, in CAD men, 425
 in soccer players, 1264
 Apolipoprotein A-2 (apo A-2) promoter, SFA effects on Sp1 induction of, 1342-1348
 Apolipoprotein B (apo B)
 atherosclerosis and, see Apolipoprotein B in atherosclerosis
 in dyslipidemic CRF subjects on HD, 1114, 1115
 erythrocyte membrane, 574
 exercise and, see Apolipoprotein B, exercise and
 and fat mass in acute SCI subjects, 991
 in FCHL, ω -3 PUFA effects in, 154
 hepatocyte, insulin regulating production of, independently of PKB α /
 Akt1 mass or activity, 228-236
 in hypercholesterolemia, serum LPL concentration and, 528
 in IDDM, see Apolipoprotein B in IDDM
 in IR, plasma NEFA regulation and, 1198
 levels of, associated with *ABCA1* polymorphism in Japanese school-age children, 183
 in MS, 312, 313, 315
 in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
 plasma, in premenopausal women, sex steroids and, 189
 in PM women, see Apolipoprotein B in PM women
 smoking effects on, 860
 in subclinical hypothyroidism, 1513
 in young men, serum adiponectin and, 590
 Apolipoprotein B (apo B), exercise and
 apo E polymorphism- $\dot{V}O_{2\max}$ association and, 111-113
 endurance exercise, 196, 198-201
 soccer playing, 1264
 Apolipoprotein B (apo B) in atherosclerosis
 in normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia, 50
 vascular dementia and carotid atherosclerosis, 477
 Apolipoprotein B (apo B) in IDDM
 in Kuwaiti children and adolescents, CV disease risk factors and, 640, 641
 plasma apo C-3 polymorphisms and, 1299, 1301
 Apolipoprotein B (apo B) in PM women
 obese women, fluvastatin effects on, 736
 sex steroids and, 189
 Apolipoprotein B-48 (apo B-48) in chronic kidney disease, obesity, and MS, 1255-1261
 Apolipoprotein B-100 (apo B-100)
 in chronic kidney disease, obesity, and MS, 1255-1261
 in HL deficiency, 522, 523
 Apolipoprotein C-2 (apo C-2)
- Apolipoprotein C-2 (apo C-2) (*Continued*)
 in dyslipidemic CRF subjects on HD, 1114
 in hypercholesterolemia, serum LPL concentration and, 528
 in obese PM women, fluvastatin effects on, 736
 serum, in CAD men, 425
 Apolipoprotein C-3 (apo C-3)
 in dyslipidemic CRF subjects on HD, 1114, 1115
 in hypercholesterolemia, serum LPL concentration and, 528
 in obese PM women, fluvastatin effects on, 736
 polymorphisms of plasma, in IDDM, 1296-1304
 serum, see Serum apolipoprotein C-3
 Apolipoprotein E (apo E)
 carotid atherosclerosis, vascular dementia and, 477
 in dyslipidemic CRF subjects on HD, 1114
 effects of circulating blood cells on atherosclerosis in apo E deficiency, 95-100
 in hypercholesterolemia, serum LPL concentration and, 528
 in obese PM women, fluvastatin effects on, 736
 serum, in CAD men, 425
 see also Apolipoprotein E genotype; Apolipoprotein E polymorphism
 Apolipoprotein E (apo E) genotype, changes in serum lipids and $\dot{V}O_{2\max}$ during endurance exercise and, 193-202
 Apolipoprotein E (apo E) polymorphism
 and changes in blood lipids and $\dot{V}O_{2\max}$ association in sedentary and exercising subjects, 108-116
 in Vietnamese children, relationship of, to plasma lipids and Lps, 1517-1521
 Appropriate-for-gestational-age newborns, normal, circulating ACTH and cortisol concentrations in newborns with respiratory distress and sepsis versus, 209-214
 Arachidonic acid
 effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
 erythrocyte membrane lipid composition in men associated with, insulin sensitivity and, 571-577
 Arg, see Arginine
 Arg16Gly polymorphism, β_2 -ADR, interaction of β_3 -ADR Trp64Arg polymorphism with, serum lipid profile and, 1184-1191
 Argininase, effects of different glucose levels on NO production and activity of, in renal cortex, 868-874
 Arginine (Arg)
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 see also β_3 -Adrenergic receptor, Trp64Arg polymorphism of: Arg16Gly polymorphism of β_2 -ADR; Arginine-vasopressin; Asymmetric dimethylarginine; Lys109Arg and Gln223Arg polymorphisms
 Arginine-vasopressin (AVP)
 and 4AP effects on delayed vasorelaxation by troglitazone, 147-152
 response of, to exercise by nondiabetic and IDDM smokers, 1140-1144
 Arginine-vasopressin₂ (AVP₂) mRNA (messenger ribonucleic acid) in IMCD, ET effects on, 1177-1183
 Arterial pressure, see Blood pressure
 Arterial stiffness, pioglitazone effects on carotid IMT and, in NIDDM nephropathy, 1382-1386
 Arteriosclerosis obliterans in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 299
 Arylesterase, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, in NIDDM, 301
 Ascorbic acid, see Vitamin C

- ASGB (adjustable silicone gastric banding), RYBG and, for morbid obesity, changes in BMC after, 918-921
- Asian Indian adolescents, postpubertal, adiponectin, CRP, and IR in, 1336-1341
- Asparagine (Asn), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Aspartate aminotransferase (AST)
- in dyslipidemic CRF subjects on HD, 1116
 - in obese Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
 - plasma, NO-1886 effects on, in STZ-DM, 261
 - WPG effects on, 1312
- Aspirin therapy of CAD, 319
- AST, *see Aspartate aminotransferase*
- Asymmetric dimethylarginine (ADMA)
- plasma, diet composition as determinant of, in mild hypercholesterolemia, 1072-1074
 - relationship between smoking, obesity and, 1574-1579
- AT, *see Adipose tissue*
- Atherogenic particles of LDLs, HC diet effects on, 823-830
- Atherosclerosis
- in apo E-deficient subjects, effects of circulating blood cells on, 95-100
 - carotid, sdLDLs, vascular dementia and, 476-482
 - premature, normocholesterolemia and daytime hypertriglyceridemia in first-degree relatives of subjects with, 49-53
 - see also Coronary artery disease*
 - 3826A→G polymorphism of UCP-1, effects of, on LDL-C level in obese Korean subjects, 1054-1059
- Athletes, *see Exercise*
- Atorvastatin, effects of, on lipids, LDLs, and CRPs in dyslipidemic CRF subjects on HD, 1113-1117
- ATPCL, *see Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA*
- At-rest subjects, *see Sedentary subjects*
- Autonomic dysfunction, cardiovascular, microalbuminuria, IR and, in NIDDM, 1359-1364
- AVP, *see Arginine-vasopressin*
- Ayurvedic herbal supplement (Pancreatic Tonic), effects of, in NIDDM, 1166-1173
- Beer ingestion, effects of sauna bathing and, on plasma concentration of purine bases, 772-776
- Beta (β)-adrenergic blockers in CAD, 319
- Beta (β)-adrenergic receptor, racial differences in density of, in subcutaneous and omental AT of obese women, 247-251
- Beta₂ (β₂)-adrenergic receptor (ADR), interaction of β₃-ADR Trp64Arg polymorphism with Arg16Gly polymorphism of, serum lipid profile and, 1184-1191
- Beta₃-adrenergic receptor, *see β₃-Adrenergic receptor, Trp64Arg polymorphism of*
- Beta (β)-carboxy terminal telopeptide of type I collagen in adrenal insufficiency, 1252
- Beta (β) cells
- dysfunctional, and development of hyperglycemia in Japanese subjects, 943-954
 - pioglitazone effects on insulin secretion and loss of mass of, in obese NIDDM subjects, 488-494
 - of relationship between BMI, IR, and function of, 1462-1466
- 7Beta (β)-hydroxy bile acids, hydrophilic, effectiveness of lovastatin, cholestyramine, chenodeoxycholic acid and, in cerebrotendinous xanthomatosis, compared, 556-562
- 11Beta (β)-hydroxysteroid dehydrogenase 1 (11β-HSD1) mRNA (messenger ribonucleic acid)
- 11Beta (β)-hydroxysteroid dehydrogenase 1 (11β-HSD1) mRNA (messenger ribonucleic acid) (*Continued*)
- in AT, effects of restricted diet on, 30-31
 - hepatic, responsiveness of body weight and, to 11β-HSD1 inhibition by glycyrrhetic acid, 600-606
- 11Beta (β)-hydroxysteroid dehydrogenase 2 (11β-HSD2) mRNA (messenger ribonucleic acid), renal, responsiveness of body weight and, to 11β-HSD1 inhibition by glycyrrhetic acid, 600-606
- Beta in cystathione-β-synthase deficiency, 594-599
- Beta lipoprotein, *see Low-density lipoprotein*
- Beta lipoprotein-cholesterol, *see Low-density lipoprotein-cholesterol*
- Bezafibrate, effects of, on lipids and glucose metabolism in obese NIDDM subjects, 405-413
- BF (blood flow), medullary, tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308
- Bile, hepatic, plasma 27-hydroxycholesterol and plasma 7α-hydroxy-4-cholest-3-one as markers of synthesis of, dietary cholesterol and, 42-48
- Bile acids, hydrophilic 7β-hydroxy, effectiveness of lovastatin, cholestyramine, chenodeoxycholic acid and, in cerebrotendinous xanthomatosis, compared, 556-562
- Bile alcohol in CTX, treatment effects on, 558, 559
- Bile duct ligation, effects of galactosamine-induced liver disease and, on cardiac protein synthesis, 964-968
- Bile transport, effects of inhibition of ileal, on plasma cholesterol level through hepatic farnesol X receptor inactivation and cholesterol 7α-hydroxylase stimulation, 927-932
- Bilirubin
- serum, *see Serum bilirubin*
 - total, *see Total bilirubin*
 - WPG effects on, in normal and mildly elevated plasma cholesterol, 1312
- Binding protein, *see Fatty acid-binding protein-4; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Insulin-like growth factor-binding protein 3 protease; Retinoic acid binding protein-1 mRNA; Sterol regulatory element binding protein-1*
- Biphosphatase, fructose-1,6-, *P. yoelli* GPI effects on, in STZ-DM with obesity, 1050
- Birth weight
- low, in normal glucose-tolerant Pima Indians, insulin secretion and insulin sensitivity in, 904-911
 - relation of intracellular cord blood platelet magnesium to, 1544-1547
- Black Americans, *see Race and ethnicity*
- Blood cells, effects of circulating, on atherosclerosis in apo E-deficient subjects, 95-100
- Blood cholesterol (C)
- apo E polymorphism association with VO_{2max} and, in exercising and sedentary subjects, 111-113
 - see also Hypercholesterolemia*
- Blood flow (BF), increase of medullary, and tempol effects on hypertension and hyperinsulinemia, 1305-1308
- Blood glucose
- in early NIDDM nephropathy, 1476
 - fasting, *see Fasting blood glucose*
 - with high-sucrose diet, NOS inhibition and pioglitazone effects on, 23
 - in postmenopausal women on ERT and at risk for CAD, 378
 - in treatment-seeking obese insulin-resistant subjects, 436
 - see also Blood glucose in STZ-DM; Glycemic control of DM; Hyperglycemia; Hypoglycemia and entries beginning with term: Normoglycemic*

- Blood glucose in STZ-DM
 leptin effects on, 1559
 with obesity, 1050
- Blood high-density lipoprotein₃-cholesterol (HDL₃-C), apo E polymorphism association with VO_{2max} and, in exercising subjects, 111-113
- Blood lipids
 apo E polymorphism and changes in VO_{2max} and, in sedentary and exercising subjects, 108-116
see also Dyslipidemia in NIDDM; High-fat/high-cholesterol diet, lipemic response to; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia; Postprandial lipemia, exercise effects on
- Blood low-density lipoprotein-cholesterol (LDL-C), apo E polymorphism and changes in VO_{2max} and, during exercise and in sedentary subjects, 111-113
- Blood pressure (BP)
 and ABCA1 gene expression-fasting glucose relationship in normoglycemic men, 19
 in adolescents, *see* Blood pressure in adolescents
 and AT distribution in Korean women, 1539
 in atherosclerosis, *see* Blood pressure in atherosclerosis
 in CAD men, *see* Blood pressure in CAD men
 CV disease risk factors and, *see* Blood pressure, CV disease risk factors and
 diet and, *see* Blood pressure, diet and
 and erythrocyte membrane lipid composition, 574
 of exercising PM women on or not on ERT, 1194
 HPA and, 722
 in hypothyroidism, T₄ therapy effects on endothelial function and, 279
 in IDDM, *see* Blood pressure in IDDM
 in IGT first-degree relatives of African American NIDDM subjects, 1553
 in IR, *see* Blood pressure in IR
 of Japanese subjects, *see* Blood pressure in Japanese subjects
 in mild hypercholesterolemia, 1073, 1074
 in MS, 312, 313, 315
 in NIDDM, *see* Blood pressure in NIDDM
 in NIDDM nephropathy, *see* Blood pressure in NIDDM nephropathy, pioglitazone effects on
 in NIDDM retinopathy, 585, 586
 of non-obese subjects, *see* Blood pressure of non-obese subjects
 in obesity, *see* Blood pressure in obesity
 PP, stevioside effects on, 75
 in preeclampsia, 1434
 and smoking-ADMA-obesity relationship, 1575, 1576
 smoking effects, 860
 of young subjects, *see* Blood pressure of young subjects
- Blood pressure (BP), CV disease risk factors and
 diet, lifestyle, and plasma CRPs associated with CV disease risk factors, 1437, 1438
 in Kuwaiti children, 640, 641
 in overweight and non-obese insulin-resistant subjects, 498
- Blood pressure (BP), diet and
 acute effects of red wine drinking and food intake on vascular reactivity and, 1082
 lifestyle, plasma CRPs, and diet associated with CV disease risk factors and, 1437, 1438
- Blood pressure (BP) in adolescents
 in Kuwaiti adolescents, 640, 641
 in postpubertal Asian Indian adolescents, 1338, 1339
see also Blood pressure of obese adolescents
- Blood pressure (BP) in atherosclerosis
- Blood pressure (BP) in atherosclerosis (*Continued*)
 carotid atherosclerosis, 477
 in normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia and in their first-degree relatives, 50
- Blood pressure (BP) in CAD men
 effects of red and white wine drinking on, 319, 320
 as risk factor for myocardial infarction, 325, 326
- Blood pressure (BP) in IDDM
 of Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 oxidation of glycated and nonglycated LDLs and, 970
- Blood pressure (BP) in IR
 CHD and, 853-855
 and cilostazol effects on microalbuminuria, 1407
 and CV disease risk factors in overweight and non-obese subjects, 498
 HPA dysfunction and, 722, 724
 with LVH, 778, 779
 measures of IR and, 1524
 plasma NEFA regulation and, 1198
see also Blood pressure in obesity with IR
- Blood pressure (BP) in Japanese subjects
 with beta-cell dysfunction, 950
 and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
- Blood pressure (BP) in NIDDM
 association of corrected QT intervals with carotid artery IMT and, 1153, 1155, 1156
 and in at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362
 insulin therapy effects on, 694, 697
 metformin effects on, 160
 with microalbuminuria, 354
 in obesity, *see* Blood pressure in obesity
 Pancreas Tonic effects on, 1169
 PP, stevioside effects on, 75
 renal cortex oxygenation, endothelial function and, 224
see also Blood pressure in NIDDM nephropathy
- Blood pressure (BP) in NIDDM nephropathy
 incipient nephropathy in Japanese subjects, 1224
see also Blood pressure in NIDDM nephropathy, pioglitazone effects on
- Blood pressure (BP) in NIDDM nephropathy, pioglitazone effects on on carotid artery IMT and stiffness, 1383
 on early NIDDM nephropathy, 1476
- Blood pressure (BP) of non-obese subjects
 and AT as fibrinogen level predictor, 985, 986
 in non-obese premenopausal women, metabolic risk and, 1068-1070
- Blood pressure (BP) of obese adolescents
 hyperuricemic male adolescents, 450, 452
 with MS components, TNF and, 864, 865
- Blood pressure (BP) of obese women
 effects of moderate weight loss and sibutramine or orlistat on, 432
 fluvastatin effects on, 735
- Blood pressure (BP) in obesity
 in adolescents, *see* Blood pressure of obese adolescents
 in children, preclinical changes in abdominal aorta and, 1244

- Blood pressure (BP) in obesity (*Continued*)

with IR, *see* Blood pressure in obesity with IR

in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055, 1056

with MS, *see* Blood pressure in obesity with MS

in women, *see* Blood pressure of obese women
- Blood pressure (BP) in obesity with IR

CV disease risk factors associated with, 498

in Japanese subjects, 651
- Blood pressure (BP) in obesity with MS

in obese adolescents, 864, 865

in treatment-seeking subjects, 436
- Blood pressure (BP) of young subjects

with NIDDM parents, and LDL susceptibility to oxidation and circulating adhesion molecules, 756

serum adiponectin and, 590

in young men with hypertensive parents, 470, 473
- Blood samples kept frozen at -80°C, analysis of HbA_{1c} in, 1496-1499
- Blood triglycerides (TGs)

in exercise, apo E polymorphism-VO_{2max} association and, 111-113

see also Hypertriglyceridemia
- Blood urea nitrogen, *see* BUN
- BMC (bone mineral content), changes in, after RYBG and ASGB for morbid obesity, 918-921
- BMD, *see* Bone mineral density
- BMI, *see* Body mass and body mass index
- BNP (brain natriuretic peptide) in IR with LVH, candesartan effects on, 778-780
- Body composition

L-carnitine effects on fat oxidation, protein turnover and, in slightly overweight subjects, 1001-1006

effects of interaction between FABP-4 and PPARγ-activated receptor polymorphism on insulin sensitivity and, in men, 303-309

effects of leptin replacement therapy for severe lipodystrophy on, 513-519

of Korean women, AT distribution and, 1539

in NIDDM, *see* Body composition in NIDDM

of PM women, *see* Body composition of PM women, exercise effects on

uncoupling protein-3 polymorphism associated with food intake and, 458-464

see also Adipose tissue; Fat mass; Fat-free mass; Skeletal muscle
- Body composition in NIDDM

in NIDDM women, resistance training effects on, 286

with obesity, effects of LF versus HF diet on, 456
- Body composition of PM women, exercise effects on

exercise effects on women on or not on ERT, 1192-1196

moderate exercise with soy isoflavone effects, 944-945
- Body fat, *see* Adipose tissue
- Body mass and body mass index (BMI)

and ABCA1 gene expression-fasting glucose relationship in normoglycemic men, 19

acute effects of nicotine and, 579

of acute SCI subjects, 990

adiponectin levels and, 2

β₂-ADR Arg16Gly polymorphism and, 1184, 1185

and AT distribution in Korean women, 1539, 1541

atherosclerosis and, *see* Body mass and body mass index of atherosclerotic subjects

of CAD men, *see* Body mass and body mass index of CAD men

of chronic renal disease patients, 1256
- Body mass and body mass index (BMI) (*Continued*)

CV disease risk factors and, *see* Body mass and body mass index

CV disease risk factors and

diet and, *see* Body mass and body mass index, diet and

in disabled hospitalized older subjects, HHcy and, 1018

of DM subjects, *see* Body mass and body mass index of DM subjects

of exercising subjects, *see* Body mass and body mass index, exercise and

of HD subjects, 1014

of HL-deficient subjects, 522

of hypercholesterolemic subjects, *see* Body mass and body mass index of hypercholesterolemic subjects

of hypogonadic men, 1175

of insulin-resistant subjects, *see* Body mass and body mass index of insulin-resistant subjects

of insulin-sensitive subjects, *see* Body mass and body mass index of insulin-sensitive subjects

of Japanese subjects, *see* Body mass and body mass index of Japanese subjects

of kidney transplantation recipients, 615

of LBW Pima Indians with normal glucose tolerance, 906

leptin levels and, 1412, 1413

of lipodystrophic subjects, *see* Body mass and body mass index of lipodystrophic subjects

in obesity, *see* Body mass and body mass index in obesity

plasma LDL clearance and, 484

plasma vitamin K transport and, 216

of PM women, *see* Body mass and body mass index of PM women

in postpubertal Asian Indian adolescents, 1338-1340

of pregnant subjects, *see* Body mass and body mass index of pregnant subjects

of premenopausal women, sex steroids, plasma Lp and, 189

and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1450

rhGH therapy effects on, in GH-deficient subjects, 741

and risk for metabolic syndrome and, 1505, 1506; *see also* Body mass and body mass index of MS subjects

of slightly overweight subjects, effects of L-carnitine and, 1002

of smokers, *see* Body mass and body mass index of smokers

of subclinical hypothyroidism subjects, 1513

and UCP-3 polymorphism-body composition association, 460

of Vietnamese children with apo E polymorphism and, 1519

and WPG effects on normal or mildly elevated plasma cholesterol, 1311

of young men, *see* Body mass and body mass index of young men

Body mass and body mass index (BMI), CV disease risk factors and diet and, 1437, 1438

in Kuwaiti children and adolescents, 640, 641

in NIDDM insulin-resistant overweight and normoponderal subjects, 495-498
- Body mass and body mass index (BMI), diet and

CV disease risk factors and, 1437, 1438

effects of ω-3 PUFAAs alone or combined with all-rac α-tocopherol, 237

high-fiber, low-fat diet and aerobic exercise effects in PM women on ERT and at risk for CAD, 378

and PP TG response to different nutrients, 621

PPARγ Pro12Ala polymorphism effects on dietary fat association with fasting insulin and physical activity, 13, 14

relationship between exercise, alcohol intake, and adiposity to HDL-C levels and, 704, 706

- Body mass and body mass index (BMI), diet and (*Continued*)
see also Body mass and body mass index, wine drinking and
- Body mass and body mass index (BMI), exercise and
 and apo E polymorphism association with changes in blood lipids
 and $\dot{V}O_{2\text{max}}$, 110
- in IDDM, insulin concentration and CHO requirement during
 moderate exercise, 1127
- OC effects on, 350
- of older hypertensive subjects, resistance exercise effects on, 399
- and plasma nitrate/nitrite assessment during OGTT, 675
- of PM women, *see* Body mass and body mass index of exercising
 PM women on ERT
- and PPAR γ Pro12Ala polymorphism effects on dietary fat
 association with fasting insulin and physical activity, 13, 14
- ω -3 PUFA with exercise effects on, 1366
- relationship of exercise, alcohol intake, and adiposity to HDL-C
 levels and, 704, 706
- of soccer players, 1263
- Body mass and body mass index (BMI), wine drinking and
 and acute effects of red wine drinking and food intake on vascular
 reactivity, 1082
- and red and white wine drinking effects in CAD men, 319
- Body mass and body mass index (BMI) of atherosclerotic subjects
 carotid atherosclerotic subjects, 477
- prematurely atherosclerotic subjects with normocholesterolemia
 and daytime hypertriglyceridemia, 50
- Body mass and body mass index (BMI) of CAD men
 red and white wine drinking effects on, 319
- as risk factor for myocardial infarction, 325, 326
- serum HDL-C, oxidized LDLs and, 424, 425
- Body mass and body mass index (BMI) of DM subjects
 and relation between plasma VEGF, ET-1 concentration, and
 glycemic control, 551
- see also* Body mass and body mass index of IDDM subjects;
- Body mass and body mass index of NIDDM subjects
- Body mass and body mass index (BMI) of exercising PM women on
 ERT
- or not on ERT, 1194
- in women at risk for CAD, aerobic exercise and high-fiber, low-fat diet effects, 378
- Body mass and body mass index (BMI) of hypercholesterolemic
 subjects
- of mildly hypercholesterolemic subjects, 1073
- serum LPL concentration and, 527, 528
- Body mass and body mass index (BMI) of IDDM subjects
 energy substrate oxidation and, 656
- of IDDM men, and AT as fibrinogen level predictor, 985, 986
- insulin concentration and CHO requirement during moderate
 exercise and, 1127
- of Kuwaiti IDDM children and adolescents, CV disease risk
 factors and, 640, 641
- oxidation of glycated and nonglycated LDLs and, 970
- plasma apo C-3 polymorphisms and, 1299
- Body mass and body mass index (BMI) of insulin-resistant subjects
 with cardiovascular autonomic dysfunction and microalbuminuria,
 1360, 1362
- and CV risk factors in overweight and normal weight insulin-resistant
 NIDDM subjects, 495-498
- with liver cirrhosis, 923, 924
- with LVH, 778, 779
- minimal model analysis of relationship between beta-cell function,
 IR and, 1462-1466
- plasma NEFA regulation and, 1198
- serum GPI-PLD and, 139
- Body mass and body mass index (BMI) of insulin-resistant subjects
 (*Continued*)
see also Body mass and body mass index of non-obese insulin-resistant subjects; Body mass and body mass index in obese insulin-resistant subjects
- Body mass and body mass index (BMI) of insulin-sensitive subjects
 estimates of insulin sensitivity and, 1109
- and isotretinoin effects on insulin sensitivity, 5
- Body mass and body mass index (BMI) of Japanese subjects
 with beta-cell dysfunction, 950, 952
- Japanese men, -1562C→T MMP-9 polymorphism association
 with BMD and, 136
- Japanese school-age children, ABCA1 gene polymorphism and,
 183
- with NIDDM and incipient nephropathy, 1224
- and relationship between leptin receptor gene Lys109Arg and
 Gln223Arg polymorphisms, HOMA IR index, serum soluble
 leptin receptor, serum leptin, serum adiponectin, and lipids,
 881-883
- Body mass and body mass index (BMI) of lipodystrophic subjects
 with HIV infection, 1567
- with severe lipodystrophy, 514, 515
- Body mass and body mass index (BMI) of MS subjects
 central HPA dysregulation and, 722, 723
- with CHD, 853-855
- effects of exercise on MS in PM women, 1194
- fatty acid TG content, VAT and, 312, 313
- Body mass and body mass index (BMI) of NIDDM subjects
 adiponectin, CRP and, 1456, 1457
- alcohol effects on, 78
- and association of corrected QT intervals with carotid artery IMT,
 1153, 1155
- with cardiovascular autonomic dysfunction, microalbuminuria, and
 IR, 1360, 1362
- correlation between serum PON1 polymorphism, vascular
 complications, plasma oxidized LDLs and, 299
- CV disease risk factors and, *see* Body mass and body mass index
 of NIDDM subjects, CV disease risk factors and
 and glyburide and metformin effects on NIDDM, 1332
 with IGT, 646
- insulin therapy effects on, 697, 698
- Japanese subjects, insulin secretion and insulin sensitivity and, 832
- microalbuminuria and, 354
- and Pancreas Tonic effects, 1169
- with retinopathy, 585, 586
- Body mass and body mass index (BMI) of NIDDM subjects, CV
 disease risk factors and
 in insulin-resistant overweight and normal weight subjects, 495-498
- metformin effects on, 160
- Body mass and body mass index (BMI) in non-obese insulin-resistant subjects
- in NIDDM Korean subjects, 142-146
- and preservation of circadian rhythm of serum insulin
 concentration at low plasma glucose during fasting by non-obese subjects, 1450
- Body mass and body mass index (BMI) in obese insulin-resistant subjects
- CV disease risk factors and, 495-498
- Japanese men, 651
- with IGT or normal FPG, 1096, 1097
- Body mass and body mass index (BMI) of obese PM women
 androgenicity, insulin sensitivity and, 508, 509
- fluvastatin effects on, 735, 736

- Body mass and body mass index (BMI) of obese women
 androgenicity, insulin sensitivity and, 508, 509
 effects of moderate weight loss and sibutramine or orlistat on, 432
 PM women, *see* Body mass and body mass index of obese PM women
 serum TNF soluble receptors, TNF- β , NO and, 1269
- Body mass and body mass index (BMI) in obesity
 in hyperuricemic Japanese male adolescents, 452
 with IR, *see* Body mass and body mass index in obese insulin-resistant subjects
 Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1055, 1056
 minimal model analysis of relationship between IR, beta-cell function and, 1462-1466
 with NIDDM, adiponectin and C-reactive protein and, 1456, 1457
 obese women, *see* Body mass and body mass index of obese women
 preadipocyte differentiation and proliferation and, 633, 634
 and smoking-ADMA-obesity relationship, 1575, 1576
- Body mass and body mass index (BMI) of PM women
 on ERT, *see* Body mass and body mass index of exercising PM women on ERT
 obese, *see* Body mass and body mass index of obese PM women
 sex steroids, plasma Lp and, 189
- Body mass and body mass index (BMI) of pregnant subjects
 leucine turnover and, 546
 with preeclampsia, 1434, 1435
- Body mass and body mass index (BMI) of smokers
 acute effects of nicotine and, 579
 and smoking-ADMA-obesity relationship, 1575, 1576
- Body mass and body mass index (BMI) of young men
 insulin sensitivity and, 470
 Japanese, Pro12Ala PPAR γ 2 polymorphism, adiponectin and, 1549, 1550
 serum adiponectin, HDL-C, LDL-C particle size, TGs and, 590
- Body weight (BW)
 of acute SCI subjects, 990
 and AT distribution in Korean women, 1539, 1541
 at birth, *see* Birth weight
 of children with glycoprotein PC-1 K121Q polymorphism, 467
 of chronic renal disease subjects, 1256
 diet effects on, *see* Body weight, diet effects on of early NIDDM nephropathy subjects, 1476
 of Ecuadorian Amazon Shuar women, 1356
 and erythrocyte membrane lipid composition, 574
 exercise effects on, *see* Body weight, exercise effects on gain of, *see* Weight gain
 of hyperinsulinemic subjects, *see* Body weight of hyperinsulinemic subjects
 of IGT subjects, *see* Body weight of IGT subjects
 and isotretinoin effects on insulin sensitivity and plasma TGs, 5
 of Japanese subjects with beta-cell dysfunction, 950
 of lipodystrophic subjects, leptin replacement therapy effects on, 515-516
 loss of, *see* Weight loss
 of NIDDM subjects, *see* Body weight of NIDDM subjects
 NN414 and DZ effects on, compared, 442
 NO-1886 effects on, 261
 and plasma vitamin K transport, 216
 of PM women, *see* Body weight of PM women
 responsiveness of, to 11 β -HSD inhibition by glycyrrhetic acid, 600-606
 and risk for metabolic syndrome and, 1505
 of smokers, *see* Body weight of smokers
- Body weight (BW) (*Continued*)
 and WPG effects on normal or mildly elevated plasma cholesterol, 1311
see also Non-obese subjects; Obesity; Overweight
- Body weight (BW), diet effects on
 beer ingestion and sauna bathing effects on, 774
 HF diet, *see* Body weight, HF diet effects on
 high-fiber, low-fat diet and aerobic exercise effects in PM women on ERT and at risk for CAD, 378
 high-sucrose diet effects, 23-24
 restricted diet effects, 30
see also Body weight, wine drinking and
- Body weight (BW), exercise effects on
 apo E genotype and changes in serum lipids and VO_{2max} and, 195, 198, 199
 and OC effects on glucoregulatory responses to exercise, 350
 and plasma nitrate/nitrite assessment during OGTT, 675
 with ω -3 PUFAs, 750, 1366
see also Body weight of PM women, exercise effects on
- Body weight (BW), HF diet effects on
 effects of LF versus HF diet and caloric intake, 455-456
 and intracellular Ca²⁺ chelator effects on IR and spontaneous hypertension, 270, 271
 reduced glucose transport in SM and, 913
 and skeletal muscle, 1033
- Body weight (BW), wine drinking and
 and acute effects of red wine drinking and food intake on vascular reactivity, 1082
 red and white wine drinking effects on, in CAD men, 319
- Body weight (BW) of exercising PM women on ERT
 or not on ERT, 1194
 with risk for CAD, high-fiber, low-fat diet and aerobic exercise effects on, 378
- Body weight (BW) of hyperinsulinemic subjects
 with hypertension, 1306
 young men, whole-body protein synthesis and, 389
- Body weight (BW) of IGT subjects
 IGT first-degree relatives of African American NIDDM subjects, 415, 417, 1553
 non-obese subjects, 625
- Body weight (BW) of insulin-resistant subjects
 and cilostazol effects on microalbuminuria, 1407
 obese subjects with normal FPG or IGT, 1096, 1097
- Body weight (BW) of NIDDM subjects
 and of at-risk for NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224
 insulin therapy effects on, 694, 695, 697
 obese, *see* Body weight of obese NIDDM subjects
- Body weight (BW) of obese subjects
 insulin-resistant subjects with normal FPG or IGT, 1096, 1097
 and preclinical changes in abdominal aorta of obese children, 1244
see also Body weight of obese insulin-resistant subjects; Body weight of obese NIDDM subjects; Body weight of obese women
- Body weight (BW) of obese women
 fluvastatin effects on, 735, 736

- Body weight (BW) of obese women (*Continued*)
 with NIDDM, effects of resistance exercise on glycemic control and, 285
 serum TNF soluble receptors, TNF- β , and NO and, 1269
- Body weight (BW) of PM women
 exercise and, *see* Body weight of PM women, exercise effects on hypercholesterolemic women, simvastatin effects on BMD and, 745
 obese women, fluvastatin effects on, 735, 736
- Body weight (BW) of PM women, exercise effects on
 on abdominal AT, body composition and, in PM on or not on ERT, 1192-1196
see also Body weight of exercising PM women on ERT
- Body weight (BW) of smokers
 acute effects of nicotine and, 579
 and smoking effects on intravascular remodeling of HDL particles, 860
- Bone loss, moderate exercise and soy isoflavone effects on AT accumulation and, in postmenopausal subjects, 942-948
- Bone matrix, strontium ranelate-induced mineralization of, in MC3T3-E1 osteogenic cells, 532-537
- Bone mineral content (BMC), changes in, after RYBG and ASGB for morbid obesity, 918-921
- Bone mineral density (BMD)
 -1562C \rightarrow T MMP-9 polymorphism associated with, in Japanese men, 135-137
 in obesity, *see* Bone mineral density in obesity
 in PM women, *see* Bone mineral density in PM women
 in severe lipodystrophy, leptin replacement therapy effects on, 516-517
- Bone mineral density (BMD) in obesity
 CL316,243 effects on, in polygenic obesity with NIDDM, 801 after RYBG and ASGB for morbid obesity, 920
- Bone mineral density (BMD) in PM women
 effects of moderate exercise and soy isoflavone on, 945
 in hypercholesterolemic PM women, simvastatin effects on, 744-748
- Bone mineralization
 strontium ranelate-induced bone matrix, in MC3T3-E1 osteogenic cells, 532-537
see also Bone mineral density
- Born small-for-gestational-age children, oral glucose metabolism and whole-body glucose oxidation in, 847-851
- BP, *see* Blood pressure
- Brain natriuretic peptide (BNP) in IR with LVH, candesartan effects on, 778-780
- Bread, PP TG response to, 622
- BUN (blood urea nitrogen)
 in NIDDM nephropathy, pioglitazone effects on, 1383
 in STZ-DM, effects of oral vanadate with tea extract on, 1148
- Butter, PP TG response to, 621, 622
- (+)-s-(1-(*p*-tert-Butylphenyl)-2-oxo-4-pyrrolidinyl) methoxybenzoic acid (S-2E), effects of PRV and, in mixed hyperlipidemia, compared, 680-685
- BW, *see* Body weight
- Bypass, Roux-en-Y, changes in BMC after ASGB and, for morbid obesity, 918-921
- C, *see* Cholesterol
- Ca, *see* Calcium
- Cachexia, melanoma-associated, ghrelin mRNA in, 84-88
- CAD, *see* Coronary artery disease
- Caffeine, effects of, on alveolar macrophages via its effects on synthesis of cAMP and prostaglandin, 687-692
- Calcium (Ca)
 in adrenal insufficiency, 1252
 serum, in severe lipodystrophy, leptin replacement therapy effects on, 516
see also Eucalcemia and entries beginning with term: Calcium
- Calcium channel blockers (CCBs), effects of dihydropyridine, on microalbuminuric NIDDM, 354
- Calcium (Ca)-dependent rebaudioside A, effects on insulin secretion, 1378-1381
- Calcium $^{2+}$ (Ca^{2+}), primary hyperthyroidism and, 1102
- Calcium $^{2+}$ (Ca^{2+}) chelator, effects of intracellular, on IR and in spontaneous hypertension subjects on high-fat diet, 269-272
- Caloric intake
 CV disease risk factors and, 1439
 effects of leptin replacement therapy and, in severe lipodystrophy, 515
 with obesity-inducing diet, 783
 role of HF and/or LF diet and, in NIDDM and obesity development, 454-457
- and UCP-3 polymorphism-body composition association, 461
see also Diet
- cAMP (cyclic adenosine monophosphate)
 effects of caffeine on alveolar macrophages via its effects on synthesis of prostaglandin and, 687-692
- low temperature blocking testosterone production and stimulatory effects of hCG on steroidogenic acute regulatory protein mRNA but not on production of, in tumor cells, 955-958
- Candesartan, effects of, on LVH and IR, 777-781
- Carbohydrate(s) (CHO)
 oxidation of, during exercise at cold temperature, 204, 205
see also Carbohydrate intake and specific carbohydrates
- Carbohydrate (CHO) intake
 insulin concentration and requirement in, by IDDM subjects during moderate exercise, 1126-1130
 with obesity-inducing diet, 783
 and plasma ADMA in mild hypercholesterolemia, 1073, 1074
 PP TG response to, 620-623
 by prematurely atherosclerotic normocholesterolemic and daytime hypertriglyceridemic subjects, 51
 and risk for metabolic syndrome, 1505-1506, 1508
 by Vietnamese children, apo E polymorphism and, 1519
- Carboxykinase, hepatic phosphoenolpyruvate, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841
- Carboxylase, acetyl-coenzyme A, upregulation of mRNA of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- β (beta)-Carboxy terminal telopeptide of type I collagen in adrenal insufficiency, 1252
- Cardiac fibroblasts, high glucose and insulin effects on DNA and collagen synthesis in, 710-715
- Cardiac function in prediabetic subjects, 1391-1394
- Cardiac myocytes, high glucose and insulin effects on protein synthesis in, 710-715
- Cardiac protein, effects of galactosamine-induced liver disease and bile duct ligation on synthesis of, 964-968
- Cardiorespiratory fitness, contribution of visceral AT and, to hyperinsulinemia, dyslipidemia, and hypertension in IGT NIDDM subjects, 644-649
- Cardiovascular autonomic dysfunction, microalbuminuria, IR and, in NIDDM, 1359-1364
- Cardiovascular disease, *see* Risk factors for CV disease
- L-Carnitine, effects of, on fat oxidation, protein turnover, and body composition in slightly overweight subjects, 1001-1006

- Carotene, association between lifestyle, plasma CRPs, CV disease risk factors, and intake of, 1439
- Carotid artery(ies)
 effects of elevated plasma Hcy on endothelial function recovery after denudation of, 760-765
 see also Carotid artery intimal-media thickness; Carotid atherosclerosis
- Carotid artery intimal-media thickness (IMT)
 in NIDDM, associated of corrected QT intervals with, 1152-1157
 in NIDDM nephropathy, pioglitazone effects on arterial stiffness and, 1382-1386
- Carotid atherosclerosis, sdLDLs, vascular dementia and, 476-482
- Casein in obesity-inducing HF diet, 783
- Cataracts in STZ-DM, effects of oral vanadate with tea extract on, 1145-1151
- Catecholamines
 pramlintide effects on response of glucagon and, and symptoms of hypoglycemia, 1227-1232
 see also Epinephrine; Norepinephrine
- CBS (cystathione- β -synthase) deficiency, betaine effects on, 594-599
- CCBs (calcium channel blockers), effects of dihydropyridine, on microalbuminuria NIDDM, 354
- CD4 $^{+}$ (and CD8 $^{+}$) T lymphocytes, activated, emergence of growth factor receptors in, 117-122
- CDCA, *see* Chenodeoxycholic acid
- Cell differentiation, adipocyte precursor, from omental and subcutaneous AT of obese subjects, compared, 632-637
- Cell proliferation
 adipocyte precursor, from omental and subcutaneous AT of obese subjects, compared, 632-637
 in head and neck squamous cell carcinoma, effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-trans retinoic acid and, 1007-1012
- Cellular retinoic acid binding protein-1 (CRABP-1) mRNA (messenger ribonucleic acid), effects of, on CYP26-mediated catabolism of A11-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
- Cellulose in HF diet, 783, 1033
- Central hypothalamic-pituitary-adrenal axis (HPA), CRH test of relation between MS and dysregulation of, 720-726
- Central (luteinizing hormone) hypothesis of PCOS, 359-361
- Cerebral vascular disease in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Cerebrotendinous xanthomatosis (CTX), effectiveness of chenodeoxycholic acid, hydrophilic 7-hydroxy bile acids, lovastatin, and cholestyramine in, compared, 556-562
- Ceruloplasmin, plasma, and effects of Cu enzymes on CF before and after Cu supplementation with or without zinc, 37-41
- CETP, *see* Cholesteryl ester transfer protein
- CF, *see* Cystic fibrosis
- CHD, *see* Coronary heart disease
- Chemoattractant protein-1, *see* Monocyte chemoattractant protein-1
- Chenodeoxycholic acid (CDCA)
 effectiveness of hydrophilic 7 β -hydroxy bile acids, lovastatin, and cholestyramine in CTX, compared, 556-562
 effects of, on 11 β -hydroxysteroid dehydrogenase in various tissues, 811-816
- Children
 born small-for-gestational-age, oral glucose metabolism and whole-body glucose oxidation in, 847-851
 obese, preclinical changes in abdominal aorta of, 1243-1246
 see also Newborns; Race and ethnicity of children
- D-Chiro-inositol for obese PCOS women, 369-370
- Chloride, serum, beer ingestion and sauna bathing effects on urinary excretion of, 774
- CHO(s), *see* Carbohydrate(s)
- Cholestanol, plasma, in CTX, 558
- Cholesterol (C)
 blood, *see* Blood cholesterol
 in CAD men, as risk factor for myocardial infarction and, 325, 326
 CV disease risk factors and, 1438
 dietary, *see* Dietary cholesterol
 erythrocyte membrane, 574
 and glycemic control effects on F₂ isoprostanate level at IDDM onset, 1119
 and GSK-3 β in transgenic subjects, 1328
 in HD subjects, 1014
 in IR, serum GPI-PLD and, 139
 MHN-01 effects on concentration of, 981
 in NIDDM, *see* Cholesterol in NIDDM
 in obesity, adiponectin, CRP and, 1456, 1457
 plasma, *see* Plasma cholesterol
 ω -3 PUFA and exercise effects on, 751
 serum, *see* Serum cholesterol
 smoking effects on, 860
 in soccer players, 1262-1267
 in STZ-DM, *see* Cholesterol in STZ-DM
 total, *see* Total cholesterol
 in young men with hypertensive parents, 470, 473
 see also Cholesterol acyltransferase; Cholesterol 7 α -hydroxylase; Cholesteryl ester transfer protein; High-density lipoprotein-cholesterol; Hypercholesterolemia; Intermediate-density lipoprotein-cholesterol; Low-density lipoprotein-cholesterol; Normocholesterolemia; Reverse cholesterol transport; Very low-density lipoprotein-cholesterol
- Cholesterol (C) acyltransferase
 role of cholesterol absorption and activity of hepatic acyl-coenzyme A; in lipemic response to HF/HC diet, 817-822
 see also Lecithin:cholesterol acyltransferase
- Cholesterol 7 α -hydroxylase (CYP7A1), effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932
- Cholesterol (C) in NIDDM
 with dyslipidemia, rosiglitazone effects on, 1123
 in obese subjects, adiponectin and C-reactive protein and, 1456, 1457
 PP, alcohol effects on, 78, 79
- Cholesterol (C) in STZ-DM
 effects of oral vanadate with tea extract on, 1148
 NO-1886 effects on, 261
- Cholesteryl ester transfer protein (CETP)
 plasma, smoking effects on concentration of, 858-862
 see also Cholesteryl ester transfer protein, ω -3 PUFA effects on
- Cholesteryl ester transfer protein (CETP), ω -3 PUFA effects on in FCHL, 155
 and on LDL and HDL subfractions, 752
- Cholestyramine, effectiveness of hydrophilic 7-hydroxy bile acids, lovastatin, and chenodeoxycholic acid in CTX, compared, 556-562
- Choline bitartrate in obesity-inducing HF diet, 783
- Choline in HF diet, 1033
- Cholinophosphotransferase (CHPT) mRNA (messenger ribonucleic acid), renal, in NIDDM, 842-846

- Chorionic gonadotropin, human, low temperature blocking stimulatory effects of, on steroidogenic acute regulatory protein mRNA and testosterone production but not on cAMP production in tumor cells, 955-958
- CHPT (cholinephosphotransferase) mRNA (messenger ribonucleic acid), renal, in NIDDM, 842-846
- Chronic disease, inflammatory markers in inflammation of, 899-903
- Chronic renal disease with obesity and MS, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
- Chronic renal failure (CRF)
atorvastatin effects on lipids, LDLs, and CRPs in dyslipidemic CRF subjects on HD, 1113-1117
upregulation of lipogenic enzyme and SREBP-1 mRNA in WAT of subjects with, 1060-1065
- Chylomicrons in IDDM, plasma apo C-3 polymorphisms and, 1299, 1301
- Cilostazol, effects of, on microalbuminuria in IR, 1405-1410
- Circadian rhythm
of leptin after weight loss to reduce HF diet-induced obesity, leptin therapy to augment, 782-789
of serum insulin concentration at low plasma glucose during fasting by lean and overweight subjects, 1449-1453
- Circulating adrenocorticotropin (ACTH; corticotropin), cortisol concentrations and, in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis, 209-214
- Circulating blood cells, effects of, on atherosclerosis in apo E-deficient subjects, 95-100
- Circulating cell adhesion molecules, and LDL susceptibility to oxidation in young Japanese subjects with NIDDM parents, 755-759
- Circulating inflammation-sensitive molecules in men with CAD, acute effects of red and white wine drinking on, 318-323
- Circulating leptin, as marker of fat mass in acute spinal cord injury, 989-994
- Cirrhosis
DCA-induced hypolactatemia in, 1087-1094
serum soluble TNF-R level associated with IR in, 922-926
- Citrate lyase, *see* Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA
- Citrulline, plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- CK (creatinine kinase) in dyslipidemic CRF subjects on HD, 1116
- CL (citrate lyase), role of adenosine triphosphate-, in platelet acetyl-CoA metabolism and function in DM, 66-72
- CL316,243, effects of, on development of diabesity, 799-808
- Clinical manifestations
of PCOS in obese and non-obese women, 365-367
see also specific conditions
- Coenzyme A, *see* Acetyl-coenzyme A; Acetyl-coenzyme A carboxylase mRNA; Hepatic acyl-coenzyme A:cholesterol acyltransferase
- Cold temperature, *see* Exercise at cold temperature, NEFA oxidation during
- Collagen
high glucose and insulin effects on synthesis of, in cardiac fibroblasts, 710-715
and SR effects on bone matrix mineralization in MC3T3-E1 osteogenic cells, 533
- Collagen (α_1) IV, expression of renal, in IR, cilostazol effects on, 1405-1410
- Collagen type 1, aminoterminal propeptide in adrenal insufficiency, 1252
- Collard greens, deuterium-labeled, plasma vitamin K transport and intake of, by men, 215-221
- Collecting duct, inner medullary, ET effects on AVP₂ mRNA in, 1177-1183
- Combined hyperlipidemia, familial, ω -3 PUFA effects on levels of plasma HDL₂-C and paraoxonase in, 153-158
- Conscious subjects
effects of hyperglycemia, glucagon, and epinephrine on renal glucose release in, 933-941
portal venous hyperinsulinemia effects on gut glucose absorption in, 1290-1295
- Contraceptives, *see* Oral contraceptives
- Contractile protein, breakdown of skeletal muscle, [²H]-3-methylhistidine estimation of, 1076-1080
- Copper (Cu), effects of micromolar concentrations of, on endothelium-dependent aorta relaxation in DM, 1315-1321
- Copper (Cu) enzymes, effects of, on CF before and after Cu supplementation with or without zinc, 37-41
- Cord blood platelets, relationship between intracellular magnesium of, and birth weight, 1544-1547
- Cornstarch in obesity-inducing HF diet, 783
- Coronary artery disease (CAD)
effects of exercise and high-fiber, low-fat diet on inflammatory and adhesion molecules in PM women on ERT and at risk for, 377-381
in men, *see* Coronary artery disease in men
see also Atherosclerosis
- Coronary artery disease (CAD) in men, 318-329
acute effects of red and white wine drinking on circulating inflammation-sensitive molecules in, 318-323
risk factors for myocardial infarction as predictors of, 324-329
serum HDL-C level effects on association between plasma oxidized LDLs and, 423-429
- Coronary flow in early DM, effects of C-peptide and insulin on, 335-339
- Coronary heart disease (CHD)
high plasma HDL-C level in Spanish children, and low CHD mortality in Spain, 1045-1047
low-grade inflammation and MS with, 852-857
see also Coronary heart disease in NIDDM
- Coronary heart disease (CHD) in NIDDM
with IGT, contribution of visceral AT and cardiorespiratory fitness to risk factors for, 644-649
serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Corrected QT intervals, association of carotid artery IMT with, in NIDDM, 1152-1157
- Cortex, *see* Renal cortex
- Corticosterone
leptin effects on, in STZ-DM, 1560
plasma, effects of 11 β -HSD inhibition by glycyrrhetic acid on, 602, 604
- Corticotropin, *see* Adrenocorticotropin hormone
- Corticotropin-releasing hormone (CRH) test of relation between central HPA dysregulation, MS and, 720-726
- Cortisol (hydrocortisone)
acute effects of nicotine on, 578-582
adrenal androgens and, in PCOS, 361
circulating ACTH and concentrations of, in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis and, 209-214
in hypoglycemia, 895
in IR, 722
in men, *see* Cortisol in men

- Cortisol (hydrocortisone) (*Continued*)
 plasma, in adrenocortical disorders, 89-94
 response of, to exercise in nondiabetic and IDDM smokers, 1142
- Cortisol (hydrocortisone) in men
 with hypogonadism, 1174-1176
- obese men, NEFA effects on levels of, 892
- COX (cyclooxygenase), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 174-181
- CP, *see* C-peptide
- C-peptide (CP)
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090
 in DM, *see* C-peptide in DM
 fasting, *see* Fasting C-peptide
 in IGT first-degree relatives of obese African American NIDDM subjects, 415
 and IR in liver cirrhosis, 923
 in obese men, NEFA effects on levels of, 892
- C-peptide (CP) in DM
 effects of insulin and, on coronary flow in early DM, 335-339
see also C-peptide in NIDDM
- C-peptide (CP) in NIDDM
 glyburide and nateglinide effects on NIDDM and, 1332
 in older NIDDM men with partial androgen deficiency, 670
- CRABP-1 (cellular retinoic acid binding protein-1) mRNA
 (messenger ribonucleic acid), effects of, on CYP26-mediated catabolism of A11-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
- C-reactive protein (CRP)
 adiponectin and, *see* Adiponectin, CRP and
 atorvastatin effects on lipids, LDLs and, in dyslipidemic CRF subjects on HD, 1113-1117
 in CHD, 853, 854
 effects of α -3 PUFAs alone or with all-rac α -tocopherol on, 236-240
 in hypothyroidism, *see* C-reactive protein in hypothyroidism
 in inflammation of chronic disease, 901, 902
 in NIDDM, *see* C-reactive protein in NIDDM
 in non-obese men, and AT as predictor of fibrinogen level, 985, 986
 in obesity, *see* C-reactive protein in obesity
 plasma, association between lifestyle, cardiovascular risk factors and, 1436-1442
 PP, OC effects on, 350, 351
 serum, *see* Serum C-reactive protein
- C-reactive protein (CRP) in hypothyroidism
 effects of T₄ therapy on endothelial function and, 279
 subclinical hypothyroidism, CV disease risk factors and, 1513
- C-reactive protein (CRP) in NIDDM
 and in at-risk NIDDM subjects, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 224, 226
 and effects of insulin therapy of NIDDM on serum high-sensitivity, 693-699
- C-reactive protein (CRP) in obesity
 obese children, 1244
 obese women, effects of moderate weight loss and sibutramine or orlistat on, 432
see also C-reactive protein in obesity, weight loss effects and
- C-reactive protein (CRP) in obesity, weight loss effects and
 effects of moderate weight loss and sibutramine or orlistat by obese women and, 432
 weight loss effects on IR and insulin release in obese subjects with normal FPG or IGT, 1097
- Creatinine
 and ABCA1 gene expression-fasting glucose relationship in normoglycemic men, 19
 beer ingestion and sauna bathing effects on, 773-774
 in chronic renal disease, 1256
 in disabled hospitalized older subjects, HHcy and, 1018
 and IR, *see* Creatinine in IR
 in NIDDM, *see* Creatinine in NIDDM
 serum, *see* Serum creatinine
 in severe lipodystrophy, leptin replacement therapy effects on, 516
 and smoking-ADMA-obesity relationship, 1575, 1576
 in STZ-DM, effects of oral vanadate with tea extract on, 1148
 in subclinical hypothyroidism, 1513
- Creatinine in IR
 with cardiovascular autonomic dysfunction, microalbuminuria, 1360, 1362
 and cilostazol effects on microalbuminuria, 1407
 with liver cirrhosis, 923
- Creatinine kinase (CK) in dyslipidemic CRF subjects on HD, 1116
- Creatinine in NIDDM
 and at-risk subjects for NIDDM, water diuresis-induced changes in renal cortex oxygenation and endothelial function and, 226
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362
 effects of glycemic control of NIDDM on, 353-357
- CRF, *see* Chronic renal failure
- CRH (corticotropin-releasing hormone) test of relation between central HPA dysregulation and MS, 720-726
- CRP, *see* C-reactive protein
- CS-045, *see* Troglitazone
- CTX (cerebrotendinous xanthomatosis), effectiveness of chenodeoxycholic acid, hydrophilic 7 β -hydroxy bile acids, lovastatin, and cholestyramine in, compared, 556-562
- Cu, *see* Copper; Copper enzymes
- Cyclic adenosine monophosphate, *see* cAMP
- Cyclooxygenase (COX), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 174-181
- CYP7A1 (cholesterol 7-hydroxylase), effects of ileal bile transport inhibition on plasma C level through FXR inactivation and stimulation of, 927-932
- CYP17 genes, mutant, in 17(α)-hydroxylase/17,20-lipoxygenase deficiency, 1527-1531
- CYP26-mediated catabolism of A11-trans retinoic acid, CRABP-1 effects on cell proliferation in head and neck squamous cell carcinoma and, 1007-1012
- Cystathione- β -synthase (CBS) deficiency, betaine effects in, 594-599
- Cystic fibrosis (CF)
 adult, effects of Cu enzymes in, before and after Cu supplementation with or without zinc, 37-41
 with impaired glucose tolerance, insulin regulating kinetics of NEFAs in, 1467-1472
- L-Cystine in obesity-inducing HF diet, 783
- Daytime hypertriglyceridemia (HTG) in normocholesterolemic and prematurely atherosclerotic subjects and in their first-degree relatives, 49-53
- Daytime hypoglycemia, differences in counterregulation of nighttime and, 894-898
- DCA (dichloroacetate), hypolactatemia induced by, in cirrhotic and noncirrhotic subjects, 1087-1094
- D-CCBs (dihydropyridine calcium channel blockers) in NIDDM, effects of, on microalbuminuria, 354
- Deaminase, adenosine, interaction between ACPI polymorphism and, in NIDDM, 995-1001

- Dehydroepiandrosterone sulfate (DHEA-S)**
 in premenopausal women, plasma Lp and, 189, 190
see also Dehydroepiandrosterone sulfate in PM women
- Dehydroepiandrosterone sulfate (DHEA-S) in PM women**
 in insulin-sensitive women, 508-509
 plasma Lp and, 189, 190
- Dehydrogenase**
 lactate, glutamate, and pyruvate, DM effects on, 68
see also Glucose-6-phosphate dehydrogenase mRNA; 6-
 Phosphogluconate-dehydrogenase mRNA and entries
beginning with terms: 11 β -Hydroxysteroid dehydrogenase
- Delayed vasorelaxation by troglitazone, 4AP effects on,** 147-152
- Dementia, vascular, sdLDLs, carotid atherosclerosis and,** 476-482
- Dense low-density lipoprotein, *see* Small-dense low-density lipoprotein**
- Denudation of carotid arteries, effects of elevated plasma Hey on endothelial function recovery after,** 760-765
- Deoxypyridinol, urinary excretion of, in severe lipodystrophy, leptin replacement therapy effects on,** 516
- Deoxyribonucleic acid, *see* DNA synthesis in fibroblasts**
- Deuterium-labeled collard greens, plasma vitamin K transport and intake of, by men,** 215-221
- Dextrin**
 maltose, in obesity-inducing HF diet, 783
 in MNH-01 formula, 978
- DHEA-S, *see* Dehydroepiandrosterone sulfate**
- Diabesity (maturity-onset hyperinsulinemia and hyperglycemia), CL316,243 effects on, in polygenic obesity,** 799-808
- Diabetes mellitus (DM)**
 β_3 -ADR Trp64Arg polymorphism in Taiwanese women with gestational, 1136-1139
 in CAD men, 424-426
 early, effects of C-peptide and insulin on coronary flow in, 335-339
 effects of exercise on hepatic insulin signaling and hepatic PEPCK activity in subjects prone to, 836-841
 effects of micromolar copper concentrations on aorta endothelium-dependent relaxation in, 1315-1321
 serum leptin, serum adiponectin, and serum soluble leptin receptor levels in Japanese subjects with, 880, 881
 stability over time of GHb, glucose, and RBC survival in hematologically stable subjects without, 1399-1403
see also Diabesity; Glycemic control of DM; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Parental diabetes mellitus; Prediabetic subjects; Streptozotocin-induced diabetes mellitus and entries
beginning with term: Diabetic
- Diabetic microangiopathies in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and,** 300
- Diabetic nephropathy, *see* Non-insulin-dependent diabetes mellitus nephropathy**
- Diabetic retinopathy, *see* Non-insulin-dependent diabetes mellitus retinopathy**
- Dialysis, *see* Hemodialyzed subjects**
- Diamine oxidase, plasma, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on,** 37-41
- Diastolic pressure, *see* Blood pressure**
- Diazoxide (DZ), effects of NN414 and, on glucose tolerance and lipids in obesity, compared,** 441-447
- Dichloroacetate (DCA), hypolactatemia induced by, in cirrhotic and noncirrhotic subjects,** 1087-1094
- Diet**
 association between lifestyle, cardiovascular risk factors, plasma CRPs and, 1436-1442
- Diet (Continued)**
 composition of, as determinant of ADMA in mild hypercholesterolemia, 1072-1075; *see also specific food groups and dietary substances*
see also Caloric intake; Drinking; Dysphagia; Energy intake; Fasting; Food intake; Total parenteral nutrition and entries
beginning with terms: Dietary, Postprandial
- Dietary carbohydrates, *see* Carbohydrate intake**
- Dietary cholesterol (C)**
 CV disease risk factors and, 1438
 intake by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51
 plasma 27-hydroxycholesterol and plasma 7 α -hydroxy-4-cholest-3-one as markers for hepatic bile synthesis and, 42-48
see also High-cholesterol diet
- Dietary fat**
 apo E polymorphism in Vietnamese children and intake of, 1519
 L-carnitine effects on protein turnover, body composition and, in slightly overweight subjects, 1001-1006
 CV disease risk factors and intake of, 1439
 PPAR γ Pro12Ala polymorphism effects on association of exercise and, with fasting insulin level, 11-16
 uncoupling protein-3 polymorphism and intake of, 460, 461
 WPG and, 1312
see also Fatty acid(s); High-fat diet; Low-fat diet and specific types of dietary fats
- Dietary fiber, *see* Fiber**
- Dietary oils, *see* specific dietary oils**
- Dietary proline (Pro) with and without glucose, metabolic response to,** 241-246
- Dietary protein intake**
 apo E polymorphism and, by Vietnamese children, 1519
 effects of, on whole-body protein synthesis in hyperinsulinemic young men, 389
 with HF diet, 783, 1033
 in MNH-01 formula, 978
 by normocholesterolemic prematurely atherosclerotic subjects with daytime hypertriglyceridemia and by their first-degree relatives, 51
 plasma ADMA in mild hypercholesterolemia and, 1073
 restricted, effects of, on proteasome production in skeletal muscle, 340-347
- Dietary restriction**
 effects of, on PPAR γ and glucocorticoid receptor signaling in AT, 28-36
 effects of protein, on proteasome production in skeletal muscle, 340-347
 of zinc, effects of, on metabolic rate and substrate utilization, 727-732
- Differentiation, proliferation and, of adipocyte precursor cells from omental and subcutaneous AT of obese subjects, compared,** 632-637
- Dihydropyridine calcium channel blockers (D-CCBs) in NIDDM, effects of, on microalbuminuria,** 354
- 3,3'-Diiodothyronine sulfate (3,3'-T₂S) in thyroidal diseases, nonthyroidal diseases, pregnancy, and fetal/neonatal life,** 538-543
- Dimethylarginine, *see* Asymmetric dimethylarginine**
- Dimethyl-BAPTA/AM [bis(o-aminophenoxyethane-N,N',N')**
 tetraacetic acetoxyethyl ester], effects of, on IR and spontaneous hypertension, high-fat diet and, 269-272
- Dimethylbiguanide, *see* Metformin**

- Dimethylsulfonylacetate (DMSA), effects of, in cystathione- β -synthase deficiency, 594-599
- Dipeptidylpeptidase (DPP) IV, effects of Lys⁹-for-Glu⁹ substitution in GLP-1(7-36) amide on resistance of, with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Disabled older subjects, hospitalized, HHcy in, 1016-1020
- Dismutase, erythrocyte superoxide, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Distress, respiratory, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with sepsis and, 209-214
- Diuresis, changes in renal cortex oxygenation and endothelial function induced by water in NIDDM and in at-risk for NIDDM subjects, 222-227
- DM, *see* Diabetes mellitus
- DMSA (dimethylsulfonylacetate), effects of, in cystathione- β -synthase deficiency, 594-599
- DNA (deoxyribonucleic acid) synthesis in fibroblasts in cardiac fibroblasts, high glucose and insulin effects on collagen, 710-715
and myocytes, 128-133
- Dose-dependent rebaudioside A, effects of, on insulin secretion, 1378-1381
- DPP (dipeptidylpeptidase) IV, effects of Lys⁹-for-Glu⁹ substitution in GLP-1(7-36) amide on resistance of, with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Drinking
effects of sauna bathing and beer, on plasma concentration of purine bases, 772-776
see also Alcohol intake; Wine drinking
- Dyslipidemia
PFPS-410 effects on, 1532-1537
see also Dyslipidemia in NIDDM; Hypercholesterolemia; Hyperlipidemia; Hypertriglyceridemia
- Dyslipidemia in NIDDM
with IGT, contribution of cardiorespiratory fitness and visceral AT to hyperinsulinemia, hypertension and, 644-649
rosiglitazone effects on insulin regulation in, 1121-1125
- Dysphagia, leptin effects on HPA axis activity, weight loss and, in STZ-DM, 1558-1564
- DZ (diazoxide), effects of NN414 and, on glucose tolerance and lipids in obesity, compared, 441-447
- E₂, *see* Estradiol
- Early diabetes mellitus (DM), C-peptide and insulin effects on coronary flow in, 335-339
- Early non-insulin-dependent diabetes mellitus (NIDDM)
nephropathy, pioglitazone effects on, 1473-1479
- Early-onset non-insulin-dependent diabetes mellitus (NIDDM), triple mutations of HNF-4 α gene associated with, in Filipino family, 959-963
- ECs (endothelial cells) in omental and subcutaneous AT in obese subjects, compared, 635
- Ecuadorian Amazon Shuar women, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358
- EFA, *see* Essential fatty acids
- Elaeic acid, effects of, on Sp1-induced apo A-1 promoter, 1344
- Elderly subjects, *see* Older subjects
- Endometrial cancer, risk for, in obese PCOS women, 366
- Endothelial cells (ECs) in omental and subcutaneous AT in obese subjects, compared, 635
- Endothelial function
effects of elevated plasma Hcy on recovery of, after denudation of carotid arteries, 760-765
effects of thyroxine therapy of hypothyroidism on, 278-279
fluvastatin effects on, in obese PM women via sdLDL reduction, 733-739
water diuresis-induced changes in renal cortex oxygenation and, in NIDDM and in at-risk for NIDDM subjects, 222-227
- Endothelial growth factor, plasma vascular, relation between concentration of plasma VEGF, glycemic control and, in DM, 550-555
- Endothelial nitric oxide synthase (eNOS) in early NIDDM nephropathy, 1474
- Endothelin (ET)
effects of, on AVP₂ mRNA in IMCD, 1177-1183
plasma, relation between concentration of plasma VEGF, glycemic control and, in DM, 550-555
- Endothelin-1 (ET-1)
high glucose and insulin effects on expression of, in cardiac fibroblasts, 712
in NIDDM and in at-risk for NIDDM subjects, 224, 226
- Endothelium-dependent relaxation of aorta in DM, effects of micromolar copper concentrations on, 1315-1321
- Endurance exercise
apo E genotype and changes in serum lipids and $\dot{V}O_{2\max}$ during, 193-202
plasma nitrate/nitrite assessment during OGTT in sedentary subjects after, 673-679
- Energy expenditure
in endurance training, $\dot{V}O_{2\max}$ and, 195
see also Resting energy expenditure
- Energy intake
with HF diet, 1033
by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51
by Vietnamese children, apo E polymorphism and, 1519
WPG and, 1312
see also Diet
- Energy substrate oxidation in IDDM, 655-659
- eNOS (endothelial nitric oxide synthase) in early NIDDM nephropathy, 1474
- Epidemiology of PCOS, 358-359
- Epinephrine (adrenaline)
effects of glucagon, hyperglycemia and, on renal glucose release in conscious subjects, 933-941
effects of ionomycin and, on skeletal muscle IL-6 mRNA and protein release, compared, 1492-1495
nighttime and daytime differences in counterregulation of hypoglycemia and, 895
in obese men, NEFA effects on levels of, 892
plasma, leptin effects on, in STZ-DM, 1560
- ERT (estrogen replacement therapy), *see* Postmenopausal women on ERT, exercise effects in
- Erythrocyte(s) (red blood cell; RBC)
stability over time of GHb, glucose, and survival of, in hematologically stable subjects without DM, 1399-1403
WPG effects on, 1312
see also Erythrocyte magnesium; Erythrocyte membrane, lipid composition of; Erythrocyte superoxide dismutase
- Erythrocyte (red blood cell; RBC) folate in subclinical hypothyroidism, 1513
- Erythrocyte (red blood cell; RBC) magnesium (Mg), levels of, and Mg metabolism, 660-665

- Erythrocyte (red blood cell; RBC) membrane, lipid composition of associated with arachidonic acid in men, insulin sensitivity and, 571-577
 in NIDDM, HbA_{1c} correlation with, 123-127
- Erythrocyte (red blood cell; RBC) superoxide dismutase (SOD), effects of Cu enzymes in CF before and after Cu supplementation with or without zinc, 37-41
- Essential fatty acids (EFA), regulation of serum lipids deficient in, in short-gut subjects on lipid-containing total parenteral nutrition, 273-277
see also Arachidonic acid; Linoleic acid; γ -Linoleic acid; 3n₃ α -Linolenic acid
- Established preeclampsia, IR and inflammation in, 1433-1435
- Estradiol (E₂), carotid atherosclerosis, vascular dementia and, 477
 in PM and premenopausal women, plasma Lp and, 189
- Estrogen, in PCOS, 361-362
 and role of androgens in estrogen-deficient state, 187-192
- Estrogen receptor modulators, effects of selective, on GH secretion, 563-570
- Estrogen replacement therapy, *see* Postmenopausal women on ERT, exercise effects in
- Estrone in PM and premenopausal women, plasma Lp and, 189
- Estrous cycle, Lp during, 140-141
- ET, *see* Endothelin
- ET-1, *see* Endothelin-1
- Ethanol, *see* Alcohol
- Eucalcemia, serum PTH relation to vitamin D profile in, after parathyroidectomy for primary hyperthyroidism, 1101-1106
- Evening primrose oil (PO), effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- Exendin (9-39), effects of Lys⁹-for-Glu⁹ substitution in GLP-1(7-36) amide on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and, 252-259
- Exercise at cold temperature, *see* Exercise at cold temperature, NEFA oxidation during
- endurance, *see* Endurance exercise
- moderate, *see* Moderate exercise
- by nondiabetic and IDDM smokers, pituitary response to, 1140-1144
- OC effects on glucoregulatory responses to, 348-352
- $\dot{V}O_{2\text{max}}$ during, *see* $\dot{V}O_{2\text{max}}$ during exercise
see also Exercise, effects of; Physical activity
- Exercise, effects of
- on cholesterol efflux in soccer players, 1262-1267
- on glycogen synthase activity and GLUT₄ mRNA but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
- hypoxic, on hepatic 8-OHdG and GSH levels, 716-719
- on inhibitory effects of NE on insulin secretion, 1424-1432
- on PP lipemia after high-fat/high-cholesterol meal, 1021-1026
- on risk for metabolic syndrome, 1505, 1508
- of swimming exercise on hepatic glucose production in response to glucagon, 1027-1031
- see also* Exercise, effects of diet and; Postmenopausal women on ERT, exercise effects in; Resistance exercise effects
- Exercise, effects of diet and
- of dietary fat association with fasting insulin level and, Pro12Ala polymorphism of PPAR γ on, 11-16
- effects of soy isoflavone with, on AT accumulation and bone loss in postmenopausal subjects, 942-948
- Exercise, effects of diet and (*Continued*)
- on hepatic insulin signaling and hepatic PEPCK activity in diabetes-prone subjects, 836-841
- of high-fiber/low-fat diet and exercise, inflammatory and adhesion molecules in postmenopausal women on ERT and at-risk for CAD, 377-381
- moderate exercise and soy isoflavone effects on AT accumulation and bone loss in PM subjects, 942-948; *see also* Postmenopausal women, effects of diet with exercise in; Postmenopausal women on ERT, exercise effects in
- on PP lipemia after high-fat/high-cholesterol meal, 1021-1026
- relationship between alcohol intake, adiposity and, on HDL-C levels, 700-709
- see also* Exercise, effects of ω -3 PUFAs with
- Exercise, effects of ω -3 PUFAs with
- on LDL and HDL subfractions, 749-754
- on postprandial lipemia, 1365-1371
- Exercise at cold temperature, NEFA oxidation during acipimox-induced plasma NEFA oxidation, 1131-1136 and substrate oxidation, 203-208
- Exogenous insulin, *see* Insulin therapy
- Exposure, long-term, to *cis* and *trans* FAs, on insulin secretion and FA oxidation in INS-1 cells, 1158-1165
- F, *see* Fructose
- F₂ isoprostanate, effects of glycemic control on level of, at IDDM onset, 1118-1120
- FA(s), *see* Fatty acid(s)
- FABP4 (fatty acid-binding protein-4) polymorphism, effects of interaction between PPAR γ -activated receptor polymorphism and, on insulin sensitivity and body composition in men, 303-309
- Factor VII in young subjects with NIDDM parents, 756
- Familial combined hyperlipidemia (FCHL), ω -3 PUFA effects on levels of plasma HDL₂-C and paraoxonase in, 153-158
- Familial early-onset non-insulin-dependent diabetes mellitus (NIDDM), triple mutations of HNF-4 α gene in Filipino family, 959-963
- Familial hypercholesterolemia, effects of S-2E and PRV in, compared, 680-685
- Farnesoid X receptor (FXR), hepatic, effects of ileal bile transport inhibition on plasma C level through cholesterol 7 α -hydroxylase stimulation and inactivation of, 927-932
- FAS (fatty acid synthase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Fasting
- by non-obese and overweight subjects, preservation of circadian rhythm of serum insulin concentration at low plasma glucose during, 1449-1453
- pinealectomy effects on AT adaptability to, 500-506
- in preeclampsia, 1434
see also entries beginning with term: Fasting
- Fasting adiponectin in insulin-resistant obese women, effects of moderate weight loss on, 281
- Fasting blood glucose (FBG)
- in adolescents, *see* Fasting blood glucose in adolescents
- in GH-deficient subjects, rhGH therapy effects on, 741
- in Korean women, AT distribution and, 1541
- in Kuwaiti IDDM children, CV disease risk factors and, 640
- in NIDDM, *see* Fasting blood glucose in NIDDM
- in obesity, *see* Fasting blood glucose in obesity
- Fasting blood glucose (FBG) in adolescents
- Kuwaiti IDDM adolescents, CV disease risk factors and, 640

- Fasting blood glucose (FBG) in adolescents (*Continued*)
 postpubertal Asian Indian adolescents, 1338
- Fasting blood glucose (FBG) in NIDDM
 with IGT, 646
 in Japanese subjects with incipient nephropathy, 1224
 in older men with partial androgen deficiency, 670
- Fasting blood glucose (FBG) in obesity
 in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
 in treatment-seeking obese subjects with IR, 436
- Fasting C-peptide (CP)
 and effects of OCs on glucoregulatory responses to exercise, 350, 351
 in GDM, β_3 -ADR Trp64Arg polymorphism and, 1138
 in IGT, *see* Fasting C-peptide in IGT
 in non-obese subjects, *see* Fasting C-peptide in non-obese subjects
 in older NIDDM men with partial androgen deficiency, 668
 in overweight subjects, 1451
- Fasting C-peptide (CP) in IGT
 of first-degree relatives of African American NIDDM subjects, 1553
 in non-obese subjects, 625, 627, 628
- Fasting C-peptide (CP) in non-obese subjects
 circadian rhythm of serum insulin concentration at low plasma glucose and, 1451
 with IGT, 625, 627, 628
- Fasting C-reactive protein (CRP) in normal FPG, IGT, or IR, 1096, 1097
- Fasting gastric inhibitory polypeptide (GIP) in non-obese IGT subjects, 625
- Fasting glucose
 adiponectin and, *see* Fasting glucose, adiponectin and blood, *see* Fasting blood glucose
 concentration of, associated with leukocyte ABCA1 gene expression in normoglycemic men, 17-21
 and erythrocyte membrane lipid composition, 574
 exercise and, *see* Fasting glucose, exercise and in GDM Taiwanese women with β_3 -ADR Trp64Arg polymorphism, 1138
 and glycemic control effects on F₂ isoprostane level at IDDM onset, 1119
 in IDDM, oxidation of glycated and nonglycated LDLs and, 970
 in IGT first-degree relatives of African American NIDDM subjects, 1553
 in IR, *see* Fasting glucose in IR
 in LBW Pima Indians with normal glucose tolerance, 906
 in lipodystrophic HIV-infected subjects, 1567
 in NIDDM, *see* Fasting glucose in NIDDM
 in non-obese subjects, *see* Fasting glucose in non-obese subjects
 in obesity, *see* Fasting glucose in obesity
 in PM women, *see* Fasting glucose in PM women
 in young subjects, *see* Fasting glucose in young subjects
- Fasting glucose, adiponectin and
 adiponectin levels and, 2
 adiponectin regulation by NEFAs and, 791
- Fasting glucose, exercise and
 exercise effects on, in overweight nondiabetic and NIDDM subjects, 1236
 and OC effects on glucoregulatory responses to exercise, 350, 351
 and plasma nitrate/nitrite in sedentary and exercising subjects, 675
- Fasting glucose in IR
 central HPA dysfunction and, 722, 724
see also Fasting glucose in IR with obesity
- Fasting glucose in NIDDM
- Fasting glucose in NIDDM (*Continued*)
 and in at-risk for NIDDM subjects, 226
 exercise effects on, 1236
 in non-obese insulin-resistant Korean subjects, BMI and, 143
 with obesity, adiponectin, C-reactive protein and, 1456, 1457
see also Fasting plasma glucose in NIDDM
- Fasting glucose in non-obese insulin-resistant subjects
 non-obese insulin-resistant Korean subjects, BMI and, 143
 prevalence of IR and associated CV disease risk factors NS, 498
- Fasting glucose in non-obese subjects
 with IGT, 625
 men, and AT as fibrinogen level predictor, 985, 986
 premenopausal women, metabolic risk and, 1068-1070
see also Fasting glucose in non-obese insulin-resistant subjects
- Fasting glucose in obese insulin-resistant subjects
 in obese women, effects of moderate weight loss on, 281
 prevalence of IR and associated CV disease risk factors and, 498
- Fasting glucose in obese women
 insulin-resistant women, effects of moderate weight loss on, 281
 insulin-sensitive women and, 508
 plasma, *see* Fasting plasma glucose
 PM women, fluvastatin effects on, 735, 736
 in SCI men, MS and, 1373, 1374
 in treatment-seeking subjects, 436
- Fasting glucose in obesity
 in children, 1244
 with NIDDM, adiponectin, C-reactive protein and, 1456, 1457
see also Fasting glucose in obese insulin-resistant subjects; Fasting glucose in obese women
- Fasting glucose in PM women
 fluvastatin effects on, 735, 736
 obese PM women, fluvastatin effects on, 735, 736
- Fasting glucose in young men
 Pro12Ala PPARY2 polymorphism, adiponectin and, in young Japanese men, 1549
 serum adiponectin and, 590
- Fasting glucose in young subjects
 with NIDDM parents, 756
see also Fasting glucose in young men
- Fasting immunoreactive insulin (IRI), and effects of weight loss by obesity with normal FPG or IGT on IR and insulin release, 1096, 1097
- Fasting insulin
 adiponectin and, *see* Fasting insulin, adiponectin and and erythrocyte membrane lipid composition, 574
 exercise and, *see* Fasting insulin, exercise and in GDM, β_3 -ADR Trp64Arg polymorphism and, 1138
 in GH-deficient subjects, rhGH therapy effects on, 741
 in IGT first-degree relatives of African American NIDDM subjects, 1553
 immunoreactive, and effects of weight loss by obese subjects with normal FPG or IGT on IR and insulin release, 1096-1097
 insulin sensitivity and, *see* Fasting insulin, insulin sensitivity and in IR, *see* Fasting insulin in IR
 in LBW Pima Indians with normal glucose tolerance, 906
 in lipodystrophic HIV-infected subjects, 1567
 in MS, *see* Fasting insulin in MS
 in NIDDM, *see* Fasting insulin in NIDDM
 in non-obese subjects, *see* Fasting insulin in non-obese subjects
 in obesity, *see* Fasting insulin in obesity
 plasma, *see* Fasting plasma insulin
 in PM women, *see* Fasting insulin in PM women
 in postpubertal Asian Indian adolescents, 1338
 in young subjects, *see* Fasting insulin in young subjects

- Fasting insulin, adiponectin and
adiponectin levels and, 2
adiponectin regulation by NEFAs and, 791
- Fasting insulin, exercise and
and OC effects on glucoregulatory responses to exercise, 350, 351
and plasma nitrate/nitrite in sedentary and exercising subjects, 675
- PPAR γ polymorphism effects on dietary fat-physical activity
association with fasting insulin level, 11-16
- Fasting insulin, insulin sensitivity and
estimates of insulin sensitivity, 1109
and relationship between BMI, IR, and beta-cell function, 1463
- Fasting insulin in IR
and associated CV disease risk factors in overweight subjects, 498
and relationship between obesity, IR, and beta-cell function, 1463
see also Fasting insulin in non-obese insulin-resistant subjects
- Fasting insulin in MS, 312
in SCI men, 1373, 1374
- Fasting insulin in NIDDM
exercise effects on, 1236
with IGT, 646
in non-obese insulin-resistant NIDDM Korean subjects, BMI and, 142
in older men with partial androgen deficiency, 668
- Fasting insulin in non-obese insulin-resistant subjects
in insulin-resistant NIDDM Korean subjects, BMI and, 142
and prevalence of IR and associated CV disease risk factors, 498
- Fasting insulin in non-obese subjects
with IGT, 625
insulin-resistant NIDDM Korean subjects, BMI and, 142
non-obese men, and AT as fibrinogen level predictor in, 985, 986
- Fasting insulin in obesity
in children, 1244
in PM women, fluvastatin effects on, 735, 736
prevalence of IR and associated CV disease risk factors and, 498
- Fasting insulin in PM women
insulin sensitivity and, 508, 509
obese PM women, fluvastatin effects on, 735, 736
- Fasting insulin in young subjects
with NIDDM parents, 756
- Pro12Ala PPAR γ 2 polymorphism, adiponectin and, in young Japanese men, 1549
- serum adiponectin and, in young men, 590
- Fasting leptin, effects of weight loss by obese subjects with normal FPG or IGT on, 1097
- Fasting nonesterified fatty acids (NEFAs; free fatty acids), serum, in obese NIDDM subjects, bezafibrate effects on, 407-408
- Fasting plasma glucose (FPG)
carotid atherosclerosis, vascular dementia and, 477
in IR, *see* Fasting plasma glucose in IR
in Japanese subjects with beta-cell dysfunction, 950-952
in NIDDM, *see* Fasting plasma glucose in NIDDM
in obesity, *see* Fasting plasma glucose in obesity
stevioside effects on, 102
- Fasting plasma glucose (FPG) in IR
in Japanese subjects, 651, 652
with LVH, candesartan effects on, 779
- Fasting plasma glucose (FPG) in NIDDM
and association of corrected QT intervals with carotid artery IMT, 1153
and in at-risk subjects for NIDDM, 224
glyburide and nateglinide effects and, 1332
insulin therapy effects on, 694, 697, 698
metformin effects on, 160, 161
microalbuminuria and, 354
- Fasting plasma glucose (FPG) in NIDDM (*Continued*)
with obesity, pioglitazone effects on, 489-490
in older men with partial androgen deficiency, 668
Pancreas Tonic effects on, 1169
with retinopathy, 583-588
- Fasting plasma glucose (FPG) in obesity
with NIDDM, pioglitazone effects on, 489-490
normal, effects of weight loss on insulin release and IR in subjects
with IGT or, 1095-1100
obese adolescents, 864, 865
- Fasting plasma insulin (FPI)
in NIDDM with obesity, pioglitazone effects on, 489-490
stevioside effects on, 102
- Fasting plasma nitrate/nitrite (NO_x), OGTT assessment of, in sedentary and exercising subjects, 675
- Fasting plasminogen activator inhibitor-1 (PAI-1), effects of weight loss by obese subjects with normal FPG or IGT on, 1097
- Fasting serum nonesterified fatty acids (NEFAs) in obese NIDDM subjects, bezafibrate effects on, 407-408
- Fasting triglycerides (TGs)
and adiponectin regulation by NEFAs, 791
plasma, pioglitazone effects on, 489-490
see also Fasting triglycerides in NIDDM
- Fasting triglycerides (TGs) in Japanese NIDDM subjects
incipient NIDDM, 1224
insulin secretion, insulin resistance and, 832
- Fasting triglycerides (TGs) in NIDDM
Pancreas Tonic effects on, 1169
see also Fasting triglycerides in Japanese NIDDM subjects;
Fasting triglycerides in obese NIDDM subjects
- Fasting triglycerides (TGs) in obese NIDDM subjects
bezafibrate effects on, 407-408
plasma, pioglitazone effects on, 489-490
- Fat-free mass (FFM)
in acute SCI subjects, 990, 991
in Ecuadorian Amazon Shur women, 1356
effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism on, in men, 304
food intake-uncoupling protein-3 polymorphism association and, 460
of hyperinsulinemic young men, whole-body protein synthesis and, 389
in IGT first-degree relatives of obese African American NIDDM subjects, 415, 417
of LBW Pima Indians with normal glucose tolerance, 906
in NIDDM, *see* Fat-free mass in NIDDM
in obesity, *see* Fat-free mass in obesity
in older hypertensive subjects, resistance exercise effects on insulin-mediated glucose disposal and, 399
and overweight women, serum TNF soluble receptors, TNF- β , and NO and, 1269
in severe lipodystrophy, leptin replacement therapy effects on, 516
- Fat-free mass (FFM) in NIDDM
Pancreas Tonic effects on, 1169
with polygenic obesity, CL316,243 effects on, 801-802
- Fat-free mass (FFM) in obesity
in insulin-resistant Japanese subjects, 651
in Korean subjects, -3826A \square G UCP-1 polymorphism and, 1056
polygenic obesity, CL316,243 effects on, 801-802
after RYBG and ASGB for morbid obesity, 920
- Fat mass (FM)
circulating leptin as marker of, in acute spinal cord injury, 989-994
in Ecuadorian Amazon Shur women, 1356

Fat mass (FM) (*Continued*)

- effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism on, 304
- and food intake-uncoupling protein-3 polymorphism association with body composition, 460
- in IDDM, and insulin concentration and CHO requirement during moderate exercise, 1127
- in IGT first-degree relatives of obese African American NIDDM subjects, 415, 417
- of LBW Pima Indians with normal glucose tolerance, 906
- in lipodystrophy, *see* Fat mass in lipodystrophy
- in MS subjects, 312, 313, 315
- in NIDDM, *see* Fat mass in NIDDM
- in obesity, *see* Fat mass in obesity
- resistance exercise and, *see* Fat mass, resistance exercise effects on
- see also* Adipose tissue

Fat mass (FM) in lipodystrophy

- in severe lipodystrophy, leptin replacement therapy effects on, 516
- total, in lipodystrophic HIV-infected subjects, 1567

Fat mass (FM), resistance exercise effects on

- in NIDDM women, 284-289
- in older hypertensive subjects, 399

Fat mass (FM) in lipodystrophy

- in severe lipodystrophy, leptin replacement therapy effects on, 516
- total, in lipodystrophic HIV-infected subjects, 1567

Fat mass (FM) in NIDDM

- Pancreas Tonic effects on, 1169
- in women, 284-289

Fat mass (FM) in obesity

- in* insulin-resistant Japanese subjects, 651
- in* Korean subjects, -3826A \rightarrow G UCP-1 polymorphism effects on level of LDL-C and, 1056, 1058
- in morbid obesity after RYBG and ASGB, 920
- in* NIDDM with polygenic obesity, CL316,243 effects on, 801-802

FATP-1 (fatty acid transporter protein-1), fiber type- and FA composition-dependent effects of HF diet on content of TAG and, in skeletal muscle, 1032-1036

Fatty acid(s) (FAs)

- effects of long-term exposure of INS cells to *cis* and *trans* FAs on oxidation of, 1158-1165

serum PP, in NIDDM, alcohol effects on, 79-80

VAT accumulation and TG content of, associated with MS components, 310-317

see also Fatty acid-binding protein-4; Fatty acid composition

cis Fatty acid(s), effects of long-term exposure of INS-1 cells to *trans* and, on insulin secretion and oxidation of, 1158-1165

trans Fatty acid(s), effects of, long-term exposure of INS-1 cells to *cis* and, on insulin secretion and oxidation of, 1158-1165

Fatty acid-binding protein-4 (FABP4), effects of interaction between PPAR γ -activated receptor polymorphism and polymorphism of, on insulin sensitivity and body composition in men, 303-309

Fatty acid (FA) composition

fiber type- and FA composition-dependent effects of HF diet on skeletal muscle TAG and FATP-1 content, 1032-1036

neutrophil, dietary oil effects on, 59-65

see also Essential fatty acids; Monounsaturated fatty acids; Nonesterified fatty acids; Polyunsaturated fatty acids; Saturated fatty acid(s)

Fatty acid synthase (FAS) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065

Fatty acid transporter protein-1 (FATP-1), fiber type- and FA composition-dependent effects of HF diet on content of TAG and, in skeletal muscle, 1032-1036

Fatty liver in STZ-DM due to high-fat diet, NO-1886 effects on, 260-263

FBG, *see* Fasting blood glucose

FBPase (fructose-1,6-biphosphatase), *P. yoelli* GPI effects on, in STZ-DM with obesity, 1050

FCHL (familial combined hyperlipidemia), \square -3 PUFA effects on levels of plasma HDL $_2$ C and paraoxonase in, 153-158

Fenofibrate, effects of

- on HF diet-induced weight gain and white adipose tissue in ovariectomized subjects, 1284-1289
- on obesity and hypertriglyceridemia in LDL-receptor null subjects, 607-613

Fetal life/neonatal life, 3,3'-T₂S in, 538-543

FFAs (free fatty acids), *see* Nonesterified fatty acids

FFM, *see* Fat-free mass

Fiber

CV disease risk factors and intake of, 1439

effects of exercise and high-fiber, low-fat diet on inflammatory and adhesion molecules in PM women on ERT and at risk for CAD, 377-381

FA composition- and fiber type-dependent effects of HF diet on skeletal muscle TAG and FATP-1 content, 1032-1036

Fibrinogen

adipose tissue in non-obese men and level of, 984-988

in CHD, IR and, 853, 854

inflammation of chronic disease, 901, 902

insulin therapy effects on, 694, 697

plasma, in IDDM, and oxidation of glycated and nonglycated

LDLs, 970

and smoking effects on intravascular remodeling of LDL particles, 860

in young subjects with NIDDM parents, 756

Fibroblasts, *see* DNA synthesis in fibroblasts

Fibronectin mRNA (messenger ribonucleic acid)

in cardiac fibroblasts, effects of high glucose and insulin on, 712

renal, in IR, cilostazol effects on, 1405-1410

Fibrosis, *see* Cystic fibrosis

-1562C \rightarrow T polymorphism of MMP-9 associated with BMD in Japanese men, 135-137

Filipino family, triple HNF-4 α gene mutations associated with early-onset NIDDM in, 959-963

First-degree relatives

of normocholesterolemic and daytime hypertriglyceridemic

subjects with premature atherosclerosis, 49-53

see also First-degree relatives, IGT, of African American NIDDM subjects

First-degree relatives, IGT, of African American NIDDM subjects

effects of rosiglitazone on insulin sensitivity, insulin secretion, and plasma adiponectin, 1552-1557

GITS prevention of NIDDM in relatives of obese African

American NIDDM subjects, 414-422

Fish oil (FO)

effects, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65

see also ω -3 Polyunsaturated fatty acids

Fitness

cardiorespiratory, contribution of visceral AT and, to

hyperinsulinemia, dyslipidemia, and hypertension in NIDDM with IGT, 644-649

see also Exercise

FIZZ3, *see* Resistin

- Flutamide for PCOS in obese women, 370
 Fluvastatin, effects of, on endothelial function in obese postmenopausal women via sdLDL reduction, 733-739
FM, *see* Fat mass
FO, *see* Fish oil
Folate
 in disabled hospitalized older subjects, HHcy and, 1018
 erythrocyte, in subclinical hypothyroidism, 1513
Follicle-stimulating hormone (FSH) in PM and premenopausal women, plasma Lp and, 189
Food intake
 correlation between AT, serum leptin and, during six-month period following kidney transplantation, 614-619
 lack of acute effects of red wine drinking and, on vascular reactivity, 1081-1086
 obesity and, *see* Food intake, and obesity
see also Diet
Food intake, and obesity
 in NIDDM subjects, bezafibrate effects on lipids and glucose metabolism and, 407
 and NN414 and DZ effects on glucose tolerance in obesity, 442
FPFS-410, antidiabetic and adipogenic properties of, 1532-1537
FPG, *see* Fasting plasma glucose
FPI, *see* Fasting plasma insulin
Free fatty acids, *see* Nonesterified fatty acids
Free testosterone
 in older NIDDM men with partial androgen deficiency, 668
 in PCOS, 366
 in PM women, insulin sensitivity and, 508, 509
Free thyroxine (T_4) in subclinical hypothyroidism, CV disease risk factors and, 1513
Free triiodothyronine (T_3) in subclinical hypothyroidism, CV disease risk factors and, 1513
Frequently sampled intravenous glucose tolerance test (FSIVGTT) and insulin resistance indices, 1522-1526
NEFA multiphasic profile unresponsive to exogenous insulin during, 1202-1207
 population and individual minimal modeling of, 1349-1354
Fresh blood samples, analysis of HbA_{1c} in, 1497, 1498
Frozen blood samples kept at -80°C, analysis of HbA_{1c} in, 1496-1499
Fructosamine
 effects of ATPCL inhibitors on, 68
 in older NIDDM men with partial androgen deficiency, 668, 670
Fructose (F), postprandial plasma, in NIDDM retinopathy, 583-588
Fructose-1,6-biphosphatase (FBPase), P yelli GPI effects on, in STZ-DM with obesity, 1050
Fruit, PP TG response to, 622
FSH (follicle-stimulating hormone) in PM and premenopausal women, plasma Lp and, 189
FSIVGTT, *see* Frequently sampled intravenous glucose tolerance test
FXR (farnesoid X receptor), hepatic, effects of ileal bile transport inhibition on plasma C level through cholesterol 7α-hydroxylase stimulation and inactivation of, 927-932

Galactosamine, effects of liver disease induced by bile duct ligation and, on cardiac protein synthesis, 964-968
Gamma (γ-linoleic acid in MS, 312
Gastric banding, adjustable silicone, changes in BMC after RYBG and, for morbid obesity, 918-921
Gastric inhibitory polypeptide (GIP)
 insulin secretion, GLP-1 and, after glucose ingestion in IGT, 624-631
PP, in NIDDM, stevioside effects on, 75
GDH (glutamate dehydrogenase), DM effects on, 68
**GDM (gestational diabetes mellitus), β_3 -ADR Trp64Arg polymorphism and, in Taiwanese women, 1136-1139
Gender, *see* Sex
Gene expression, *see* mRNA
Genetic variations, *see* Polymorphism
Genetics
 of PCOS, 358-359
see also DNA synthesis in fibroblasts; First-degree relatives; Genotype; mRNA; Mutations; Parent(s); Polymorphism
entries beginning with terms: Familial, Polygenic, Transgenic specific genes and conditions
Genotype, apo E, changes in serum lipids and $\dot{V}O_{2\max}$ in endurance exercise and, 193-202
Geriatric subjects, *see* Older subjects
Gestational age
 birth weight and, 1545
 circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and sepsis, 209-214
 whole-body glucose oxidation and oral glucose metabolism in born small-for-gestational-age children, 847-851
Gestational diabetes mellitus (GDM), β_3 -ADR Trp64Arg polymorphism and, in Taiwanese women, 1136-1139
GF (growth factor) receptors, emergence of, in activated CD4⁺ and CD8⁺ T lymphocytes, 117-122
GFR (glomerular filtration rate) in chronic renal disease, 1256
GH, *see* Growth hormone
GHb (glycohemoglobin), stability over time of glucose, RBC survival and, in hematologically stable subjects without DM, 1399-1403
GHBP (growth hormone-binding protein) in lipodystrophic HIV-infected subjects, 1565-1563
Ghrelin mRNA (messenger ribonucleic acid) in melanoma-associated cachexia, 84-88
GIP, *see* Gastric inhibitory polypeptide
GITS (glipizide gastrointestinal therapeutic system), prevention of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with, 414-422
Glargine (insulin analogue), action of, on protein and lipid metabolism, 1037-1044
Glc, *see* Glucagon
Gliclazide in NIDDM, effects of, on microalbuminuria, 353-357
Glipizide gastrointestinal therapeutic system (GITS), prevention of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with, 414-422
Gln, *see* Glutamine
Glomerular filtration rate (GFR) in chronic renal disease, 1256
GLP-1, *see* Glucagon
Glu, *see* Glutamic acid
Glucagon (Glc; hyperglycemic-glycogenolytic factor)
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090
 effects of epinephrine, hyperglycemia and, on renal glucose release in conscious subjects, 933-941
 effects of swimming on hepatic glucose production in response to, 1027-1031
 in obese men, NEFA effects on levels of, 892
PP, in NIDDM, stevioside effects on, 75
 short-term effects of NEFAs on secretion of, at low-to-normal glucose concentrations, 1443-1448
see also entries beginning with term: Glucagon-like peptide-1
Glucagon (Glc; hyperglycemic-glycogenolytic factor) in hypoglycemia**

- Glucagon (Glc; hyperglycemic-glycogenolytic factor) in hypoglycemia (Continued)**
- and nighttime and daytime differences in counterregulation of hypoglycemia, 895
 - pramlintide effects on response of hypoglycemic symptoms to, 1227-1232
- Glucagon-like peptide-1 (GLP-1)**
- insulin secretion, glucose-dependent insulinotropic polypeptide and, after glucose ingestion in IGT, 624-631
 - PP, in NIDDM, stevioside effects on, 75
 - Glucagon-like peptide-1(7-36) [GLP-1(7-36)] amide, effects of Lys⁹-for-Glu⁹ substitution in, on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
 - Glucagon-like peptide-1(9-36) [GLP-1(9-36)] amide, effects of Lys⁹-for-Glu⁹ substitution in GLP-1(7-36) amide on DPP IV resistance with cellular and metabolic actions similar to exendin (9-39) and, 252-259
- Glucocorticoid receptor (GR)**
- leptin effects on mRNA of, in STZ-DM, 1560-1561
 - signaling by, in AT, restricted diet effects on, 28-36
- Glucoregulatory responses to exercise, effects of OCs on, 348-352**
- Glucosamine, effects of, on apo A-I stabilization and expression in HepG2 cells, 766-771**
- Glucose**
- blood, see Blood glucose**
 - diet and, see Glucose, diet and**
 - differential effects of alcohol and, on ROS generation and intranuclear nuclear factor- \square B in mononuclear cells, 330-334
 - effects of different levels of, on arginase activity and NO production in renal cortex, 868-874
 - effects of high insulin and, on protein synthesis in cardiac myocytes and DNA and collagen synthesis in cardiac fibroblasts, 710-715
 - in exercise, *see* Glucose in exercise
 - fasting, *see* Fasting glucose
 - glargin effects on, 1038
 - and glycoprotein PC-1 K121Q polymorphism associated with race but not IR in children, 466, 467
 - in hypercholesterolemia, serum LPL concentration and, 528
 - isotretinoin effects on, 7, 8
 - leptin levels and, 1412-1414
 - and leucine turnover in third trimester of uncomplicated pregnancy, 547
 - in overweight women, serum TNF soluble receptors, TNF- β , and NO and, 1269
 - plasma, *see* Plasma glucose
 - in PM and premenopausal women, sex steroids and plasma Lps and, 189
 - postprandial, *see* Postprandial glucose
 - proline ingestion with and without, 241-246
 - rebaudioside A effects on insulin secretion dependent on, 1378-1381
 - and relation of intracellular cord blood platelet magnesium to birth weight, 1545
 - and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, in Japanese subjects, 881-883
 - serum, *see* Serum glucose
 - short-term effects of NEFAs on secretion of glucagon at low-to-normal concentrations of, 1443-1448
 - stability over time of GHb, RBC survival and, in hematologically stable subjects without DM, 1399-1403
- Glucose (Continued)**
- whole-body, and glucose metabolism in born small-for-gestational-age children, 847-851
 - see also* Glucose, diet and; Glucose, smoking effects on; Glucose-dependent insulinotropic polypeptide; Glucose in hyperinsulinemia; Glucose in IR; Glucose in obesity; Glucose-6-phosphatase; Glucose-6-phosphate dehydrogenase; Glucose-stimulated insulin secretion; Glucose tolerance; Glucose transport in SM; GLUT₄ in IR; Insulin-dependent diabetes mellitus; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus and entries beginning with prefixes: Gluc-, Glyc-
 - Glucose, diet and**
 - and CV disease risk factors, 1437, 1438
 - see also* Glucose, HF diet effects on
 - Glucose, HF diet effects on**
 - HF diet effects on, 1034
 - and insulin-nonspecific reduction of glucose transport in SM, 912-917
 - Glucose, smoking effects on**
 - and smoking-ADMA-obesity relationship, 1575, 1576
 - and smoking effects on intravascular HDL particle remodeling, 860
 - Glucose control, see Glycemic control of DM**
 - Glucose-dependent insulinotropic polypeptide, alcohol effects on, in NIDDM, 77-83**
 - Glucose in exercise**
 - and acipimox-induced reduction of plasma NEFAs during exercise at cold temperature, 1133
 - in exercising PM women on or not on ERT, 1194
 - hepatic production of, in response to glucagon, effects of swimming on, 1027-1031
 - resistance exercise effects on TNF- α and insulin-mediated glucose disposal in older hypertensive subjects, 397-402
 - Glucose-glutamine (Gln) cycle during hypoglycemia and normoglycemic hyperinsulinemia, 1208-1214**
 - Glucose in hyperinsulinemia**
 - portal venous hyperinsulinemia effects on gut absorption of, in conscious subjects, 1290-1295
 - see also* Plasma glucose in hyperinsulinemia
 - Glucose intolerance**
 - development of, in male transgenic subjects with GSK-3 β overexpression in skeletal muscle, 1322-1330
 - see also* Glucose tolerance
 - Glucose in IR**
 - IR measures and, 1524
 - with liver cirrhosis, 923
 - plasma NEFA regulation and, 1198
 - serum GPI-PLD and, 139
 - Glucose in obesity**
 - and smoking-ADMA-relationship, 1575
 - in women, serum TNF soluble receptors, TNF- β , and NO and, 1269
 - Glucose-6-phosphatase (G6Pase), effects of exercise on activity of hepatic, in diabetes-prone subjects, 836-841**
 - Glucose-6-phosphate dehydrogenase (G6PD) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065**
 - Glucose-stimulated insulin secretion, LSF effects on, in STZ-DM, prediabetic, and nondiabetic subjects, 290-296**
 - Glucose tolerance**
 - HF diet effects on, 1034
 - insulin secretion and insulin sensitivity at different stages of, in Japanese NIDDM subjects, 831-835

- Glucose tolerance (Continued)**
- LBW Pima Indians with normal, insulin secretion, insulin sensitivity in, 904-911
 - in obesity, effects of NN414 and DZ on lipids and, compared, 441-447
 - see also* Frequently sampled intravenous glucose tolerance test; Impaired glucose tolerance; Normal glucose tolerance, insulin release and secretion in; Oral glucose tolerance test
- Glucose transport in SM**
- HF diet and insulin-nonspecific reduction in, 912-917
 - of insulin-sensitive and insulin-resistant subjects, stevioside effects on, 101-107
- GLUT₄ in IR**
- adipocyte, hypertension and, 382-387
 - after 1-day hindlimb suspension, 1217
- GLUT₄ mRNA (messenger ribonucleic acid), exercise effects on**
- glycogen synthase activity and, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
- Glutamate dehydrogenase (GDH), DM effects on, 68**
- Glutamic acid (Glu)**
- effects of GLP-1(7-36) amide lys⁹-for-Glu⁹ substitution on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
 - plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Glutamine (Gln)**
- muscle, changes in release of, during hyperinsulinemia, normoglycemia, and hypoglycemia, 1208-1214
 - plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- relation between leptin receptor gene Lys109Arg and Gln 223Arg polymorphisms, HOMA IR index, serum leptin, soluble leptin receptor, serum adiponectin, and lipids in Japanese subjects, 881-883**
- Glutathione (GSH), effects of hypoxia and hypoxic training on levels of hepatic, 716-719**
- Gly, *see* Glycine**
- Glycated hemoglobin, *see* HbA_{1c}**
- Glycated low-density lipoprotein (LDL), susceptibility to oxidation of nonglycated LDLs and, in IDDM, compared, 969-975**
- Glycemia, *see* Glycemic control of DM; Hyperglycemia; Hypoglycemia; Normoglycemic hyperinsulinemia; Normoglycemic men**
- Glycemic control of DM**
- with PPES-410, 1532-1537
 - relation between plasma ET, plasma VEGF concentration and, 550-555
 - see also* Glycemic control of IDDM; Glycemic control of NIDDM and specific therapies
- Glycemic control of IDDM**
- effects of, on F₂ isoprostanate level at IDDM onset, 1118-1120
 - with modified insulin, 54-58
- Glycemic control of NIDDM**
- effects of, on microalbuminuria, 353-357
 - with insulin, effects of, on serum high-sensitivity CRP, 693-699
 - in NIDDM women, effects of resistance exercise on, 284-289
 - in older men with partial androgen deficiency, 666-672
 - see also* specific therapies; for example: Non-insulin-dependent diabetes mellitus, pioglitazone effects on
- Glycerol**
- acipimox-induced reduction of, during exercise at cold temperature, 1133
 - effects of exercise at cold temperature on, *see* Glycerol, effects of exercise at cold temperature on
- Glycerol (Continued)**
- isotretinoin effects on, 7
 - skeletal muscle, in insulin-resistant lipolysis, HF diet and, 794-798
 - see also* Triacylglycerol
- Glycerol, effects of exercise at cold temperature on**
- acipimox-induced reduction of, 1133
 - and substrate oxidation, 204
- Glycine (Gly)**
- Arg16Gly β₂-ADR polymorphism interaction with β₂-Arg16Arg and β₃-ADR Trp64Arg polymorphisms, serum lipid profile and, 1184-1191
 - plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Glycogen, *see* Hepatic glycogen**
- Glycogen synthase (GS), exercise effects on GLUT₄ mRNA and activity of, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242**
- Glycogen synthase kinase-3β (GSK-3β) mRNA (messenger ribonucleic acid) in skeletal muscle of transgenic male subjects, 1322-1330**
- Glycohemoglobin (GHb), stability over time of glucose, RBC survival and, in hematologically stable subjects without DM, 1399-1403**
- Glycoprotein**
- α₁-acid, in inflammation of chronic disease, 901, 902
 - PC-1 K121Q polymorphism, association of, with race but not with IR, in children, 465-468
- Glycosylphosphatidylinositol (GPI), *P. yoelli*, effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053**
- Glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), serum, IR effects on, 138-139**
- Glycyrrhetic acid, responsiveness of body weight, hepatic 11β-HSD1 mRNA, and renal 11β-HSD2 mRNA to 11β-HSD inhibition by, 600-606**
- Gonadotropin(s)**
- in central hypothesis of PCOS, 359-361
 - human chorionic, low temperature blocking stimulatory effects of, on steroidogenic acute regulatory protein mRNA and testosterone production but not on cAMP production in tumor cells, 955-958
- G-6-Pase (glucose-6-phosphatase), effects of exercise on activity of hepatic, in diabetes-prone subjects, 836-841**
- G6PD (glucose-6-phosphate dehydrogenase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065**
- GPI (glycosylphosphatidylinositol), *P. yoelli*, effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053**
- GPI-PLD (glycosylphosphatidylinositol-specific phospholipase D), serum, IR effects on, 138-139**
- GR, *see* Glucocorticoid receptor**
- Growth factor (GF) receptors, emergence of, in activated CD4⁺ and CD8⁺ T lymphocytes, 117-122**
- Growth hormone (GH)**
- long-term monitoring of insulin sensitivity in GH-deficient subjects on GH therapy, 740-743
 - LY117018 effects on secretion of, 563-570
 - nighttime and daytime differences in counterregulation of hypoglycemia and, 895
 - in smokers, *see* Growth hormone in smokers
- Growth hormone-binding protein (GHBp) in lipodystrophic HIV-infected subjects, 1565-1563**
- Growth hormone (GH) in smokers**
- acute effects of nicotine on, 578-582

- Growth hormone (GH) in smokers (*Continued*)
 response of, to exercise by nondiabetic and IDDM smokers, 1140-1144
- GS (glycogen synthase), exercise effects on GLUT₄ mRNA and activity of, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
- GSH (glutathione), effects of hypoxia and hypoxic training on levels of hepatic, 716-719
- GSK-3β (glycogen synthase kinase-3β) mRNA messenger ribonucleic acid in skeletal muscle of transgenic male subjects, 1322-1330
- G276T adiponectin polymorphism in Japanese NIDDM subjects with incipient nephropathy, 1223-1226
- Gut
 portal venous hyperinsulinemia effects on glucose absorption by, in conscious subjects, 1290-1295
 short, regulation of serum lipid EFAD in subjects with, and on lipid-containing total parenteral nutrition, 273-277
- Haptoglobin, serum, correlation between HbA_{1c}, retinocytes, serum bilirubin and, 1498
- Hb (hemoglobin)
 in disabled hospitalized older subjects, HHcy and, 1018
 WPG effects on, 1312
see also HbA_{1c}
- HbA_{1c} (glycated hemoglobin A_{1c})
 and ABCA1 gene expression-fasting glucose relationship in normoglycemic men, 19
 in blood samples kept frozen at -80°C, analysis of, 1496-1499
 carotid atherosclerosis, vascular dementia and, 477
 in DM, *see* HbA_{1c} in DM
 in hypercholesterolemia, serum LPL concentration and, 528
 in IGT first-degree relatives of African American NIDDM subjects, 1553
 in IR, *see* HbA_{1c} in IR
 in Japanese subjects, *see* HbA_{1c} in Japanese subjects
 in obesity, *see* HbA_{1c} in obesity
 and smoking-ADMA-obesity relationship, 1575, 1576
 in young subjects, *see* HbA_{1c} in young subjects
- HbA_{1c} (glycated hemoglobin A_{1c}) in DM
 effects of ATCPL inhibitors on, 68
 and relation between plasma VEGF, ET-1 concentration, and glycemic control, 551
see also HbA_{1c} in IDDM; HbA_{1c} in NIDDM
- HbA_{1c} (glycated hemoglobin A_{1c}) in IDDM
 energy substrate oxidation and, 656
 glycemic control effects on F₂ isoprostane level at IDDM onset, 1119
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 oxidation of glycated and nonglycated LDLs and, 970
 plasma apo C-3 polymorphisms and, 1299
- HbA_{1c} (glycated hemoglobin A_{1c}) in IR
 with cardiovascular autonomic dysfunction and microalbuminuria, 1360, 1362
 in non-obese subjects, BMI and, 143
- HbA_{1c} (glycated hemoglobin A_{1c}) in Japanese subjects
 in insulin-resistant obese subjects, 651, 652
 with NIDDM and incipient nephropathy, 1224
 and relation between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms of leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
- HbA_{1c} (glycated hemoglobin A_{1c}) in NIDDM
- HbA_{1c} (glycated hemoglobin A_{1c}) in NIDDM (*Continued*)
 ACP-I and ADA effects on, 998, 999
 alcohol effects on PP lipemia and, 78
 and association of corrected QT intervals with carotid artery IMT, 1153, 1155, 1156
 and at-risk for NIDDM subjects, 224, 226
 correlation between erythrocyte membrane lipid composition and, 123-127
 glyburide and nateglinide effects and, 1332
 insulin therapy effects on, 694
 metformin effects on, 160, 161
 microalbuminuria and, 354
 in obesity, *see* HbA_{1c} in obesity
 in older NIDDM men with partial androgen deficiency, 668, 670
 Pancreas Tonic effects on, 1169
 with retinopathy, 585, 586
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
see also HbA_{1c} in NIDDM nephropathy
- HbA_{1c} (glycated hemoglobin A_{1c}) in NIDDM nephropathy
 in Japanese subjects with incipient nephropathy, 1224
 pioglitazone effects on, 1383
- HbA_{1c} (glycated hemoglobin A_{1c}) in obesity
 adiponectin, CRP and, 1456, 1457
 in insulin-resistant obese Japanese subjects, 651, 652
 with NIDDM, 1456, 1457
 NN414 and DZ effects on, 443, 444
- HbA_{1c} (glycated hemoglobin A_{1c}) in young subjects
 with NIDDM parents, 756
 in young men with hypertensive parents, 470
- HC diet, *see* High-cholesterol diet
- HC/HF diet, *see* High-fat/high cholesterol diet, lipemic response to hCG (human chorionic gonadotropin), low temperature blocking stimulatory effects of, on steroidogenic acute regulatory protein mRNA and testosterone production but not on cAMP production in tumor cells, 955-958
- Hey, *see* Homocysteine
- HD, *see* Hemodialyzed subjects
- HDL, *see* High-density lipoprotein
- HDL-C, *see* High-density lipoprotein-cholesterol
- Head and neck squamous cell carcinoma (HNSCC), effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-trans retinoic acid and on cell proliferation in, 1007-1012
- Heart
 weight of, in liver disease, 965
see also Heart disease; Heart rate and entries beginning with element: Card-
- Heart disease
 coronary, *see* Coronary heart disease
 ischemic, carotid atherosclerosis, vascular dementia and, 477
see also Risk factors for CV disease
- Heart rate (pulse rate; HR)
 of CAD men, effects of red and white wine drinking on, 320
 in early NIDDM nephropathy, pioglitazone effects on, 1476
 effects of red wine drinking and food intake on, 1082
 exercise effects on, *see* Heart rate, exercise effects on in IR with LVH, candesartan effects on, 778, 779
 in NIDDM, *see* Heart rate in NIDDM
 in obese PM women, fluvastatin effects on, 735
 resting, of young subjects with NIDDM parents, 756
 Heart rate (pulse rate; HR), exercise effects on at cold temperature, 1131-1135
 in overweight nondiabetic and NIDDM subjects, 1236

- Heart rate (pulse rate; HR) in NIDDM
with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362
in overweight NIDDM subjects, 1236
- Height
of children with glycoprotein PC-1 K121Q polymorphism, 467
of Ecuadorian Amazon Shuar women, 1356
of hyperinsulinemic young men, whole-body protein synthesis and, 389
of IDDM subjects, insulin concentration and CHO requirement in IDDM during moderate exercise, 1127
of insulin-resistant subjects with central HPA dysfunction, 722
and isotretinoin effects on insulin sensitivity and plasma TGs, 5
of LBW Pima Indians with normal glucose tolerance, 906
of lipodystrophic subjects, 514
of NIDDM subjects, *see* Height of NIDDM subjects
of obese adolescents, *see* Height of obese adolescents
of smokers, *see* Height of smokers
- Height of exercising subjects
of exercising women on or not on ERT, 1194
and OC effects on glucoregulatory responses to exercise, 350
- Height of NIDDM subjects
and of at-risk for NIDDM subjects, 224
of NIDDM women, resistance exercise effects on glycemic control in, 285
- Height of obese adolescents
with components of MS, 864
hyperuricemic Japanese male adolescents, 450
- Height of smokers
acute effects of nicotine and, 579
and smoking effects on intravascular of HDL particle remodeling, 860
- Hematocrit, WPG effects on, 1312
- Hematologically stable subjects without DM, stability over time of GHb, glucose, and RBC survival in, 1399-1403
- Hemodialyzed subjects (HD)
for dyslipidemic CRF, atorvastatin effects on lipids, LDLs, and CRP in, 1113-1117
utility of non-HDLs in, 1013-1015
- Hemoglobin, *see* Hb
- Hemolysis, effects of, on HbA_{1c}, 1496-1499
- Hepatic acyl-coenzyme A:cholesterol acyltransferase (ACAT), role of cholesterol absorption and activity of, in lipemic response to HF/HC diet, 817-822
- Hepatic apolipoprotein B (apo B), insulin regulating production of, independently of PKB/Akt1 mass or activity, 228-236
- Hepatic bile, plasma 27-hydroxycholesterol and plasma 7α-hydroxy-4-cholesteno-3-one as markers for synthesis of, dietary cholesterol, 42-48
- Hepatic farnesoid X receptor (FXR), effects of ileal bile transport inhibition on plasma C level through cholesterol 7-hydroxylase stimulation and inactivation of, 927-932
- Hepatic glucose-6-phosphatase (G6Pase), effects of exercise on activity of, in diabetes-prone subjects, 836-841
- Hepatic glucose production (HGP) in response to glucagon, effects of swimming on, 1027-1031
- Hepatic glutathione (GSH), effects of hypoxia and hypoxic training on levels of hepatic 8-OHdG and, 716-719
- Hepatic glycogen
and GSK-3β in transgenic subjects, 1325-1326
in obese men, NEFA effects on levels of, 886-893
- Hepatic 8-hydroxydeoguanosine (8-OHdG), effects of hypoxia and hypoxic training on levels of hepatic GSH and, 716-719
- Hepatic 11β (beta)-hydroxysteroid dehydrogenase 1 (11β-HSD1)
mRNA (messenger ribonucleic acid), responsiveness of body weight and, to 11β-HSD inhibition by glycyrrhetic acid, 600-606
- Hepatic insulin signaling, effects of exercise on hepatic PEPCK and, in diabetes-prone subjects, 836-841
- Hepatic lipase (HL)
HF/HC diet effects on, 1023
Lp metabolism and deficiency in, 520-525
- Hepatic lipids, fenofibrate effects on accumulation of, 610
- Hepatic phosphoenolpyruvate carboxykinase (PEPCK), effects of exercise on hepatic insulin signaling and, in diabetes-prone subjects, 836-841
- Hepatic triglyceride lipase (HTGL), endurance exercise effects on, 196, 198-200
- Hepatocytes, thioctic acid effects on pyruvate metabolism and NEFA oxidation in, 165-173
- Hepatoma cells, *see* HepG2 cells, apo A-I and
HepG2 (hepatoma) cells, apo A-I and
effects of COX inhibition on apo A-I promoter activity in, 174-181
glucosamine effects on apo A-I stabilization and expression in, 766-771
- Herbal supplement, effects of Ayurvedic, in NIDDM, 1166-1173
- Heredity, *see* Genetics
- Hexyl-insulin monoconjugate 2 (HIM2; modified insulin), oral, for IDDM, 54-58
- HF diet, *see* High-fat diet
- HF/HC diet, *see* High-fat/high-cholesterol diet, lipemic response to HGP (hepatic glucose production) in response to glucagon, effects of swimming on, 1027-1031
- HHcy, *see* Hyperhomocysteinemia
- High-cholesterol (HC) diet
effects, on atherogenic LDL particles, 823-830
see also High-fat/high-cholesterol diet, lipemic response to
- High-density lipoprotein (α lipoprotein; HDL)
erythrocyte membrane, 574
in hypothyroidism, effects of T₄ therapy on endothelial function and, 279
in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
in NIDDM, PP, alcohol effects on, 78
plasma, *see* Plasma high-density lipoprotein
plasma vitamin K transport and, 216, 218
ω-3 PUFA and exercise effects on subfractions of, 749-754
RCT system and smoking effects on intravascular remodeling of particles of, 858-862
in SCI men, MS and, 1373, 1374
utility of non-HDLs in HD subjects, 1013-1015
see also High-density lipoprotein-cholesterol
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C)
in acute SCI, 991
in atherosclerosis, *see* High-density lipoprotein-cholesterol in atherosclerosis
in CAD men, *see* High-density lipoprotein-cholesterol in CAD men
and CV disease risk factors, 1437
in dyslipidemic CRF subjects on HD, 1114
and erythrocyte membrane lipid composition, 574
during estrous cycle, 140
exercise and, *see* High-density lipoprotein-cholesterol, exercise effects and
in HD subjects, 1014

- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) (Continued)**
- in hypercholesterolemia, *see* High-density lipoprotein-cholesterol in hypercholesterolemia
 - in IDDM, *see* High-density lipoprotein-cholesterol in IDDM
 - in IGT first-degree relatives of African American NIDDM subjects, 1553
 - in IR, *see* High-density lipoprotein-cholesterol in IR
 - in Korean women, AT distribution and, 1541
 - leptin levels and, 1412-1414
 - in mild hypercholesterolemia, 1073
 - in mixed hyperlipidemia, S-2E and PRV effects on, 682-683
 - in NIDDM, *see* High-density lipoprotein-cholesterol in NIDDM
 - in non-obese subjects, *see* High-density lipoprotein-cholesterol in non-obese subjects
 - in obesity, *see* High-density lipoprotein-cholesterol in obesity
 - in overweight women, serum TNF soluble receptors, TNF- β , and NO and, 1269
 - plasma, *see* Plasma high-density lipoprotein-cholesterol
 - and plasma LDL clearance, 484
 - and plasma vitamin K transport, 216
 - in PM women, *see* High-density lipoprotein-cholesterol in PM women
 - in postpubertal Asian Indian adolescents, 1338
 - and ω -3 PUFA effects on, in FCHL, 154
 - and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, in Japanese subjects, 881-883
 - serum, *see* Serum high-density lipoprotein-cholesterol
 - in subclinical hypothyroidism, 1513
 - in Vietnamese children with apo E polymorphism, 1519
 - WPG effects on, 1311-1312
 - in young subjects, *see* High-density lipoprotein-cholesterol in young subjects
 - see also* High-density lipoprotein₂-cholesterol; High-density lipoprotein₃-cholesterol
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C), exercise effects and**
- blood, apo E polymorphism association with changes in $\dot{V}O_{2\text{max}}$ and, 111-113
 - endurance exercise effects, 196, 198-200
 - in overweight nondiabetic and NIDDM subjects, 1236
 - relationship of exercise, alcohol intake, and adiposity to levels of, 700-709
 - soccer playing effects, 1264
 - see also* High-density lipoprotein-cholesterol in exercising PM women on ERT
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in atherosclerosis**
- in carotid atherosclerosis, vascular dementia and, 477
 - in normocholesterolemic premature atherosclerosis with daytime hypertriglyceridemia, 50
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in CAD men**
- red and white wine drinking effects on, 320
 - risk factors for myocardial infarction and, 325, 326
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in exercising PM women on ERT**
- or not on ERT, 1194
 - with risk for CAD, aerobic exercise and high-fiber, low-fat diet effects on, 378
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in hypercholesterolemia**
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in hypercholesterolemia (Continued)**
- in mild hypercholesterolemia, 1073
 - serum LPL concentration and, 527, 528
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in IDDM**
- energy substrate oxidation and, 656
 - and oxidation of glycated and nonglycated LDLs, 970
 - plasma apo C-3 polymorphisms and, 1299
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in IR**
- CV disease risk factors and, in obese and overweight subjects, 498
 - with LVH, candesartan effects on, 779
 - with microalbuminuria, *see* High-density lipoprotein-cholesterol in microalbuminuric IR; High-density lipoprotein-cholesterol in microalbuminuric NIDDM
 - in non-obese subjects, *see* High-density lipoprotein-cholesterol in non-obese insulin-resistant subjects
 - in normoglycemic men, ABCA1 gene expression-fasting glucose relationship and, 19
 - serum GPI-PLD and, 139
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in microalbuminuric IR**
- cilostazol effects on, 1407
 - see also* High-density lipoprotein-cholesterol in microalbuminuric NIDDM
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in microalbuminuric NIDDM**
- cardiovascular autonomic dysfunction and, 1360, 1362
 - effects of glycemic control on, 354
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in NIDDM**
- and association of corrected QT intervals with carotid artery IMT, 1155
 - and in at-risk for NIDDM subjects, 224, 226
 - and HbA_{1c} in RBC membrane, 124
 - insulin therapy effects on, 694, 697, 698
 - Japanese NIDDM subjects, insulin secretion and insulin sensitivity and, 832
 - metformin effects on, 160, 161
 - with microalbuminuria, *see* High-density lipoprotein-cholesterol in microalbuminuric NIDDM
 - Pancreas Tonic effects on, 1169
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in non-obese insulin-resistant subjects**
- CV disease risk factors and, 498
 - in non-obese NIDDM Korean subjects, 143, 144
 - serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in non-obese subjects**
- in men, AT as fibrinogen level predictor and, 985, 986
 - in premenopausal women, metabolic risk and, 1068-1070
 - see also* High-density lipoprotein-cholesterol in non-obese insulin-resistant subjects
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in obese women**
- effects of moderate weight loss and sibutramine or orlistat on, 432
 - in PM women, fluvastatin effects on, 736
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in obesity**
- CV disease risk factors and, 498
 - in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057

- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in obesity (*Continued*)
 with MS in chronic renal disease, 1257
 smoking-ADMA-obesity relationship and, 1575, 1576
see also High-density lipoprotein-cholesterol in obese women;
 High-density lipoprotein-cholesterol in obesity with MS
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in obesity with MS
 in adolescents, 864, 865
 in treatment-seeking subjects, 436
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in PM women
 of exercising women on ERT, 1194
 obese women, fluvastatin effects on, 736
 simvastatin effects on BMD and, 745, 746
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in young men
 with hypertensive parents, 470
 serum adiponectin association with, 589-593
- High-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C) in young subjects
 with NIDDM parents, 756
see also High-density lipoprotein-cholesterol in young men
- High-density lipoprotein₁, *see* Lipoprotein(a)
- High-density lipoprotein₂-cholesterol (α lipoprotein₂-cholesterol; HDL₂-C)
 erythrocyte membrane, 574
 exercise and, *see* High-density lipoprotein₂-cholesterol, exercise and
 HF/HC diet effects on, 1023
 in MS, 312, 313, 315
 plasma, in FCHL, ω -3 PUFA effects on levels of paraoxonase and, 153-158
 serum, *see* Serum high-density lipoprotein₂-cholesterol
- High-density lipoprotein₂-cholesterol (α lipoprotein₂-cholesterol; HDL₂-C), exercise and
 blood, apo E polymorphism association with $\dot{V}O_{2\max}$ and, 111-113
 serum, apo E genotype and changes in $\dot{V}O_{2\max}$ and, in endurance exercise, 196, 198-200
 soccer playing effects on, 1264
- High-density lipoprotein₃-cholesterol (α lipoprotein₃-cholesterol; HDL₃-C)
 erythrocyte membrane, 574
 exercise and, *see* High-density lipoprotein₃-cholesterol, exercise and
 in FCHL, ω -3 PUFA effects and, 154, 155
 HF/HC diet effects on, 1023
 serum, *see* Serum high-density lipoprotein₃-cholesterol
- High-density lipoprotein₃-cholesterol (α lipoprotein₃-cholesterol; HDL₃-C), exercise and
 blood, apo E polymorphism association with $\dot{V}O_{2\max}$ and, 111-113
 serum, apo E genotype and changes in $\dot{V}O_{2\max}$ and, in endurance exercise, 196, 198-200
 soccer playing effects on, 1264
- High-fat (HF) diet
 fenofibrate and, *see* High-fat diet, fenofibrate and
 and intracellular Ca^{2+} chelator effects on IR and spontaneous hypertension, 269-272
 NO-1886 effects on fatty liver in STZ-DM due to, 260-263
 obesity and, *see* High-fat diet, obesity and
 SM and, *see* High-fat diet, effects of, on SM
see also High-fat/high-cholesterol diet, lipemic response to
- High-fat (HF) diet, effects of, on SM (*Continued*)
 effects of fiber type and, on skeletal muscle TAG and FATP-1 content, 1032-1036
 and insulin-nonspecific reduction in SM glucose transport, 912-917
 on insulin-resistant lipolysis in SM, 794-798
- High-fat (HF) diet, fenofibrate and
 fenofibrate effects on white adipose tissue and HF diet-induced weight gain by ovariectomized subjects, 1284-1289
 fenofibrate prevention of HF diet-induced obesity and HTG in LDL-receptor null subjects, 607-613
- High-fat (HF) diet, obesity and
 fenofibrate prevention of HF diet-induced obesity in LDL-receptor null subjects, 607-613
 leptin therapy to augment leptin circadian rhythm after weight loss in HF diet-induced obesity, 782-789
 role of caloric intake and low-fat diet versus, in development of NIDDM with obesity, 454-457
- High-fat/high-cholesterol (HF/HC) diet, lipemic response to exercise effects on PP lipemic response after, 1021-1026
 role of cholesterol absorption and hepatic ACAT activity in, 817-822
- High-fiber/low-fat diet, effects of exercise and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
- High-sensitivity C-reactive protein (CRP), effect of insulin therapy of NIDDM on, 693-699
- High-sucrose (S) diet, NOS inhibition and pioglitazone effects on insulin action in subjects on, 22-27
- HIM2 (hexyl-insulin monoconjugate 2), oral, for IDDM, 54-58
- Hindlimb suspension, 1-day, whole-body and skeletal muscle IR development after, 1215-1222
- Hirsutism in PCOS, 366
- Histidine (His), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Histology, pancreatic islet, bezafibrate effects on, in obese NIDDM subjects, 408-409
- HIV (human immunodeficiency virus)-infected subjects, lipodystrophic, IGFs, GHBP, IGFBPs, and IGFBP-3 protease, in 1565-1573
- HL, *see* Hepatic lipase
- HNF-4 α gene, triple mutations of, associated with early-onset NIDDM in Filipino family, 959-963
- HNSCC (head and neck squamous cell carcinoma), effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-trans retinoic acid and on cell proliferation in, 1007-1012
- HOMA (homeostasis model assessment) IR index
 adiponectin and, *see* HOMA IR index, adiponectin and in Ecuadorian Amazon Shuar women, 1356
 effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism on, 304
 and glycoprotein PC-1 K121Q polymorphism association with race but not IR in children, 466, 467
 in insulin sensitivity, 1109, 1110
 in Japanese subjects with beta-cell dysfunction, 950
 in liver cirrhosis, 922-926
 in NIDDM, *see* HOMA IR index in NIDDM
 in obesity, *see* HOMA IR index in obesity
 in PM women, *see* HOMA IR index in PM women
 in postpubertal Asian Indian adolescents, 1338, 1339
 serum GPI-PLD and, 139
- HOMA (homeostasis model assessment) IR index, adiponectin and adiponectin levels and, 2

- HOMA (homeostasis model assessment) IR index, adiponectin and
(Continued)
 in daytime hypertriglyceridemic prematurely atherosclerotic
 normocholesterolemic subjects and their first-degree relatives,
 50
 in hypercholesterolemia, serum LPL concentration and, 528
 and NEFA regulation of adiponectin, 791
 relationship between serum adiponectin, serum soluble leptin
 receptor, serum leptin, lipids, leptin receptor gene Lys109Arg
 and Gln223Arg polymorphisms and, in Japanese subjects,
 879-885
- HOMA (homeostasis model assessment) IR index in NIDDM
 and BMI in non-obese insulin-resistant NIDDM Korean subjects,
 142-146
 in Japanese subjects, insulin sensitivity and insulin secretion and,
 831-835
 with obesity, pioglitazone effects on, 490
- HOMA (homeostasis model assessment) IR index in obesity
 in children, 1244
 in Japanese subjects, 652
 with NIDDM, pioglitazone effects on, 490
 in PM women, fluvastatin effects on, 736
- HOMA (homeostasis model assessment) IR index in PM women
 on ERT and at risk for CAD, 378
 obese women, fluvastatin effects on, 736
- Homeostasis model assessment, *see* HOMA IR index
- Homocysteine (Hey)
 plasma, effects of elevated, on endothelial function recovery after
 denudation of carotid arteries, 760-765
 remethylation and trans-sulfuration of, 1480-1483
 total, in subclinical hypothyroidism, 1513
see also Hyperhomocysteinemia
- HPA, *see* Hypothalamic-pituitary-adrenal axis
- HPRT (hypoxanthine phosphoribosyl transferase), point mutation in,
 responsible for hyperuricemia in women, 1500-1502
- HR, *see* Heart rate
- 11-HSD, *see* 11 β -Hydroxysteroid dehydrogenase; Hepatic 11 β -
 hydroxysteroid dehydrogenase 1 mRNA; 11 β -hydroxysteroid
 dehydrogenase 2 mRNA
- HTG, *see* Hypertriglyceridemia
- HTGL (hepatic triglyceride lipase), endurance exercise effects on,
 196, 198-200
- HTN, *see* Hypertension
- Human chorionic gonadotropin (hCG), low temperature blocking
 stimulatory effects of, on steroidogenic acute regulatory
 protein mRNA and testosterone production but not on cAMP
 production in tumor cells, 955-958
- Human immunodeficiency virus (HIV)-infected subjects,
 lipodystrophic, IGFs, GHBP, IGFBPs, and IGFBP-3 protease,
 in 1565-1573
- Hydrocortisone, *see* Cortisol
- Hydrophilic 7 β (beta)-hydroxy bile acids, effectiveness of lovastatin,
 cholestyramine, and chenodeoxycholic acid in
 cerebrodendinous xanthomatosis, compared, 556-562
- 7 β (beta)-Hydroxy bile acids, hydrophilic, effectiveness of
 lovastatin, cholestyramine, and chenodeoxycholic acid in
 cerebrodendinous xanthomatosis, compared, 556-562
- 7 α -Hydroxy-4-cholestolen-3-one, plasma 27-hydroxycholesterol and
 plasma, as markers for hepatic bile synthesis, dietary
 cholesterol and, 42-48
- 27-Hydroxycholesterol, plasma, and plasma 7 α -hydroxy-4-cholestolen-
 3-one and plasma, as markers for hepatic bile synthesis,
 dietary cholesterol and, 42-48
- (-)Hydroxycitrate, effects of, on platelet function in DM, 66-72
- 8-Hydroxydeoxyguanosine (8-OHDG), effects of hypoxia and
 hypoxic training on hepatic levels of, 716-719
- 7 α (alpha)-Hydroxylase, cholesterol, effects of ileal bile transport
 inhibition on plasma C level through FXR inactivation and
 stimulation of, 927-932
- 17 α (alpha)-Hydroxylase/17,20-lyase deficiency, mutant CYP17
 genes in, 1527-1531
- Hydroxyproline, urinary excretion of, in severe lipodystrophy, leptin
 replacement therapy effects on, 516
- 11 β -Hydroxysteroid dehydrogenase (11 β -HSD)
 CDCA effects on, in various tissues, 811-816
see also 11 β -Hydroxysteroid dehydrogenase 1 mRNA; 11 β -
 Hydroxysteroid dehydrogenase 2 mRNA
- 11 β (beta)-Hydroxysteroid dehydrogenase 1 (11 β -HSD1) mRNA
 (messenger ribonucleic acid)
 in AT, effects of restricted diet on, 30-31
 hepatic, responsiveness of body weight and, to 11 β -HSD
 inhibition by glycyrrhetic acid, 600-606
- 11 β (beta)-Hydroxysteroid dehydrogenase 2 (11 β -HSD2) mRNA
 (messenger ribonucleic acid), responsiveness of body weight
 and, to 11 β -HSD inhibition by glycyrrhetic acid, 600-606
- 1,25 Hydroxyvitamin D, serum, in severe lipodystrophy, leptin
 replacement therapy effects on, 516
- 25 Hydroxyvitamin D, serum, in severe lipodystrophy, leptin
 replacement therapy effects on, 516
- Hypercholesterolemia
 familial, effects of S-2E and PRV in, compared, 680-685
 mild, diet composition as determinant of plasma ADMA in, 1072-
 1075
 in obese hyperuricemic Japanese male adolescents, 450
 serum LPL concentration related to TG metabolism in, 526-531
 simvastatin effects on BMD in PM women with, 744-748
- Hyperglycemia
 beta-cell dysfunction and development of, in Japanese subjects,
 943-954
 effects of glucagon, epinephrine and, on renal glucose release in
 conscious subjects, 933-941
 PPFS-410 effects on, 1532-1537
 and hyperinsulinemia, *see* Hyperglycemia, hyperinsulinemia and
 Hyperglycemia, hyperinsulinemia and
 in maturity-onset hyperinsulinemia with polygenic obesity and
 hyperglycemia, CL316,243 effects on, 799-808
 PP, MNH-01 effects on PP hyperinsulinemia, 977-983
- Hyperglycemic-glycogenolytic factor, *see* Glucagon
- Hyperhomocysteinemia (HHcy)
 causes of, 1481
 in disabled hospitalized older subjects, 1016-1020
- Hyperinsulinemia
 contribution of cardiorespiratory fitness and visceral AT to
 dyslipidemia, hypertension and, in NIDDM with IGT, 644-
 649
 effects of portal venous, on gut glucose absorption in conscious
 subjects, 1290-1295
 hyperglycemia and, *see* Hyperglycemia, hyperinsulinemia and
 normoglycemic, *see* Normoglycemic hyperinsulinemia
 obesity and, *see* Hyperinsulinemia, obesity and
 plasma amino acid concentrations and whole-body protein
 synthesis in, in young men, 388-396
 tempol effects on hypertension and, based on increase in
 medullary BF, 1305-1308
- Hyperinsulinemia, obesity and
 in obese PCOS women, 359
 polygenic obesity, CL316,243 effects on hyperglycemia and
 maturity-onset hyperinsulinemia, 799-808

- Hyperlipidemia**
 carotid atherosclerosis, vascular dementia and, 477
 familial combined, ω -3 PUFA effects on levels of plasma HDL₂-C and paraoxonase in, 153-158
 in hypothyroidism, 278
 mixed, effects of S-2E and PRV in, compared, 680-685
 in obese PCOS women, 366
see also Hypercholesterolemia; Hypertriglyceridemia
- Hypertension (HTN)**
 in CAD men, 424-426
 carotid atherosclerosis, vascular dementia and, 477
 effects of increased medullary blood flow by tempol on hyperinsulinemia and, 1305-1308
 in exercise, *see* Hypertension in exercise
 of hypercholesterolemic PM women, simvastatin effects on, 745
 in hypothyroidism, 278
 insulin secretion, insulin sensitivity and, and metabolic profile of young men with hypertensive parents, 469-475
 IR and, *see* Hypertension, IR and
 in NIDDM, *see* Hypertension in NIDDM
 in obesity, *see* Hypertension in obesity
- Hypertension (HTN), IR and**
 cardiovascular autonomic dysfunction, microalbuminuria and, 1360
 GLUT₄ in adipocytes and, 382-387
 intracellular Ca²⁺ chelator effects on, high-fat diet and, 269-272
- Hypertension (HTN) in exercise**
 in nondiabetic and IDDM smokers, 1140-1144
 resistance exercise effects on insulin-mediated glucose disposal and TNF- α in older subjects with, 397-402
- Hypertension (HTN) in NIDDM**
 and association of corrected QT intervals with carotid artery IMT, 1155
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360
 with IGT, contribution of cardiorespiratory fitness and visceral AT to hyperinsulinemia, dyslipidemia and, 644-649
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- Hypertension (HTN) in obesity**
 in obese PCOS women, 366
 and smoking-ADMA-obesity relationship, 1575
- Hyperthyroidism**
 parathyroidectomy for primary, serum PTH relation to vitamin D profile in eucalcemia after, 1101-1106
 3,3'-T₂S in, 540
- Hypertriglyceridemia (HTG)**
 daytime, in normocholesterolemic prematurely atherosclerotic subjects with, and in their first-degree relatives, 49-53
 fenofibrate preventing obesity and, due to high-fat diet in LDL-receptor null subjects, 607-613
- Hypertrophy, left ventricular, candesartan effects on IR and, 777-781**
- Hyperuricemia**
 in obese Japanese male adolescents, 448-453
 in women, point mutation in HPRT responsible for, 1500-1502
- Hypoglycemia**
 in IDDM during moderate exercise, CHO intake to prevent, 1129-1130
insulin-induced, see Insulin-induced hypoglycemia
 muscle glutamine release of, during normoglycemia, normoglycemic hyperinsulinemia and, 1208-1214
 nighttime and daytime differences in counterregulation of, 894-898
- Hypoglycemia (Continued)**
 pramlintide effects on response of catecholamines, glucagon, and symptoms of, 1227-1232
- Hypogonadism, cortisol production in men with, 1174-1176**
- Hypolactatemia, DCA-induced, in cirrhotic and noncirrhotic subjects, 1087-1094**
- Hypothalamic-pituitary-adrenal axis (HPA)**
 central, CRH test of relation between MS and dysregulation of, 720-726
 leptin effects on weight loss, dysphagia, and activity of, in STZ-DM, 1558-1564
- Hypothyroidism**
 effects of T₄ therapy of, on endothelial function, 278-279
 subclinical, CV disease risk factors in, 1512-1515
 3,3'-T₂S in, 540
- Hypoxanthine, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776**
- Hypoxanthine phosphoribosyl transferase (HPRT), point mutation in, responsible for hyperuricemia in women, 1500-1502**
- Hypoxemia-stimulated glucose transport in SM, 914**
- Hypoxia, effects of hypoxic training and, on hepatic 8-OHDG and GSH levels, 716-719**
- ICAM-1, *see* Intercellular adhesion molecule-1**
- IDDM, *see* Insulin-dependent diabetes mellitus**
- IDL, *see* Intermediate-density lipoprotein**
- IDL-C, *see* Intermediate-density lipoprotein-cholesterol**
- IGF, *see entries beginning with terms:* Insulin-like growth factor**
- IGT, *see* Impaired glucose tolerance**
- IL-1 β (interleukin-1 β), effects of ω -3 PUFAs alone or with *all-rac* α -tocopherol on, 236-240**
- IL-6, *see* Interleukin-6**
- Ile (isoleucine), *see* Plasma isoleucine**
- Ileal bile transport, effects of inhibition of, on plasma cholesterol level through hepatic farnesoid X receptor inactivation and cholesterol 7 α -hydroxylase stimulation, 927-932**
- IMCD (inner medullary collecting duct), ET effects on AVP₂ mRNA in, 1177-1183**
- IM-FSIVGTT (insulin-modified frequently sampled intravenous glucose tolerance test), population and individual minimal modeling of, 1349-1354**
- Immunofluorescence of eNOS and iNOS in early NIDDM nephropathy, 1474**
- Immunoreactive insulin (IRI)**
 fasting, in IR with LVH, 779
 in NIDDM, microalbuminuria and, 354
- Impaired glucose tolerance (IGT)**
 effects of weight loss on IR with normal FPG or, in obese subjects 1095-1100
 insulin regulating kinetics of NEFAs in adult CF with, 1467-1472
*in NIDDM, *see* Impaired glucose tolerance in NIDDM in non-obese subjects, insulin secretion, GLP-1, and glucose-dependent insulinotropic polypeptide after glucose ingestion in, 624-631*
- Impaired glucose tolerance (IGT) in NIDDM**
 contribution of visceral AT and cardiorespiratory fitness to hyperinsulinemia, dyslipidemia, and hypertension in, 644-649
see also First-degree relatives, IGT, of African American NIDDM subjects
- IMT (intimal-media thickness), *see* Carotid artery intimal-media thickness**
- Incipient nephropathy in Japanese NIDDM subjects, G276T adiponectin polymorphism and, 1223-1226**

- Incretins**
 alcohol intake effects on PP lipemia and PP levels of, in NIDDM, 77-83
see also specific incretins
- Individual minimal modeling, population and, of IM-FSIVGTT, 1349-1354
- Inducible nitric oxide synthase (iNOS) in early NIDDM nephropathy, 1474
- Infants, *see* Newborns
- Infarction, risk factors for myocardial, as predictors of CAD in men, 324-329
- Infertility in obese PCOS women, 366
- Inflammation
 in chronic disease, markers of, 899-903
 in established preeclampsia, IR and, 1433-1435
 low-grade, and MS in CHD, 852-857
see also Inflammation-sensitive molecules; Inflammatory molecules
- Inflammation-sensitive molecules in men with CAD, acute effects of red and white wine drinking on circulating, 318-323
- Inflammatory molecules
 effects of different oils on neutrophil FA composition and generation of, 59-65
 in postmenopausal women on ERT and at risk for CAD, effects of high-fiber, low-fat diet and exercise on adhesion molecules and, 377-381
see also specific inflammatory molecules
- Inner medullary collecting duct (IMCD), ET effects on AVP₂ mRNA in, 1177-1183
- iNOS (inducible nitric oxide synthase) in early NIDDM nephropathy, 1474
- INS-1 cells, effects of long-term exposure of, to *cis* and *trans* FAs, on insulin secretion and FA oxidation, 1158-1165
- Insulin**
 acute effects of nicotine on, in smokers, 578-582
 in CAD men, risk factors for myocardial infarction and, 325
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1090
 diet and, *see* Insulin, diet and
 effects of high glucose and high, on protein synthesis in cardiac myocytes and DNA, and collagen synthesis in cardiac fibroblasts, 710-715
 in exercising PM women on or not on ERT, 1194
 exogenous, unresponsiveness of NEFA multiphasic profile to, during FSIVGTT, 1202-1207
 fasting, *see* Fasting insulin
 hepatic apo B production regulated by, independently of PKBα/
Akt1 mass or activity, 228-236
 leptin levels and, 1412-1414
 and leucine turnover in third trimester of uncomplicated pregnancy, 547
 in obese and overweight women, serum TNF soluble receptors, TNF-β, and NO and, 1269
 plasma, *see* Plasma insulin
 PP, OC effects on, 350, 351
 in premenopausal women, sex steroids, plasma Lp and, 189, 190
 regulation of NEFA kinetics by, in adult cystic fibrosis with impaired glucose tolerance, 1467-1472
 and relation of intracellular cord blood platelet magnesium to birth weight, 1545
 serum, *see* Serum insulin
 smoking and, *see* Insulin, smoking effects and
- Insulin (Continued)**
see also Diabetes mellitus; Hyperinsulinemia; Hypoglycemia; Insulin analogue; Insulin-dependent diabetes mellitus; Insulin-induced hypoglycemia; Insulin/insulin-like growth factor hypothesis; Insulin-like growth factor-1; Insulin-mediated glucose disposal; Insulin monoconjugate 2; Insulin in obesity; Insulin in PM women; Insulin release and secretion; Insulin resistance; Insulin sensitivity; Insulin signaling, effects of exercise on; Insulin-stimulated glucose transport; Insulin therapy; Insulinotropic polypeptide; Non-insulin-dependent diabetes mellitus; Streptozotocin-induced diabetes mellitus
- Insulin, diet and**
 NOS inhibition and pioglitazone effects on action of insulin in subjects on high-sucrose diet, 22-27
see also Insulin, HF diet effects on, in SM
- Insulin, HF diet effects on, in SM**
 insulin-nonspecific reduction and HF effects on glucose transport, 912-917
 and on SM TAG and FATP-1 content, 1033-1034
- Insulin, smoking effects and**
 effects on intravascular HDL particle remodeling, 860
 smoking-ADMA-obesity relationship and, 1575, 1576
- Insulin analogue, glargine as, effects of, on protein and lipid metabolism, 1037-1044
- Insulin-dependent diabetes mellitus (IDDM; type 1 diabetes mellitus)
 ATP-citrate lyase role in acetyl-CoA and function of platelets in, 66-72
 cardiovascular disease risk factors associated with serum sialic acid in Kuwaiti children and adolescents with, 638-643
 energy substrate oxidation in, 655-659
 glycated and nonglycated LDL oxidation in, compared, 969-975
 glycemic control of, *see* Glycemic control of IDDM
 insulin concentration and CHO requirement in, during moderate exercise, 1126-1130
 kinetics of interstitial glucose in, 1484-1492
 oral HbM2 for, 54-58
 pituitary response to exercise by smokers with, 1140-1144
 plasma apo C-3 polymorphisms in, 1296-1304
 serum resistin levels in, before and after pancreatic islet transplantation, 403-404
- Insulin-induced hypoglycemia**
 acute, effects of normoglycemic hyperinsulinemia and, on retinal glucose uptake and ocular glucose metabolism, 1274-1283
 effects of, on plasma PTH level in adrenal insufficiency 1251-1254
- Insulin/insulin-like growth factor (IGF) hypothesis of PCOS, 360, 363-365
- Insulin-like growth factor(s) (IGF)**
 IGFBPs, IGFBP-3 protease, GHBP and, in lipodystrophic HIV-infected subjects, 1565-1573
see also Insulin-like growth factor-1
- Insulin-like growth factor-1 (IGF-1)**
 in acromegaly, 565
 carotid atherosclerosis, vascular dementia and, 477
 and relation of intracellular cord blood platelet magnesium to birth weight, 1545
 rhGH therapy effects on, in GH-deficient subjects, 741
- Insulin-like growth factor-binding protein(s) (IGFBP), IGFs**
 IGFBPs, IGFBP-3 protease, GHBP and, in lipodystrophic HIV-infected subjects, 1565-1573
- Insulin-like growth factor-binding protein 3 (IGFBP-3) protease, IGFs, IGFBPs, GHBP and, in lipodystrophic HIV subjects, 1565-1573**

- Insulin-mediated glucose disposal, resistance exercise effects on TNF- α and, in older hypertensive subjects, 397-402
- Insulin-modified frequently sampled intravenous glucose tolerance test (IM-FSIVGTT), population and individual minimal modeling of, 1349-1354
- Insulin monconjugate 2, oral hexyl-, for IDDM, 54-58
- Insulin in obesity
- men, NEFA effects on hepatic glycogen level and, 892
 - women, effects of moderate weight loss and sibutramine or orlistat on, 432
- Insulin in PM women
- on ERT and at risk for CAD, aerobic exercise and high-fiber, low-fat diet effects on inflammatory and adhesion molecules and, 378
 - sex steroids and plasma Lp and, 189, 190
- Insulin release and secretion
- dose-, glucose-, and calcium-dependent rebaudioside A effects on, 1378-1381
 - effects of long-term exposure of INS-1 cells to *cis* and *trans* FAs on, 1158-1165
 - exercise effects on inhibitory effects of NE on, 1424-1432
 - glucose-stimulated, LSF effects on, in STZ-DM, prediabetic, and normal subjects, 290-296
 - in IGT, *see* Insulin release and secretion in IGT
 - insulin sensitivity, *see* Insulin release and secretion, S, and in NIDDM, *see* Insulin release and secretion in NIDDM
 - normal glucose tolerance and, *see* Normal glucose tolerance, insulin release and secretion in
 - in obesity, *see* Insulin release and secretion in obesity
 - S_i, *see* Insulin release and secretion, S, and
- Insulin release and secretion, S, and
- in Japanese subjects at different stages of glucose tolerance, 831-835
 - metabolic profile and, in young men with hypertensive parents, 469-475
 - in normal glucose-tolerant Pima Indians with LBW, 904-911
 - rosiglitazone effects on plasma adiponectin and, in IGT first-degree relatives of African American NIDDM subjects, 1552-1557
- Insulin release and secretion in IGT
- effects of weight loss by obese subjects with IGT on, 1095-1100
 - GLP-1, glucose-dependent insulinotropic polypeptide and, after glucose ingestion by non-obese IGT subjects, 624-631
- Insulin release and secretion in NIDDM
- insulin sensitivity and, at different stages of glucose tolerance in Japanese subjects, 831-835
 - with obesity, pioglitazone effects on prevention of beta-cell mass loss and, 488-494
- Insulin release and secretion in obesity
- effects of weight loss on, in IGT or normal glucose-tolerant subjects, 1095-1100
 - with NIDDM, pioglitazone effects on prevention of beta-cell mass loss and, 488-494
- Insulin resistance (IR)
- adiponectin, CRP and, in postpubertal Asian Indian adolescents, 1336-1341
 - candesartan effects on LVH and, 777-781
 - in cirrhosis, levels of serum soluble TNF-R associated with, 922-926
 - development of whole-body and skeletal muscle, after 1-day hindlimb suspension, 1215-1222
 - glycoprotein PC-1 K121Q polymorphism associated with race but not with, in children, 465-468
- Insulin resistance (IR) (*Continued*)
- HF diet effects on insulin-resistant lipolysis in skeletal muscle, 794-798
 - hypertension and, *see* Hypertension, IR and with increased serum glycosylphosphatidylinositol-specific phospholipase D, 138-139
 - indices of, 1522-1526
 - and inflammation in established preeclampsia, 1433-1435
 - with microalbuminuria, *see* Microalbuminuria in IR
 - HF diet effects on insulin-resistant lipolysis in skeletal muscle, 794-798
 - in non-obese subjects, *see* Non-obese subjects, insulin-resistant obesity and, *see* Insulin resistance in obesity
 - plasma NEFA regulation in, 1197-1201
 - prevalence of, and associated CV disease risk factors in overweight and normoponderal subjects with, 495-499
 - relationship between BMI, beta-cell function and, 1462-1466
 - SSPG in, *see* Steady-state plasma glucose in IR
 - stevioside effects on skeletal muscle glucose transport in, 101-107
 - see also* HOMA IR index; Insulin sensitivity; Metabolic syndrome
- Insulin resistance (IR) in obesity
- and HF diet effects on insulin-resistant lipolysis in skeletal muscle, 794-798
 - with normal FPG or IGT, effects of weight loss on, 1095-1100
 - Ob-R gene polymorphism associated with, in Japanese men, 650-654
 - prevalence of associated CV disease risk factors with, 495-499
- Insulin sensitivity (S_i)
- effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism on body composition and, in men, 303-309
 - erythrocyte membrane lipid composition association with arachidonic acid and, 571-577
 - estimates of, 1107-1112
 - insulin secretion and, *see* Insulin release and secretion, S, and isoretinoic effects on, 4-10
 - long-term monitoring of, in GH-deficient subjects on GH therapy, 740-743
 - in PM women, independent association of androgenicity and obesity with, 507-512
 - and relationship between BMI, IR, and beta-cell function, 1462-1466
- stevioside effects on skeletal muscle glucose transport in, 101-107
- Insulin signaling, effects of exercise on
- on hepatic insulin signaling and hepatic PEPCK, 836-841
 - in overweight nondiabetic and NIDDM subjects, 1233-1242
- Insulin-stimulated glucose transport, reduced SM, high-fat diet and, 912-917
- Insulin therapy
- of NIDDM, effects of, on serum high-sensitivity CRP, 693-699;
 - see also* Glycemic control of NIDDM
 - unresponsiveness of NEFA multiphasic profile to, during FSIVGTT, 1202-1207
 - see also entries beginning with terms:* Glycemic control
- Insulinotropic polypeptide, glucose-dependent, alcohol effects on, in NIDDM, 77-83
- Intercellular adhesion molecule-1 (ICAM-1)
- in CAD, *see* Intercellular adhesion molecule-1, CAD and in NIDDM, metformin effects on, 161
- Intercellular adhesion molecule-1 (ICAM-1), CAD and
- high-fiber, low-fat diet and exercise effects on, in postmenopausal women on ERT and at risk for CAD, 377-381
 - red and white wine effects on, in CAD men, 318-323

- Interleukin-1 (IL-1), effects of ω -3 PUFAs alone or with *all-rac* - tocopherol on, 236-240
- Interleukin-6 (IL-6)
CAD and, *see* Interleukin-6, CAD and
in CHD, IR and, 853, 854
effects of ω -3 PUFAs alone or with *all-rac* α -tocopherol on, 236-240
in inflammation of chronic disease, 901, 902
and IR in liver cirrhosis, 923, 924
in non-obese men, and AT as fibrinogen level predictor, 985, 986
see also Interleukin-6 mRNA; Interleukin-6 receptor
- Interleukin-6 (IL-6), CAD and
aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 379
plasma, red and white wine effects on, in CAD men, 318-323
- Interleukin-6 (IL-6) mRNA (messenger ribonucleic acid), SM,
effects of epinephrine and ionomycin on protein release and, compared, 1492-1495
- Interleukin-6 (IL-6R) receptor, and IR in liver cirrhosis, 923, 924
- Intermediate-density lipoprotein (IDL)
in HL deficiency, 523
plasma, in PM and premenopausal women, sex steroids and, 189
and plasma vitamin K transport, 216
see also Intermediate-density lipoprotein-cholesterol
- Intermediate-density lipoprotein-cholesterol (IDL-C)
in HD subjects, 1104, 1115
in IDDM, plasma apo C-3 polymorphisms and, 1301
 ω -3 PUFA and exercise effects on, 751
S-2E and PRV effects on, in mixed hyperlipidemia, compared, 682-683
- Interstitial glucose, kinetics of, in IDDM, 1484-1492
- Intimal-media thickness, *see* Carotid artery intimal-media thickness
- Intracellular Ca^{2+} , *see* Calcium $^{2+}$; Calcium $^{2+}$ chelator
- Intracellular cord blood platelet magnesium (Mg), relation of, to birth weight, 1544-1547
- Intramuscular triglycerides (TGs) after 1-day hindlimb suspension, 1217
- Intranuclear nuclear factor- κ B (NF κ B), differential effects of glucose and alcohol on ROS generation and, in mononuclear cells, 330-334
- Intravascular remodeling of HDL particles, smoking effects on, and its implications for RCT system, 858-862
- Intravenous glucose tolerance test, *see* Frequently sampled intravenous glucose tolerance test
- Ionomycin, effects of epinephrine and, on skeletal muscle IL-6 mRNA and protein release, compared, 1492-1495
- IR, *see* Insulin resistance
- IRI, *see* Immunoreactive insulin
- Ischemic heart disease, carotid atherosclerosis, vascular dementia and, 477
- Islets of Langerhans, *see* Pancreatic islets
- Isoflavone, soy, effects of moderate exercise and, on AT accumulation and bone loss in postmenopausal subjects, 942-948
- Isoleucine, *see* Plasma isoleucine
- Isoprostanate, F₂, effects of glycemic control on level of, at IDDM onset, 1118-1120
- Isotretinoin, effects of, on plasma TGs and insulin sensitivity, 4-10
- IVGTT (intravenous glucose tolerance test), *see* Frequently sampled intravenous glucose tolerance test
- Japanese adolescents, hyperuricemic obese, 448-453
- Japanese men, polymorphism in
- 1562C→T MMP-9 polymorphism associated with BMD in, 135-137
- Japanese men, polymorphism in (*Continued*)
obese, Ob-R gene polymorphism associated with IR in, 650-654
young, Pro12Ala PPAR γ 2 polymorphism associated with adiponectin levels in, 1548-1551
- Japanese NIDDM subjects
with incipient diabetic nephropathy in, G276T adiponectin polymorphism in, 1223-1226
insulin secretion and sensitivity at different stages of glucose tolerance in, 831-835
- Japanese subjects
NIDDM, *see* Japanese NIDDM subjects
role of beta-cell dysfunction in development of hyperglycemia in, 943-954
see also Japanese adolescents; Japanese subjects, polymorphism in Japanese subjects, polymorphism in ABCA1 gene, serum HDL-C or apo A-I levels associated with, in Japanese school-age children, 182-186
G276T adiponectin polymorphism and incipient diabetic nephropathy in NIDDM subjects, 1223-1226
leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, relationship between lipids, serum soluble leptin receptor, serum leptin, HOMA IR index, 879-885
see also Japanese men, polymorphism in
- K (potassium) channel inhibitors, and 4AP effects on delayed vasorelaxation by troglitazone, 147-152
- K121Q polymorphism of glycoprotein PC-1, association of, with race but not with IR in children, 465-468
- Kidney, *see* Nephropathy and entries beginning with term: Renal Kinase
creatine, in dyslipidemic CRF subjects on HD, 1116
see also Glycogen synthase; Glycogen synthase kinase- β 3 mRNA; Protein kinase; Protein kinase Ba/Akt1
- Kinetics
apo A-1, apo B-48, and apo B-100, in obese MS subjects with chronic renal disease, 1255-1261
of apo B-100 in HL deficiency, 523
interstitial glucose, in IDDM, 1488-1492
plasma leucine, and whole-body leucine synthesis in hyperinsulinemic young men, 392-393
regulation of NEFA, by insulin in adult cystic fibrosis with impaired glucose tolerance, 1467-1472
- Korean subjects
effects of PPAR γ 2 Pro12Ala polymorphism on AT distribution, in Korean women, 1538-1543
non-obese insulin-resistant NIDDM, BMI as determining factor of IR degree in, 142-146
obese, effects of UCP-1 – 3826A→G polymorphism on LDL-C level in, 1054-1059
- Kuwaiti children and adolescents, IDDM, cardiovascular disease risk factors associated with serum sialic acid in, 638-643
- Lactate, DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1087-1094
- Lactate dehydrogenase (LDH), DM effects on, 68
- Lactic acid, beer ingestion and sauna bathing effects on, 774-775
- Lard in HF diet, 1033
- Late-onset propionic acidemia, fatal outcome of, 809-810
- LBM (lean body mass), *see* Fat-free mass
- LBW (low birth weight) Pima Indians with normal glucose tolerance, insulin secretion, insulin sensitivity in, 904-911
- LCAT, *see* Lecithin:cholesterol acyltransferase
- LDH (lactate dehydrogenase), DM effects on, 68
- LDL, *see* Low-density lipoprotein

- LDL-C**, *see* Low-density lipoprotein-cholesterol
- LDLR** (low-density lipoprotein receptor)-null subjects, fenofibrate preventing obesity and hypertriglyceridemia in, 607-613
- Lean body mass**, *see* Fat-free mass
- Lean subjects**, *see entries beginning with terms:* Non-obese subjects
- Lecithin:cholesterol acyltransferase (LCAT)**
- smoking effects on concentrations of, 858-862
 - *see also* Lecithin:cholesterol acyltransferase, ω -3 PUFA effects on
- Lecithin:cholesterol acyltransferase (LCAT), ω -3 PUFA effects on**
- in FCHL, 155
 - on LCAT activity, 752
- Left ventricular hypertrophy (LVH)**, candesartan effects on IR and, 777-781
- Leptin**
- circulating, as marker of fat mass in acute spinal cord injury, 989-994
 - effects of, on HPA activity, weight loss, and dysphagia in STZ-DM, 1558-1564
 - effects of agricultural versus traditional lifestyle on, in Ecuadorian Amazon Shuar women, 1355-1358
 - increased levels of, associated with Trp64Arg polymorphism of β_3 -adrenergic receptor but not with $-3826A \rightarrow G$ polymorphism of UCP-1 gene in Spanish subjects, 1411-1416
 - and relation of intracellular cord blood platelet magnesium to birth weight, 1545
 - in young Japanese men, Pro12Ala PPAR γ 2 polymorphism, adiponectin and, 1549
 - *see also* Leptin mRNA; Leptin in obesity; Leptin receptor; Leptin receptor gene; Leptin therapy; Plasma leptin; Serum leptin
- Leptin mRNA** (messenger ribonucleic acid), fenofibrate effects on, in ovariectomized subjects, 1286
- Leptin in obese women**
- effects of moderate weight loss and sibutramine or orlistat on, 432 with PCOS, 362-363
- Leptin in obesity**
- effects of leptin therapy on circadian rhythm of, and weight loss after HF diet-induced obesity, 782-789
 - in insulin-resistant obese Japanese subjects, 652
 - plasma, NN414 and DZ effects on, compared, 443, 444
 - *see also* Leptin in obese women
- Leptin receptor, soluble**, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and leptin receptor gene Lys109Arg and Gln223Arg polymorphisms in Japanese subjects, 879-885
- Leptin receptor gene**, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and Lys109Arg and Gln223Arg polymorphisms of, in Japanese subjects, 879-885
- Leptin therapy**
- leptin circadian rhythm after weight loss by diet-induced obese subjects increased by, 782-789
 - severe lipodystrophy on body composition, 513-519
- Leucine (Leu)**
- turnover of, during third trimester of uncomplicated pregnancy, 545-549
 - *see also* Plasma leucine
- Leukocyte ABCA1 gene**, expression of, associated with fasting glucose concentration in normoglycemic men, 17-21
- LF** (low-fat diet), role of caloric intake and high-fat diet versus, in development of NIDDM and obesity, 454-457
- LH**, *see* Luteinizing hormone; Luteinizing hormone hypothesis of PCOS
- Lifestyle**
- association between diet, cardiovascular risk factors, plasma CRPs and, 1436-1442
 - **Lifestyle (Continued)**
 - effects of, on leptin in Ecuadorian Amazon Shuar women, 1355-1358
 - effects of, on risk for metabolic syndrome, 1503-1511
- Linoleic acid**
- effects of, on SPI-induced apo A-1 promoter, 1343
 - TG content of, in MS, 312
 - (γ -Linoleic acid in MS, 312
- Linolenic acid**, effects of, on Sp1-induced apo A-1 promoter, 1344
- Linolenic acid**, effects of, on Sp1-induced apo A-1 promoter, 1343
- 3n3 α (alpha)-Linolenic acid in MS, 312
- Lipase**, *see Hepatic lipase; Hepatic triglyceride lipase; Lipoprotein lipase; Phospholipase D*
- Lipemia**, *see Blood lipids*
- Lipid(s)**
- blood, *see Blood lipids*
 - endurance exercise effects on, 195-196
 - erythrocyte membrane, *see Erythrocyte membrane, lipid composition*
 - glargine action on metabolism of, 1037-1044
 - hepatic, fenofibrate effects on accumulation of, 610
 - in HL deficiency, 520-525
 - in obesity, *see Lipid(s) in obesity*
 - plasma, *see Plasma lipids*
 - relationship between serum soluble leptin receptor, serum leptin, HOMA IR index, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, and levels of, in Japanese subjects, 879-885
 - serum, *see Serum lipids*
 - smoking effects on concentrations of, 858-862
 - *see also* Lipid peroxides; Phospholipid(s) *entries beginning with element: Lip- and specific lipids*
- Lipid(s) in obesity**
- effects of NN414 and DZ on glucose tolerance and, compared, 441-447
 - with NIDDM, bezafibrate effects on glucose metabolism and, 405-413
- Lipid peroxides**, carotid atherosclerosis, vascular dementia and, 477, 479
- Lipid transfer inhibitor protein (LTIP)**, smoking effects on, 858-862
- Lipodystrophic human immunodeficiency virus**
- Lipodystrophy**
- with HIV infection, IGFs, IGFbps, GHBP, and IGFBP-3 protease in 1565-1573
 - severe, effects of leptin replacement therapy of, on body composition, 513-519
- Lipogenic enzyme mRNA** (messenger ribonucleic acid), upregulation of SREBP-1 and, in white adipose tissue of CRF subjects, 1060-1065
- R-(+)- α -Lipoic acid (R-LA; thioctic acid)**, effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- Lipolysis in IR**
- IR estimates and, 1199
 - skeletal muscle, HF diet effects on, 794-798
- Lipoprotein (Lp)**
- during estrous cycle, 140-141
 - metabolism of, in hepatic lipase deficiency, 520-525
 - plasma, *see Plasma lipoprotein*
 - triglyceride-rich, plasma vitamin K transport and, 215-221
 - *see also* High-density lipoprotein; Intermediate-density lipoprotein; Lipoprotein(a); Lipoprotein lipase; Low-density lipoprotein
- Lipoprotein(a) [Lp(a)]**
- carotid atherosclerosis, vascular dementia and, 477, 479

- Lipoprotein(a) [Lp(a)] (Continued)**
- in FCHL, ω -3 PUFA effects in, 154
 - serum, in CAD men, 425
 - smoking effects on, 860
 - in subclinical hypothyroidism, 1513
- Lipoprotein lipase (LPL)**
- effects of NO-1886 as activator of, on fatty liver in STZ-DM subjects due to high-fat diet, 260-263
 - endurance exercise effects on, 196, 198-200
 - HF/HC diet effects on, 1023
 - serum, relation between concentration of, and TG metabolism in hypercholesterolemia, 526-531
 - smoking effects on, 861
- Lisofylline (LSF), effects of, on glucose-stimulated insulin secretion in STZ-DM, and prediabetic and normal subjects, 290-296**
- Liver**
- fatty, in STZ-DM, due to high-fat diet, NO-1886 effects on, 260-263
 - see also Liver weight and entries beginning with element: Hepat and specific conditions*
- Liver adipose tissue (AT), and metabolic risk in non-obese premenopausal women, 1066-1071**
- Liver cirrhosis, *see Cirrhosis***
- Liver disease, effects of bile duct ligation- and galactosamine-induced, on cardiac protein synthesis, 964-968**
- Liver weight**
- leptin replacement therapy effects on, in severe lipodystrophy, 515-516
 - MHN-01 effects on, 981
 - in STZ-DM, NO-1886 effects on, 261
- Long-term exposure of INS-1 cells to *cis* and *trans* FAs, effects of, on insulin secretion and FA oxidation, 1158-1165**
- Long-term monitoring of insulin sensitivity in GH-deficient subjects on rhGH therapy, 740-743**
- Long-term stored frozen blood samples, analysis of HbA_{1c} in, 1497, 1498**
- Lovastatin, effectiveness of hydrophilic 7 β -hydroxy bile acids, lovastatin, and cholestyramine and, in CTX, compared, 556-562**
- Low birth weight (LBW) Pima Indians with normal glucose tolerance, insulin secretion, and insulin sensitivity in, 904-911**
- Low-density lipoprotein (β lipoprotein; LDL)**
- atorvastatin effects on, dyslipidemic CRF subjects on HD, 1113-1117
 - diet and, *see Low-density lipoprotein, diet and effects of T₄ therapy in hypothyroidism on endothelial function and, 279*
 - in MS, 312, 313, 315
 - in NIDDM, *see Low-density lipoprotein in NIDDM*
 - oxidation of, *see Oxidation, LDL*
 - plasma, *see Plasma low-density lipoprotein*
 - plasma vitamin K transport and, 218
 - ω -3 PUFA and exercise effects on subfractions of, 749-754
 - serum adiponectin association with particle size of, in young men, 589-593
 - small-dense, *see Small-dense low-density lipoprotein*
 - see also Low-density lipoprotein-cholesterol; Low-density lipoprotein receptor-null subjects; Very-low-density lipoprotein*
- Low-density lipoprotein (β lipoprotein; LDL), diet and and CV disease risk factors, 1438**
- HC diet effects on atherogenic particles of, 823-830
- Low-density lipoprotein (β lipoprotein; LDL) in NIDDM**
- insulin therapy effects on, 694, 697
- Low-density lipoprotein (β lipoprotein; LDL) in NIDDM (Continued)**
- plasma oxidized, correlation between vascular complications, serum PON1 polymorphism and, 297-302
 - PP, alcohol effects on, 78
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C)**
- β_2 -ADR Arg16Gly polymorphism and, 1184
 - carotid artery IMT and, 1155
 - carotid atherosclerosis, vascular dementia and, 477, 479
 - in children, *see Low-density lipoprotein-cholesterol in children*
 - diet and, *see Low-density lipoprotein-cholesterol, diet and in dyslipidemic CRF subjects on HD, 1114*
 - during estrous cycle, 140
 - exercise and, *see Low-density lipoprotein-cholesterol, exercise effects on*
 - in HD subjects, 1014
 - in hypercholesterolemia, *see Low-density lipoprotein-cholesterol in hypercholesterolemia*
 - in hyperlipidemia, *see Low-density lipoprotein-cholesterol in hyperlipidemia*
 - in IDDM, *see Low-density lipoprotein-cholesterol in IDDM*
 - in IGT first-degree relatives of African American NIDDM subjects, 1553
 - in IR, *see Low-density lipoprotein-cholesterol in IR*
 - in Japanese school-age children, ABCA1 gene polymorphism association with, 183
 - in Korean women, AT distribution and, 1541
 - leptin and, *see Low-density lipoprotein-cholesterol, leptin and in MS* *see Low-density lipoprotein-cholesterol in MS*
 - in NIDDM, *see Low-density lipoprotein-cholesterol in NIDDM*
 - in non-obese men, and AT as level of fibrinogen predictor, 985, 986
 - in obesity, *see Low-density lipoprotein-cholesterol in obesity*
 - in overweight women, serum TNF soluble receptors, TNF- β , NO and, 1269
 - plasma, anti-inflammatory effects of ω -3 PUFA alone or combined with *all-rac* α -tocopherol on, 237
 - plasma LDL clearance and, 484
 - plasma vitamin K transport and, 216
 - in PM women, *see Low-density lipoprotein-cholesterol in PM women*
 - in postpubertal Asian Indian adolescents, 1338
 - serum, in CAD men, 425
 - smoking effects on, 860
 - in subclinical hypothyroidism, 1513
 - WPG effects on, 1311-1312
 - in young subjects, *see Low-density lipoprotein-cholesterol in young subjects*
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C), diet and**
- aerobic exercise and high-fiber, low-fat diet effects in postmenopausal women on ERT and at risk for CAD, 378
 - and CV disease risk factors, 1437
 - HF/HC diet effects, 1023
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C), exercise effects on**
- exercise effects on, in overweight nondiabetic and NIDDM subjects, 1236
 - in PM women, *see Low-density lipoprotein-cholesterol, exercise effects on, in PM women on ERT*
 - ω -3 PUFA and exercise effects, 749-751
 - in soccer players, 1264

- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C), exercise effects on (*Continued*)
see also Low-density lipoprotein-cholesterol in exercise, $\dot{V}O_{2\max}$ and
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C), exercise effects on, in PM women on ERT or not on ERT, 1194
 with risk for CAD, aerobic exercise and high-fiber, low-fat diet effects, 378
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C), leptin and
 leptin levels and, 1412-1414
 and leptin receptor gene polymorphism, 881-883
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in children
 in Japanese school-age children, ABCA1 gene polymorphism association with, 183
 in Vietnamese children with apo E polymorphism, 1519
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in exercise, $\dot{V}O_{2\max}$ and
 blood, apo E polymorphism and, 111-113
 serum, in endurance exercise, apo E genotype and changes in $\dot{V}O_{2\max}$, 196, 198-200
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in hypercholesterolemia
 in mild hypercholesterolemia, 1073
 serum LPL concentration and, 527, 528
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in hyperlipidemia
 anti-inflammatory effects of ω -3 PUFAs in FCHL and, 154
 S-2E and PRV effects on, in mixed hyperlipidemia, 682-683
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in IDDM
 and oxidation of glycated and nonglycated LDLs, 970
 plasma apo C-3 polymorphisms and, 1299, 1301
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in IR
 associated with CV disease risk factors, 498
 in insulin-resistant obese Japanese subjects, 651
 in non-obese Korean NIDDM subjects, 143, 144
see also Low-density lipoprotein-cholesterol in obesity with IR
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in MS, 312
 with acute SCI, 991
 with obesity and chronic renal disease, 1257
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in NIDDM
 and at-risk for NIDDM subjects, 224, 226
 HbA_{1c}-lipid composition correlation in RBC membrane and, 124
 metformin effects on, 160, 161
 in non-obese insulin-resistant Korean subjects, 143, 144
- Pancreas Tonic effects on, 1169
 rosiglitazone effects on, 1123
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 301
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in obese women
 fluvastatin effects on, 736
 sibutramine or orlistat effects on, after moderate weight loss, 432
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in obesity
 with MS and chronic renal disease, 1257
 in obese adolescents, 864
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in obesity (*Continued*)
 in obese Korean subjects, -3826A→G UCP-1 polymorphism effects on level of, 1054-1059
 and smoking-ADMA-obesity relationship, 1575, 1576
see also Low-density lipoprotein-cholesterol in obese women;
 Low-density lipoprotein-cholesterol in obesity with IR
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in obesity with IR
 in obese Japanese men, 651
 prevalence of associated CV disease risk factors with, 498
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in PM women
 simvastatin effects on BMD and, 745, 746
see also Low-density lipoprotein-cholesterol, exercise effects on, in PM women on ERT
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in young men
 with hypertensive parents, 470, 473
 serum adiponectin association with, 590
- Low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in young subjects
 with NIDDM parents, 756
see also Low-density lipoprotein-cholesterol in young men
- Low-density lipoprotein receptor (LDLR)-null subjects, fenofibrate preventing obesity and hypertriglyceridemia in, 607-613
- Low-fat (LF) diet, role of caloric intake and high-fat diet versus, in NIDDM and obesity development, 454-457
- Low-fat/high-fiber diet, effects of exercise and, on inflammatory and adhesion molecules in postmenopausal women on ERT and at risk for CAD, 377-381
- Low-grade inflammation, role of, in MS with CHD, 852-857
- Low temperature, hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production blocked by, but not cAMP production in tumor cells, 955-958
- Lp, *see* Lipoprotein
- Lp(a), *see* Lipoprotein(a)
- LPL, *see* Lipoprotein lipase
- LSF (lisofylline), effects of, on glucose-stimulated insulin secretion in STZ-DM, prediabetic, and normal subjects, 290-296
- LTIP (lipid transfer inhibitor protein), smoking effects on, 858-862
- Leuteinizing hormone (LH)
 in older NIDDM men with partial androgen deficiency, 668
 plasma Lp and, in PM women, 189, 190
- Leuteinizing hormone (central) hypothesis of PCOS, 359-361
- LVH (left ventricular hypertrophy), candesartan effects on IR and, 777-781
- LY117018, effects of, on GH secretion, 563-570
- Lyase, *see* Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA; 17 α (alpha)-Hydroxylase/17,20-lyase deficiency
- Lymphocytes, activated CD4 $^{+}$ and CD8 $^{+}$ T, in growth factor receptors, 117-122
- Lys109Arg and Gln223Arg polymorphisms, relation between leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, lipids and, in Japanese subjects, 879-885
- Lys 9 -for-Glu 9 substitution, effects of GLP-1(7-36) amide, on DPP IV resistance with cellular and metabolic actions similar to GLP-1(9-36) amide and exendin (9-39), 252-259
- Lysine (Lys)
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

- Lysine (Lys) (Continued)**
see also Lys109Arg and Gln223Arg polymorphisms; Lys⁹-for-Glu⁹ substitution
- Macrophages, effects of caffeine on alveolar, via its effects on synthesis of cAMP and prostaglandin, 687-692
- Macrovascular diseases in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 298-300
- Magnesium (Mg)
 erythrocyte levels in, and metabolism of, 660-665
 in primary hyperthyroidism, 1102
 relationship of intracellular cord blood platelet, to birth weight, 1544-1547
 serum, in adrenal insufficiency, 1252
- Male adolescents, Japanese obese hyperuricemic, 448-453
- Male subjects
 transgenic, glucose intolerance development in, with GSK-3β overexpression in skeletal muscle, 1322-1330
see also Male adolescents; Men
- Malic enzyme (ME) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Malonyl dialdehyde (MDA), DM effects on, 66-72
- Maltose dextrin in obesity-inducing HF diet, 783
- Margarine, PP TG response to, 621, 622
- Matrix metalloproteinase-9 (MMP-9), -1562C→T polymorphism of, associated with BMD in Japanese men, 135-137
- Maturity-onset hyperinsulinemia and hyperglycemia (diabesity), CL316,243 effects on, in polygenic obesity, 799-808
- Maximum oxygen uptake, *see* $\dot{V}O_{2\text{max}}$
- MBF (medullary blood flow), tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308
- MCP-1, *see* Monocyte chemoattractant protein-1
- MCR (metabolic clearance rate) of hypogonadic men, 1175
- MC3T3-E1 osteogenic cells, strontium ranelate-induced bone matrix mineralization in, 532-537
- MDA (malonyl dialdehyde), DM effects on, 66-72
- ME (malic enzyme) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Medullary blood flow (MBF), tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308
- Medullary collecting duct, inner, ET effects on AVP₂ mRNA in, 1177-1183
- Melanoma-associated cachexia, ghrelin mRNA in, 84-88
- Men
 with CAD, *see* Coronary artery disease in men
 cortisol in, *see* Cortisol in men
 erythrocyte membrane lipid composition in, associated with arachidonic acid and insulin sensitivity, 571-577
 HC diet effects on atherogenic LDL particles in, 823-830
 Japanese, *see* Japanese men, polymorphism in
 non-obese, adipose tissue as marker of fibrinogen level in, 994-998
 normoglycemic, fasting glucose concentration and leukocyte ABCA1 gene expression in, 17-21
 obese, *see* Men, obese
 older NIDDM, partial androgen deficiency and glycemic control in, 666-672
 plasma vitamin K transport and deuterium-labeled collard green intake by, 215-221
 spinal cord-injured, MS in, 1372-1377
 young, *see* Young men
see also Sex entries beginning with term: Male and specific conditions
- Men, obese
 Japanese, Ob-R gene polymorphism associated with IR in, 650-654
 NEFA effects on hepatic glycogen content in, 886-893
 Mental stress, and lipolysis activation in IR, 1199
- Messenger ribonucleic acid, *see* mRNA
- Met, *see* Methionine
- Metabolic clearance rate (MCR) of hypogonadic men, 1175
- Metabolic rate (MR)
 effects of dietary zinc restriction on substrate utilization and, 727-732
 resting, in advanced NIDDM nephropathy, 1395-1398
- Metabolic research, accuracy and precision of peristaltic and syringe pumps in, compared, 875-878
- Metabolic risk in non-obese premenopausal women, abdominal and liver AT and, 1066-1071
- Metabolic syndrome (MS)
 in CHD, low-grade inflammation and, 852-857
 CRH test of relation between central HPA dysfunction and, 720-726
 exercise effects on abdominal AT, body composition and, in PM women on or not on ERT, 1192-1196
 fatty acid TG content and VAT accumulation associated with components of, 310-317
 lifestyle effects on risk for, 1503-1511
 with obesity, *see* Metabolic syndrome with obesity
 in SCI men, 1372-1377
- Metabolic syndrome (MS) with obesity
 and chronic renal disease, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
 serum TNF- β and components of, in obese adolescents, 863-867
 in treatment-seeking subjects, 435-440
- Metformin (dimethylbiguanide)
 effects of, on multiple CV disease risk factors in NIDDM, 159-164
 effects of, Pancreas Tonic and, in NIDDM, compared, 1169
 for obese PCOS women, 366, 368, 370
- Methionine (Met)
 in HF diet, 1033
 plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 $[^3\text{H}_3]\text{-3-Methylhistidine}$, contractile skeletal muscle protein breakdown estimated with, 1076-1080
- Mg, *see* Magnesium
- MI (myocardial infarction), risk factors for, as predictors of CAD in men, 324-329
- Microalbuminuria
 in Kuwaiti NIDDM children and adolescents, CV disease risk factors and, 640, 641
see also Microalbuminuria in IR; Microalbuminuria in NIDDM
- Microalbuminuria in IR
 with cardiovascular autonomic dysfunction and IR, 1359-1364
 cilostazol effects on, 1405-1410
- Microalbuminuria in NIDDM
 and in at-risk for NIDDM subjects, 228
 with cardiovascular autonomic dysfunction and IR, 1359-1364
 glycemic control effects on, 353-357
- Microangiopathies, diabetic, in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 301
- Micromolar concentrations of Cu, effects of, on endothelium-dependent on aorta relaxation in DM, 1315-1321
- Mild hypercholesterolemia, diet composition as determinant of plasma ADMA in, 1072-1075

- Mildly elevated plasma cholesterol (C), wheat germ policosanol effects on, 1309-1314
- Mineral content, changes in bone, after RYBG and ASGB for morbid obesity, 918-921
- Mineral density, *see* Bone mineral density
- Mineral mix in HF diet, 1033
- Mineralization, *see* Bone mineralization
- Minimal model analysis
- population and individual, of FSIVGTT, 1349-1354
 - of relationship between BMI, beta-cell function, and IR, 1462-1466
 - of weight loss effects in obese subjects with normal FPG or IGT on IR and insulin release, 1095-1100
- Mixed hyperlipidemia, effects of S-2E and PRV in, compared, 680-685
- MMP-9 (matrix metalloproteinase-9), -1562C→T polymorphism of, associated with BMD in Japanese men, 135-137
- MNCs (mononuclear cells), differential effects of glucose and alcohol on ROS generation and intranuclear nuclear factor- κ B in, 330-334
- MNH-01 formula (palatinose-based liquid balanced formula), effects of, on PP hyperglycemia and hyperinsulinemia, 977-983
- Moderate exercise
- effects of soy isoflavone and, on AT accumulation and bone loss in postmenopausal subjects, 942-948
 - insulin concentration and CHO requirement in IDDM during, 1126-1130
- Moderate weight loss by obese women
- effects of sibutramine or orlistat treatment and, on waist circumference and serum adipocytokines, 430-434
 - by insulin-resistant obese women, effects of, on plasma adiponectin, 280-283
- Modified insulin (hexyl-insulin monoconjugate 2), oral, for IDDM, 54-58
- Monocyte chemoattractant protein-1 (MCP-1)
- effects of insulin therapy of NIDDM on, 695, 697
 - effects of ω -3 PUFAs alone or with *all-rac* on, 238
- Monodrug therapy, adiponectin, C-reactive protein and, in obesity and NIDDM, 1454-1461
- Mononuclear cells (MNCs), differential effects of glucose and alcohol on ROS generation and intranuclear nuclear factor- κ B in, 330-334
- Monophosphate, *see* Adenosine monophosphate
- Monounsaturated fatty acids (MUFA)
- CV disease risk factors and intake of, 1439
 - intake of, by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51
 - in MNH-01 formula, 978
 - plasma ADMA in mild hypercholesterolemia and, 1073
 - WPG effects and, 1312
- Morbid obesity, changes in BMC after RYBG and ASGB for, 918-921
- Morbidity of STZ-DM, effects of oral vanadate with tea extract on, 1145-1151
- Morphometry of early NIDDM nephropathy subjects, pioglitazone effects on, 1476
- Mortality
- late-onset propionic acid, 809-810
 - low CHD, in Spain, plasma HDL-C level in Spanish children and, 1045-1047
 - STZ-DM-associated, effects of oral vanadate with tea extract on, 1145-1151
- MR, *see* Metabolic rate
- mRNA (messenger ribonucleic acid)
- apo A-1, in HepG2 cells, glucosamine effects on, 766-771
 - AVP₂, in IMCD, ET effects on, 1177-1183
 - CRABP-1, effects of, on CYP26-mediated catabolism of A11-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
 - effects of epinephrine and ionomycin on protein release and IL-6, in SM, compared, 1492-1495
 - fibronectin, *see* Fibronectin mRNA
 - ghrelin peptide, in melanoma-associated cachexia, 84-88
 - glucocorticoid receptor, leptin effects on, in STZ-DM, 1560-1561
 - GLUT₄, exercise effects on glycogen synthase activity and, but not on insulin signaling in overweight nondiabetic and NIDDM subjects, 1233-1242
 - GSK-3 β , in skeletal muscle of transgenic male subjects, 1322-1330
 - 11 β -HSD1, *see* 11 β -Hydroxysteroid dehydrogenase 1 mRNA
 - leptin, fenofibrate effects on, in ovariectomized subjects, 1286
 - leukocyte ABCA1, relationship of fasting glucose to, in normoglycemic men, 19
 - PPAR α , *see* Peroxisome proliferator-associated receptor α mRNA
 - PPAR γ , effects of restricted diet on, 30-31
 - preproglucagon, palmitate effects on, 1445-1446
 - renal CHPT, in NIDDM, 842-846
 - renal 11 β -HSD2, responsiveness of body weight and, to 11 β -HSD inhibition by glycyrrhetic acid, 600-606
 - renal TGF- β ₁, fibronectin, and collagen, cilostazol effects on, in IR, 1405-1410
 - steroidogenic acute regulatory protein, low temperature blocking testosterone production and stimulatory effects of hCG on, but not on cAMP production in tumor cells, 955-958
 - TGF- β 1 endothelin-1, effects high glucose and insulin on, in cardiac fibroblasts, 712
 - UCP-1, *see* Uncoupling protein-1 mRNA
 - UCP-2, adiponectin, and myostatin, in diabetes, CL316,243 effects on, 804
 - UCP-3, CL316,243 effects on, in diabetes, 804
 - upregulation of lipogenic enzyme and SREBP-1, in WAT of CRF subjects, 1060-1065
- MS, *see* Metabolic syndrome
- MUFAs, *see* Monounsaturated fatty acids
- Multiphasic profile of NEFAS, unresponsiveness of, to exogenous insulin during FSIVGTT, 1202-1207
- Multiple cardiovascular (CV) disease, metformin effects on risk factors for, 159-164
- Muscle, *see* Muscle glutamine; Skeletal muscle and entries beginning with element: Myo-
- Muscle glutamine (Gln), changes in release of, during normoglycemic hyperinsulinemia and hypoglycemia, 1208-1214
- Mutations
- of CYP17 genes in 17(α)-hydroxylase/17,20-lyase deficiency, 1527-1531
 - hypoxanthine phosphoribosyl transferase point, responsible for hyperuricemia in women, 1500-1502
 - triple HNF-4 α gene, associated with early-onset NIDDM in Filipino family, 959-963
- see also* Polymorphism
- Myocardial infarction (MI), risk factors for, as predictors of CAD in men, 324-329
- Myocytes
- cardiac, high glucose and insulin effects on protein synthesis in, 710-715
 - DNA synthesis from different pathways in fibroblasts, 128-133

- Myofibrillar protein in skeletal muscle, effects of dietary protein restriction on conservation of, 340-347
- Myostatin mRNA (messenger ribonucleic acid), CL316,243 effects on, in diabetes, 804
- Myristic acid
effects of, on *Spl*-induced apo A-1 promoter, 1343
TG content of, in MS, 312
- Na (sodium), serum, beer ingestion and sauna bathing effects on urinary excretion of, 774
- Nateglinide in NIDDM
effects of glyburide and, compared, 1331-1335
with obesity, effects of pioglitazone and, on beta-cell mass loss and insulin secretion in, 488-494
- Natriuretic peptide, brain, in IR with LVH, candesartan effects on, 778-780
- NE, *see* Norepinephrine
- NEFAs, *see* Nonesterified fatty acids
- Newborns, *see* Newborns
- Nephropathy
chronic, with obesity and MS, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
NIDDM, *see* Non-insulin-dependent diabetes mellitus nephropathy
Neuropathy, peripheral, in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Neutrophils, dietary oil effects on FA composition in, 59-65
- Newborns (infants)
with respiratory distress and sepsis, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age versus, 209-214
and 3,3'-T₂S in neonatal life, 538-543
- NFκB (nuclear factor-κB), intranuclear, differential effects of glucose and alcohol on ROS generation and, in mononuclear cells, 330-334
- Nicotine
acute effects of, on serum glucose, insulin, GH, and cortisol, 578-582
see also Smoking
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nighttime hypoglycemia, differences between daytime and, in counterregulation of, 894-898
- Nitrate/nitrite (NO₃)
OGTT of plasma, in sedentary and endurance training subjects, 673-679
renal cortex, effects of different glucose levels on, 868-874
- Nitric oxide (NO)
effects of different glucose levels on arginase activity and production of, in renal cortex, 868-874
serum concentration of TNF soluble receptors, TNF-β and, in overweight and obese women, 1268-1273
- Nitric oxide synthase (NOS)
effects of inhibition of, on pioglitazone action on insulin in subjects on high-sucrose diet, 22-27
inducible and endothelial, in early NIDDM nephropathy, 1474
renal cortex, effects of different glucose levels on, 868-874 and smoking-ADMA-obesity relationship, 1575, 1576
- Nitrite, *see* Nitrate/nitrite
- Nitrogen, *see* BUN
- NN414, effects of DZ and, on glucose tolerance and lipids in obesity, compared, 441-447
- NO, *see* Nitric oxide
NO-1886, effects of, on fatty liver in STZ-DM subjects due to high-fat diet, 260-263
- Noncirrhotic subjects, DCA-induced hypolactatemia in, 1087-1094
- Nondiabetic subjects
LSF effects on glucose-stimulated insulin secretion in, 290-296
overweight, effects of exercise on GLUT₄ mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242
pituitary response to exercise by nondiabetic smokers, 1140-1144
- Nonesterified fatty acids (NEFAs; free fatty acids)
adiponectin regulation by, 790-793
in adult CF, insulin regulating kinetics of, 1467-1472
in hypercholesterolemia, serum LPL concentration and, 528
insulin regulating kinetics of, in adult cystic fibrosis with impaired glucose tolerance, 1467-1472
in IR, and cilostazol effects on microalbuminuria, 1407
- isotretinoin effects on, 6
- MHN-01 effects on concentration of, 981
- in obesity, *see* Nonesterified fatty acids in obesity
oxidation of, *see* Oxidation, NEFA
plasma, *see* Plasma nonesterified fatty acids
short-term effects of, on glucagon secretion at low-to-normal glucose concentrations, 1443-1448
- smoking effects on, 860
- unresponsiveness of multiphasic profile of, to exogenous insulin during FSIVGTT, 1202-1207
- Nonesterified fatty acids (NEFAs; free fatty acids) in obesity
effects of, on hepatic glycogen content in obese men, 886-893
effects of weight loss by obese subjects with normal FPG or IGT on, 1097
- fasting serum, in obese NIDDM subjects, bezafibrate effects on, 407-408
in obese PM women, fluvastatin effects on, 736
- Nonglycated low-density lipoprotein (LDL), susceptibility to oxidation of glycated LDLs and, in IDDM, compared, 969-975
- Non-high-density lipoprotein (α lipoprotein; HDL), utility of, in hemodialyzed subjects, 1013-1015
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus)
alcohol effects on PP lipemia in, 77-83
association of corrected QT intervals with carotid artery IMT in, 1152-1157
coronary heart disease in, *see* Coronary heart disease in NIDDM
dyslipidemia in, *see* Dyslipidemia in NIDDM
early-onset, triple mutations of HNF-4α associated with, in Filipino family, 959-963
glycemic control in, *see* Glycemic control of NIDDM
HbA_{1c} in, *see* HbA_{1c} in NIDDM
hypertension in, *see* Hypertension in NIDDM
with IGT, *see* Impaired glucose tolerance in NIDDM
in Japanese subjects, *see* Japanese NIDDM subjects
LDL oxidation in, *see* Non-insulin-dependent diabetes mellitus, LDL oxidation in
microalbuminuria in, *see* Microalbuminuria in NIDDM
in non-obese Korean subjects, BMI as determining factor of IR degree in, 141-146
with obesity, *see* Obesity, NIDDM with
overweight subjects with, effects of exercise on GLUT₄ mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242
- Pancreas Tonic effects in, 1166-1173
- polymorphism in, *see* Non-insulin-dependent diabetes mellitus, polymorphism in
renal CHPT in, 842-846
- risk factors for CV disease in, *see* Risk factors for CV disease in NIDDM
stevioside effects on, 73-76

- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) (*Continued*)
see also Non-insulin-dependent diabetes mellitus nephropathy;
 Non-insulin-dependent diabetes mellitus retinopathy
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), LDL oxidation in
 correlation between vascular complications, plasma oxidized LDL level, serum PON1 polymorphism in, 297-302
- LDL susceptibility to oxidation and circulating cell adhesion molecules in young subjects with NIDDM parents, 755-759
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), pioglitazone effects on
 on beta-cell mass loss prevention and insulin secretion in obese subjects, 488-494
- effects of NOS inhibition and, on insulin action in subjects on high-sucrose diet, 22-27
- on microalbuminuria, 353-357
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus), polymorphism in
 ACP1 polymorphism-ADA interaction in, 995-1001
- correlation between vascular complications, plasma oxidized LDL level, and serum PON1 polymorphism in, 297-302
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) nephropathy
 advanced, resting metabolic rate in, 1395-1398
 incipient, in Japanese NIDDM subjects, G276T adiponectin polymorphism in, 1223-1226
- see also* Non-insulin-dependent diabetes mellitus nephropathy, pioglitazone effects in
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) nephropathy, pioglitazone effects in
 on carotid artery IMT and stiffness in, 1382-1386
 in early NIDDM nephropathy, 1473-1479
- Non-insulin-dependent diabetes mellitus (NIDDM; type 2 diabetes mellitus) retinopathy
 microalbuminuria and, 354
 postprandial plasma fructose in, 583-588
 serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Non-obese subjects
 apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
 hepatic 11 β -HSD1 and renal 11 β -HSD2 mRNA responsiveness to 11 β -HSD inhibition by glycyrrhetic acid in, 600-606
 IGT, insulin secretion and GLP-1 and glucose-dependent insulinotropic polypeptide after glucose ingestion by, 624-631
 in IR, *see* Non-obese subjects, insulin-resistant
 non-obese men, AT as marker of fibrinogen level in, 994-998
 preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by, 1449-1453
see also Non-obese women
- Non-obese subjects, insulin-resistant
 and HF diet effects on insulin-resistant lipolysis in skeletal muscle, 794-798
 in NIDDM Korean subjects, BMI as determining factor in IR degree in, 142-146
- Non-obese women
 clinical manifestations of PCOS in, 365-367
 premenopausal, abdominal and liver AT and metabolic risk in, 1066-1071
- Nonthyroidal diseases
 3,3'-T₂S in, 538-543
see also specific conditions
- Noradrenaline, *see* Norepinephrine
- Norepinephrine (NE; noradrenaline) (*Continued*)
 effects of exercise on inhibitory effects of, on insulin secretion, 1424-1432
- 4AP effects on delayed vasorelaxation of, by troglitazone, 147-152
 nighttime and daytime differences in counterregulation of hypoglycemia and, 895
- in obese men, NEFA effects on levels of, 892
- plasma, *see* Plasma norepinephrine
- Normal fasting plasma glucose (FPG), effects of weight loss by obese subjects with IGT or, on insulin release and IR, 1095-1100
- Normal glucose tolerance, insulin release and secretion in and effects of weight loss by obese subjects with, on insulin release, 1095-1100
- and insulin sensitivity in LBW Pima Indians with, 904-911
- Normocholesterolemia
 daytime hypertriglyceridemia and, in prematurely atherosclerotic subjects and in their first-degree relatives, 49-53
 wheat germ policosanol effects on, 1309-1314
- Normoglycemic hyperinsulinemia
 effects of acute insulin-induced hypoglycemia and, on retinal glucose uptake and ocular glucose metabolism, 1274-1283
 muscle glutamine release during hypoglycemia and, 1208-1214
- Normoglycemic men, fasting glucose concentration and leukocyte ABCA1 gene expression in, 17-21
- Normoponderal subjects, *see* Non-obese subjects
- NOS, *see* Nitric oxide synthase
- No_x, *see* Nitrate/nitrite
- Nuclear factor- κ B (NF κ B), intranuclear, differential effects of glucose and alcohol on ROS generation and, in mononuclear cells, 330-334
- Nutrition, *see* Diet
- Nutritional status of Vietnamese children, apo E polymorphism and, 1518-1519
- O₂, *see* Oxygenation; $\dot{V}O_{2\max}$
- Obesity
 adaptive thermogenesis and resistance to, 1417-1423
 chronic renal disease with MS and, apo A-1, apo B-48, and apo B-100 metabolism in, 1255-1261
 CV disease risk factors and, 1439
 effects of *P. yoelii* GPIs on glucose homeostasis in STZ-DM with, 1048-1053
 fenofibrate effects on hypertriglyceridemia and, in LDL-receptor null subjects, 607-613
 hepatic 11 β -HSD1 and renal 11 β -HSD2 mRNA responsiveness to 11 β -HSD inhibition by glycyrrhetic acid in, 600-606
 high-fat diet and, *see* High-fat diet, obesity and
 hyperinsulinemia and, *see* Hyperinsulinemia, obesity and insulin release in, *see* Insulin release and secretion in obesity
 insulin sensitivity and, 1109
 IR and, *see* Insulin resistance in obesity
 in Korean subjects, -382A \rightarrow G UCP-1 polymorphism effects on level of LDL-C in, 1054-1059
 lipids in, *see* Lipid(s) in obesity
 morbid, changes in BMC after RYBG and ASGB for, 918-921
 MS with, *see* Metabolic syndrome with obesity
 NIDDM with, *see* Obesity, NIDDM with
 omental and subcutaneous AT in, *see* Omental adipose tissue, subcutaneous and, in obese subjects
 preclinical changes in abdominal aorta of children with, 1243-1246
 relationship between smoking, ADMA and, 1574-1579
 weight loss in, *see* Weight loss by obese subjects

- Obesity (Continued)**
- see also* Adolescents, obese; Men, obese; Polycystic ovary syndrome, obesity and; Postmenopausal women, obese; Women, obese
 - Obesity, NIDDM with
 - adiponectin, C-reactive protein, and monodrug therapy in, 1454-1461
 - bezafibrate effects on lipids and glucose metabolism in, 405-413
 - CL316,243 effects on NIDDM with polygenic obesity, 799-808
 - GITS preventing NIDDM in IGT first-degree relatives of obese NIDDM African American subjects, 414-422
 - pioglitazone and nateglinide effects on insulin secretion and beta-cell mass loss in, 488-494
 - role of HF versus LF diet and caloric intake in development of, 454-457
 - Ob-R gene polymorphism associated with IR in Japanese men, 650-654
 - OCs, *see* Oral contraceptives
 - Ocular glucose metabolism, effects of acute insulin-induced hypoglycemia and normoglycemic hyperinsulinemia on retinal glucose uptake and, 1274-1283
 - OGTT, *see* Oral glucose tolerance test
 - 8-OHDG (8-hydroxydeoxyguanosine), hepatic, effects of hypoxia and hypoxic training on levels of, 716-719
 - Oil(s)
 - effects of different dietary, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
 - see also* Oil in HF diet; Olive oil
 - Oil in HF diet
 - soybean, 783
 - sunflower, 1033
 - Older (elderly) subjects
 - disabled hospitalized, HHcy in, 1016-1020
 - hypertensive, resistance exercise effects on insulin-mediated glucose disposal with minimal effect on TNF- α in, 397-402
 - older NIDDM men, partial androgen deficiency and glycemic control in, 666-672
 - Oleate, short-term effects of, on glucagon secretion, 1444-1445
 - Oleic acid
 - effects of, on Sphl-induced apo A-1 promoter, 1343, 1344
 - TG content of, in MS, 312
 - Oligomenorrhea in obese PCOS women, 366
 - Olive oil (OO)
 - effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
 - PP TG response to, 621, 622
 - Omega-3 polyunsaturated fatty acids, *see* ω -3 Polyunsaturated fatty acids
 - Omental adipose tissue (AT), subcutaneous and, in obese subjects proliferation and differentiation of adipocyte precursor cells from obese subjects, compared, 632-637
 - racial differences in β -adrenergic receptor density in subcutaneous and, in obese women, 247-251
 - One-day hindlimb suspension, whole-body and skeletal muscle IR development after, 1215-1222
 - Onset of IDDM, effects of glycemic control on F₂ isoprostanate level at, 1118-1120
 - OO, *see* Olive oil
 - Oral contraceptives (OCs)
 - effects of, on glucoregulatory responses to exercise, 348-352
 - for PCOS in obese women, 366, 370
 - Oral glucose tolerance test (OGTT)
 - in CF with impaired glucose tolerance, 1468
 - exercise and, *see* Oral glucose tolerance test of exercising subjects
 - Oral glucose tolerance test (OGTT) (Continued)
 - insulin sensitivity and, *see* Oral glucose tolerance test, insulin sensitivity and
 - of lisofylline effects on glucose-stimulated insulin secretion, 290, 291
 - nicotine effects on, 578-582
 - after 1-day hindlimb suspension, 1217
 - plasma nitrate/nitrite assessment with, in sedentary subjects, 673-679
 - of stevioside effects on glucose transport in skeletal muscle of insulin-resistant subjects, 101-103, 106
 - of young men with hypertensive parents, 471
 - see also* Impaired glucose tolerance - Oral glucose tolerance test (OGTT), insulin sensitivity and estimates of insulin sensitivity based on, 1107-1112
 - normal, in LBW Pima Indians, 904-911
 - of stevioside effects on glucose transport in skeletal muscle of insulin-sensitive subjects, 101-103, 106
 - Oral glucose tolerance test (OGTT) of exercising subjects
 - of exercising NIDDM women, 284, 285, 287
 - and OC effects on glucoregulatory responses to exercise, 348-352
 - plasma nitrate/nitrite assessment of, 673-679
 - Oral modified insulin (hexyl-insulin monoconjugate 2) for IDDM, 54-58
 - Oral vanadate with tea extract, effects of, on morbidity and mortality of STZ-DM, 1145-1151
 - Organ weight
 - heart, in liver disease, 965
 - kidney, in IR, with microalbuminuria, 1407
 - see also* Liver weight
 - Orlistat, effects of moderate weight loss and, on waist circumference and serum adipocytokines in obese women, 430-434
 - Ornithine, hyperinsulinemia effects on whole-body synthesis of, in young men, 392
 - Osteocalcin, serum, in severe lipodystrophy, leptin replacement therapy effects on, 516
 - Osteogenic cells, MC3T3-E1, strontium ranelate-induced bone matrix mineralization in, 532-537
 - Ovarian (peripheral) hypothesis of PCOS, 360, 361
 - Ovariectomized subjects, fenofibrate effects on white adipose tissue and HF diet-induced weight gain by, 1284-1289
 - Overweight
 - L-carnitine effects on fat oxidation, protein turnover, and body composition in slight, 1001-1006
 - concentration of serum TNF soluble receptors, TNF- β , and NO in overweight women, 1268-1273
 - in nondiabetic and NIDDM subjects, effects of exercise on GLUT₄ mRNA and glycogen synthase activity in, but not on insulin signaling, 1233-1242
 - preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by overweight subjects, 1449-1453
 - prevalence of IR with associated CV disease risk factors in, 495-499
 - see also* Obesity
 - Oxidase, plasma diamine, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
 - Oxidation
 - AT, L-carnitine effects on fat, in slightly overweight subjects, 1001-1006
 - energy substrate, in IDDM, 655-659
 - cis and trans FA, effects of long-term exposure of INS-1 cells to, on insulin secretion and, 1158-1165

- Oxidation (Continued)**
see also Oxidation, glucose; Oxidation, LDL; Oxidation, NEFA;
 Oxidative stress
- Oxidation, glucose**
P. yoelii GPI effects on, in STZ-DM with obesity, 1050
 whole-body, and oral glucose metabolism in born small-for-gestational-age children, 847-851
- Oxidation, LDL**
 circulating cell adhesion molecules and susceptibility to, in young NIDDM men, 755-759
 of glycated and nonglycated LDLs in IDDM, 969-975
see also Oxidized low-density lipoprotein
- Oxidation, NEFA**
 R-(+)- α -lipoic acid effects on pyruvate metabolism and, in hepatocytes, 165-173
see also Exercise at cold temperature, NEFA oxidation during
- Oxidative stress in NIDDM with obesity, pioglitazone protecting beta cells from, 488-494**
- Oxidized low-density lipoprotein (ox-LDL)**
 smoking-ADMA-obesity relationship and, 1575-1576
see also Oxidation, LDL; Plasma oxidized low-density lipoprotein
- Oxygen uptake, see $\dot{V}O_{2\text{max}}$**
- Oxygenation, renal cortex, water diuresis-induced changes in endothelial function and, in NIDDM and in at-risk for NIDDM subjects, 222-227**
- P (phosphorus), see Serum phosphorus**
- P. yoelii (*Plasmodium yoelii*)** GPIs (glycosylphosphatidylinositols), effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053
- PA (plasminogen activator)-antigen, tissue, in NIDDM and at-risk for NIDDM subjects, 224, 226**
- PAI (plasminogen activator inhibitor)-antigen, in NIDDM and at-risk for NIDDM subjects, 224, 226**
- PAI-1, see Plasminogen activator inhibitor-1**
- Palatinose-based liquid balanced formula (MNH-01), effects of, on PP hyperglycemia and hyperinsulinemia, 977-983**
- Palmitate, short-term effects of, on glucagon secretion, 1444-1446**
- Palmitic acid**
 effects of, on Sp1-induced apo A-1 promoter induction, 1343
 TG content of, in MS, 312
- Palmitoleic acid, TG content of, in MS, 312**
- Pancreas, MHN-01 effects on, 981**
- Pancreas Tonic, effects of, in NIDDM, 1166-1173**
- Pancreatic islets**
 bezafibrate effects on, in obese NIDDM subjects, 408-409, 411
 effects of transplantation of, on serum resistin levels in IDDM, 403-404
see also Beta cells
- PAO, see Paraoxonase**
- Paraoxonase (PON1; PAO)**
 in FCHL, ω -3 PUFA effects on levels of plasma HDL₂-C and, 153-158
 polymorphism of serum, correlation between vascular complications, plasma oxidized LDL level and, in NIDDM, 297-302
- Parathyroid hormone (PTH)**
 plasma, in adrenal insufficiency, insulin-induced hypoglycemia effects on levels of, 1251-1254
 relation of serum, to vitamin D profile in eucalcemia after parathyroidectomy for primary hyperthyroidism, 1101-1106
- Parathyroidectomy for primary hyperthyroidism, serum PTH relation to vitamin D profile in eucalcemia after, 1101-1106**
- Parent(s)**
 insulin secretion, insulin sensitivity, and metabolic profile of young men with hypertensive, 469-475
see also Children; Parental diabetes mellitus and entries beginning with term: Familial
- Parental diabetes mellitus (DM)**
 and insulin secretion and sensitivity in normal glucose-tolerant LBW Pima Indians, 906
 NIDDM, LDL susceptibility to oxidation and circulating cell adhesion molecules in young adult offspring of, 755-759
- Parenteral nutrition, total, lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277**
- Partial androgen deficiency in aging NIDDM men, glycemic control and, 666-672**
- PCOS, see Polycystic ovary syndrome, obesity and**
- PDH (pyruvate dehydrogenase), DM effects on, 66-72**
- Pentols, plasma, in CTX, 558**
- PEPCK (phosphoenolpyruvate carboxykinase), hepatic, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841**
- Peptides, see specific peptides**
- Peripheral (ovarian) hypothesis of PCOS, 360, 361**
- Peripheral neuropathy in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299**
- Peristaltic pumps in metabolic research, accuracy and precision of, 875-878**
- Peroxides, lipid, carotid atherosclerosis, vascular dementia and, 477, 479**
- Peroxisome proliferator-associated receptor α (PPAR α) mRNA (messenger ribonucleic acid)**
 CL316,243 effects on, in diabetes, 804
 fenofibrate effects on, *see* Peroxisome proliferator-associated receptor mRNA, fenofibrate effects on
- Peroxisome proliferator-associated receptor α (PPAR α) mRNA (messenger ribonucleic acid), fenofibrate effects on**
 in LDLR-null subjects, 610
 in ovariectomized subjects, 1286
- Peroxisome proliferator-associated receptor γ (PPAR γ)**
 effects of, on glucocorticoid receptor signaling and, in AT, 28-36
 FFPS-410 effects on activation of, 1533
see also Pro12Ala polymorphism of PPAR γ
- Peroxisome proliferator-associated receptor $\gamma 2$, see Pro12Ala polymorphism of PPAR $\gamma 2$**
- PG (prostaglandin), caffeine effects on alveolar macrophages via its effects on synthesis of cAMP and, 687-692**
- 6-PGDH (6-phosphogluconate-dehydrogenase) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065**
- PGE₁ (prostaglandin E₁), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177**
- PGE₂ (prostaglandin E₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177**
- PGI₂ (prostaglandin I₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177**
- Phenylalanine (Phe), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392**
- Phosphatase, *see* Acid phosphatase locus 1; Alkaline phosphatase; Biphosphatase; Glucose-6-phosphatase**
- Phosphate**
 serum, in adrenal insufficiency, 1252
see also Adenosine monophosphate; Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA; Glucose-6-phosphate dehydrogenase mRNA and entries beginning with element: Phosph-

- Phosphoenolpyruvate carboxykinase (PEPCK), hepatic, effects of exercise on hepatic insulin signaling and activity of, in diabetes-prone subjects, 836-841
- 6-Phosphogluconate-dehydrogenase (6-PGDH) mRNA (messenger ribonucleic acid), upregulation of SREBP-1 and, in WAT of CRF subjects, 1060-1065
- Phospholipase D (PLD), serum glycosylphosphatidylinositol-specific, IR and increased, 138-139
- Phospholipid(s) (PLs)
- in FCHL, ω -3 PUFA effects on, 154
 - serum, regulation of EFAs in, in short-gut subjects on PL-containing TPN, 273-277
 - smoking effects on, 860
 - in soccer players, 1264
- Phospholipid transfer protein (PLTP), smoking effects on, 858-862
- Phosphoribosyl transferase, point mutation in hypoxanthine, responsible for hyperuricemia in women, 1500-1502
- Phosphorus, *see* Serum phosphorus
- Phylloquinone (vitamin K), transport of plasma, in men consuming deuterium-labeled collard greens, 215-221
- Physical activity
- effects of interaction between FABP-4 and PPAR γ -activated receptor polymorphism and, 305, 306
 - see also* Exercise
- Pima Indians, LBW, with normal glucose tolerance, insulin secretion and insulin sensitivity in, 904-911
- Pinealectomy (PINX), effects of, on AT adaptability to fasting, 500-506
- Pioglitazone, *see* Non-insulin-dependent diabetes mellitus nephropathy, pioglitazone effects in
- Pituitary response to exercise by nondiabetic and IDDM smokers, 1140-1144
- PK (protein kinase), HF diet effects on adenosine monophosphate-activated glucose transport in SM, 914
- PKB α (protein kinase B α /Akt1), hepatic apo B production regulated by insulin independently of mass or activity of, 228-236
- PL(s), *see* Phospholipid(s)
- Plasma adiponectin
- adiponectin levels and, 2
 - effects of moderate weight loss by insulin-resistant obese women on, 280-283
 - effects of rosiglitazone on insulin sensitivity, insulin secretion and, in IGT first-degree relatives of African-American NIDDM subjects, 1552-1557
 - in NIDDM Japanese subjects with incipient nephropathy, 1224
- Plasma adrenocorticotropin hormone (ACTH; corticotropin)
- effects of restricted diet on, 30
 - leptin effects on, in STZ-DM, 1560
- Plasma alanine (Ala), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Plasma alanine aminotransferase (ALT), NO-1886 effects on, in STZ-DM, 261
- Plasma albumin in disabled hospitalized older subjects, HHcy and, 1018
- Plasma alcohol, beer ingestion and sauna bathing effects on, 774-775
- Plasma amino acids (AA), concentrations of, and whole-body protein synthesis in young men, 388-396
- Plasma apolipoprotein (apo)
- in HL deficiency, 521-522
 - see also specific apolipoproteins*
- Plasma apolipoprotein A-1 (apo A-1)
- in HL deficiency, 522-524
 - in PM and premenopausal women, sex steroids and, 189
- Plasma apolipoprotein A-2 (apo A-2) in HL deficiency, 522-524
- Plasma apolipoprotein B (apo B) in PM and premenopausal women, sex steroids and, 189
- Plasma apolipoprotein C-3 (apo C-3) polymorphisms in IDDM, 1296-1304
- Plasma aspartate aminotransferase (AST), NO-1886 effects on, in STZ-DM, 261
- Plasma asymmetric dimethylarginine (ADMA), diet composition as determinant of, in mild hypercholesterolemia, 1072-1075
- Plasma ceruloplasmin, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Plasma cholestanol in CTX, 558
- Plasma cholesterol (C)
- in CT, 558
 - in Ecuadorian Amazon Shur women, 1356
 - ideal bile transport inhibition effects on, through hepatic farnesoid receptor inactivation and cholesterol 7 α -hydroxylase stimulation, 927-932
 - normal or mildly elevated, wheat germ policosanol effects on, 1309-1314
 - in PM and premenopausal women, sex steroids and, 189
 - PP, in NIDDM, alcohol effects on, 79
 - total, *see* Total plasma cholesterol
- Plasma cholestryler ester transfer protein (CETP), smoking effects on, 858-862
- Plasma corticosterone, effects of 11 β -HSD inhibition by glycyrrhetic acid on, 602
- Plasma corticotropin (adrenocorticotropin hormone), effects of restricted diet on, 30
- Plasma cortisol (hydrocortisone) in adrenocortical disorders, 89-94
- Plasma C-reactive proteins (CRP), association between lifestyle, cardiovascular risk factors and, 1436-1442
- Plasma diamine oxidase, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Plasma endothelin (ET) in DM, relation between concentration of plasma VEGF, glycemic control and, 550-555
- Plasma epinephrine (adrenaline), leptin effects on, in STZ-DM, 1560
- Plasma fibrinogen in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Plasma fructose (F), postprandial, in NIDDM retinopathy, 583-588
- Plasma glucagon (Glc; hyperglycemic-glycogenolytic factor) in Ecuadorian Amazon Shur women, 1356
- Plasma glucose
- in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
 - in DM, *see* Plasma glucose in DM
 - in Ecuadorian Amazon Shur women, 1356
 - effects of ATPCL inhibitors on, 68
 - fasting, *see* Fasting plasma glucose
 - HF diet and reduced glucose transport in SM and, 913
 - in hyperinsulinemia, *see* Plasma glucose in hyperinsulinemia
 - isotretinoin effects on, 6
 - in lipodystrophic HIV-infected subjects, 1567
 - in obesity, NN414 and DZ effects on, compared, 444
 - preservation of circadian rhythm of serum insulin concentration at low concentration of during fasting by lean and overweight subjects, 1449-1453
 - steady-state, *see* Steady-state plasma glucose in IR
- Plasma glucose in DM
- effects of ATPCL inhibitors on, 68
 - in IDDM, *see* Plasma glucose in IDDM
 - in NIDDM, *see* Plasma glucose in NIDDM in STZ-DM, NO-1886 effects on, 261
- Plasma glucose in hyperinsulinemia with hypertension, 1306

- Plasma glucose in hyperinsulinemia (*Continued*)
in young men, whole-body protein synthesis and, 391
- Plasma glucose in IDDM
HIM2 effects on, 56-57
relationship between interstitial glucose and, 1487
- Plasma high-density lipoprotein (α lipoprotein; HDL)
in PM and premenopausal women, sex steroids and, 189
see also Plasma high-density lipoprotein-cholesterol
- Plasma high-density lipoprotein-cholesterol (α
lipoprotein-cholesterol; HDL-C)
effects of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol on, 237
HF/HC diet effects on, 819
high, in Spanish children, and low CHD mortality in Spain, 1045-1047
in HL deficiency, 522
- Plasma high-density lipoprotein₂-cholesterol (α
lipoprotein₂-cholesterol; HDL₂-C), ω -3 PUFA effects on, in FCHL, 153-158
- Plasma high-density lipoprotein₃-cholesterol (α
lipoprotein₃-cholesterol; HDL₃-C), ω -3 PUFA effects on levels of, in FCHL, 154, 155
- Plasma homocysteine (Hcy), effects of elevated, on endothelial function recovery after denudation of carotid arteries, 760-765
- Plasma hydrocortisone (cortisol) in adrenocortical disorders, 89-94
- Plasma 7 α -hydroxy-4-cholesten-3-one, as marker for hepatic bile synthesis, dietary cholesterol and, 42-48
- Plasma 27-hydroxycholesterol, as marker for hepatic bile synthesis, dietary cholesterol and, 42-48
- Plasma hypoxanthine, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma insulin
in Ecuadorian Amazon Shuar women, 1356
and GSK-3 β in transgenic subjects, 1328
HF diet effects on, 913
isotretinoin effects on, 6
leptin effects on, in STZ-DM, 1559
in NIDDM, *see* Plasma insulin in NIDDM
NOS inhibition effects on pioglitazone action on, in subjects on high-sucrose diet, 23
in obesity, *see* Plasma insulin in obesity
- Plasma insulin in NIDDM
and at-risk for NIDDM subjects, 224, 226
with obesity, effects of LF versus HF diet and caloric intake on, 456
- Plasma insulin in obesity
with NIDDM, effects of LF versus HF diet and caloric intake on, 456
NN414 effects on, 443, 444
with STZ-DM, *P. yoelii* GPI effects on, 1050
- Plasma intercellular adhesion molecule-1 (ICAM-1), effects of red and white wine on, in CAD men, 318-323
- Plasma interleukin-6 (IL-6), effects of red and white wine on, in CAD men, 318-323
- Plasma intermediate-density lipoprotein (IDL) in PM and premenopausal women, sex steroids and, 189
- Plasma isoleucine (Ile)
effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
effects of dietary proline with and without glucose on concentration of, 244
- Plasma leptin
effects of glycyrrhetic acid 11 β -HSD inhibition on, 602, 604
- Plasma leptin (*Continued*)
in obesity, NN414 and DZ effects on, compared, 443, 444
- Plasma leucine (Leu)
effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
effects of dietary proline with and without glucose on, 244
- Plasma lipids
NO-1886 effects on, in STZ-DM, 261
in obesity, NN414 and DZ effects on, compared, 443
in PM women, effects of moderate exercise and soy isoflavone on, 945
relationship of apo E polymorphism to, in Vietnamese children, 1517-1521
see also specific plasma lipids
- Plasma lipoprotein (Lp)
relationship of apo E polymorphism to, in Vietnamese children, 1517-1521
sex steroids and, in women, 187-192
- Plasma lipoprotein(a) [Lp(a)] in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Plasma low-density lipoprotein (γ lipoprotein; LDL)
correlation between vascular complications, serum PON1 polymorphism and, 297-302
particle diameter and clearance of, 483-487
in PM and premenopausal women, sex steroids and, 189
see also Plasma low-density lipoprotein-cholesterol; Plasma oxidized low-density lipoprotein
- Plasma low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C)
anti-inflammatory effects of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol on, 237
HF/HC diet effects on, 819
in HL deficiency, 522, 523
in Spanish children, 1046
- Plasma methionine (Met), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Plasma nitrate/nitrite, OGTT assessment of, in sedentary subjects and after endurance training, 673-679
- Plasma nonesterified fatty acids (NEFAs; free fatty acids)
acipimox-induced reduction of, during exercise at cold temperature, 1131-1135
in obesity, NN414 and DZ effects on, compared, 444
regulation of, in IR, 1197-1201
restricted diet effects on, 30
stevioside effects on, 102
- Plasma norepinephrine (NE)
leptin effects on, in STZ-DM, 1560
in NIDDM with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1362
- Plasma oxidized low-density lipoprotein (ox-LDL)
correlation between vascular complications, serum PON1 polymorphism, and levels of, in NIDDM, 297-302
serum HDL-C level effects on association between CAD and, in men, 423-429
and smoking-ADMA-obesity relationship, 1575, 1576
- Plasma parathyroid hormone (PTH) in adrenal insufficiency, insulin-induced hypoglycemia effects on levels of, 1251-1254
- Plasma pentols in CTX, 558
- Plasma ω (omega)-3 polyunsaturated fatty acids (PUFAs), anti-inflammatory effects of, alone or with *all-rac* α -tocopherol, 236-240
- Plasma proline (Pro), effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392

- Plasma protein, total, beer ingestion and sauna bathing effects on, 774
- Plasma purine bases, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma 25-tetrol in CTX, 558
- Plasma triacylglycerol (TAG) during exercise at cold temperature, 204
- Plasma triglycerides (TGs)
- in Ecuadorian Amazon Shur women, 1356
 - effects of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol on, 237
 - fasting, pioglitazone effects on, 489-490
 - in HL deficiency, 522
 - in IDDM, *see* Plasma triglycerides in IDDM
 - isotretinoin effects on, 4-10
 - in obesity, NN414 effects on, 444
 - in PM and premenopausal women, sex steroids and, 189, 190
 - in prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and in their first-degree relatives, 50
 - self-monitoring of, in evaluation of PP TG response to nutrients, 620-623
 - smoking effects on, 858-860
- Plasma triglycerides (TGs) in IDDM
- plasma apo C-3 polymorphisms and, 1299
 - total, oxidation of glycated and nonglycated LDLs and, 970
- Plasma tumor necrosis factor- α (TNF- α) in older hypertensive subjects, resistance exercise effects on insulin-mediated glucose disposal with minimal effects on, 399-400
- Plasma urea in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- Plasma uric acid (UA), sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasma valine (Val)
- effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 - effects of dietary proline with and without glucose on, 244
- Plasma vascular cell adhesion molecule-1 (VCAM-1), effects of red and white wine on, in CAD men, 318-323
- Plasma vascular endothelial growth factor (VEGF), relation between plasma ET, glycemic control and, in DM, 550-555
- Plasma very-low-density lipoprotein(s) (VLDL) in PM and premenopausal women, sex steroids and, 189, 190
- Plasma very-low-density lipoprotein-cholesterol (VLDL-C), HF/HC diet effects on, 819
- Plasma vitamin K (phylloquinone), transport of, in men consuming deuterium-labeled collard greens, 215-221
- Plasma xanthine, sauna bathing and beer ingestion effects on concentration of, 772-776
- Plasminogen activator (PA) antigen, tissue, in NIDDM and at-risk for NIDDM subjects, 224, 226
- Plasminogen activator inhibitor (PAI) antigen, in NIDDM and at-risk for NIDDM subjects, 224, 226
- Plasminogen activator inhibitor-1 (PAI-1)
- fasting, effects of weight loss with normal FPG or IGT on, 1097
 - in inflammation of chronic disease, 901
 - in young subjects with NIDDM patients, 756
- Plasmodium yoelii* (*P. yoelli*) glycosylphosphatidylinositol (GPI), effects of, on glucose homeostasis in obese STZ-DM subjects, 1048-1053
- Platelet(s)
- relationship between intracellular magnesium of cord blood, to birth weight, 1544-1547
 - WPG effects on, 1312
- Platelet acetyl-coenzyme (CoA), ATPCL role in metabolism and function of, in DM, 66-72
- PLD (phospholipase D), serum glycosylphosphatidylinositol-specific, IR and increased, 138-139
- PLTP (phospholipid transfer protein), smoking effects on, 858-862
- PM subjects, *see* Postmenopausal subjects
- PO (primrose oil), evening, effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- Point mutation in hypoxanthine phosphoribosyl transferase responsible for hyperuricemia in women, 1500-1502
- Policosanol, effects of wheat germ, on normal and mildly elevated plasma cholesterol, 1309-1314
- Polyclastic ovary syndrome (PCOS), obesity and, 358-376
- adrenal androgens and cortisol in, 361
 - clinical manifestations of, in obese and non-obese women, 365-367
 - definition, genetics, and epidemiology of PCOS, 358-359
 - estrogen and progesterone in, 361-362
 - gonadotropins and central hypothesis of, 359-361
 - insulin/insulin growth factor hypothesis of, 360, 363-365
 - IR, hyperinsulinemia and, 359
 - leptin in, 362-363
 - ovarian androgens and ovarian hypothesis of, 360, 361
 - therapy of, 367-370
- Polygenic obesity, CL316,243 effects on NIDDM with, 799-808
- Polymorphism, 458-468
- β_2 -ADR, interaction of, with β_3 -ADR Trp64Arg and Arg16Gly polymorphisms of, 1184-1191; *see* β_3 -Adrenergic receptor, Trp64Arg polymorphism of
 - apo E, *see* Apolipoprotein E polymorphism
 - in Japanese subjects, *see* Japanese subjects, polymorphism in K121Q glycoprotein PC-1, associated with race but not with IR in children, 465-468
 - Lys109Arg and Gln223Arg, relation between leptin receptor gene, HOMA IR index, serum soluble leptin receptor, serum leptin, lipids and, in Japanese subjects, 879-885
 - in NIDDM, *see* Polymorphism in NIDDM
 - plasma apo C-3, in IDDM, 1296-1304
- Pro12Ala, *see* Pro12Ala polymorphism of PPAR γ ; Pro12Ala polymorphism of PPAR γ
- UCP-1 gene, *see* Uncoupling protein-1 -3826A→G polymorphism
 - UCP-3, food intake and body composition associated with, 458-464
- Polymorphism in NIDDM
- ACPI, and adenosine deaminase-NIDDM interaction, 995-1001
 - serum PON1, correlation between vascular complications, plasma oxidized LDL level and, 297-302
- Polypeptides, *see specific polypeptides*
- Polphenols, red and white wine drinking effects on, in CAD men, 320
- Polyunsaturated fatty acids (PUFA)
- CV disease risk factors and intake of, 1439
 - effects of, in premature atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and in their first-degree relatives, 51
- in MNH-01 formula, 978
- plasma ADMA in mild hypercholesterolemia and, 1073
 - WPG and, 1312
 - see also* ω -3 Polyunsaturated fatty acids; ω -6 Polyunsaturated fatty acids
- ω (omega)-3 Polyunsaturated fatty acids (PUFA)
- skeletal muscle cell and erythrocyte membrane, in men, 573-575
 - see also* ω -3 Polyunsaturated fatty acids, effects of

- ω (omega)-3 Polyunsaturated fatty acids (PUFA), effects of anti-inflammatory effects of, alone or combined with *all-rac* α -tocopherol, on IL-1 β , IL-6, and TNF- α , 236-240 on CV disease risk factors, 1439 on plasma HDL₂-C and paraoxonase levels in FCHL, 153-158 *see also* Exercise, effects of ω -3 PUFA with
- ω (omega)-6 Polyunsaturated fatty acids (PUFA) CV disease risk factors and intake of, 1439 skeletal muscle cell and erythrocyte membrane, in men, 573-575
- PON1, *see* Paraoxonase
- Population minimal modeling, individual and, of IM-FSIVGTT, 1349-1354
- Portal venous hyperinsulinemia, effects of, on gut glucose absorption in conscious subjects, 1290-1295
- Postheparin lipoprotein lipase (LPL), relation between concentration of, and TG metabolism in hypercholesterolemia, 526-531
- Postmenopausal (PM) subjects moderate exercise and soy isoflavone effects on AT accumulation and bone loss in, 942-948 *see also* Postmenopausal women
- Postmenopausal (PM) women exercising, *see* Postmenopausal women, effects of diet with exercise in; Postmenopausal women on ERT, exercise effects in hypercholesterolemic, simvastatin effects on BMD in, 744-748 MP-9 gene polymorphism association with BMD and, 136 obese, *see* Postmenopausal women, obese sex steroids and plasma Lp in, 187-192
- Postmenopausal (PM) women, effects of diet with exercise in low-fat, high-fiber diet and aerobic exercise effects on inflammatory and adhesion molecules in PM women on ERT and at risk for CAD, 377-381 soy isoflavone and exercise effects on AT accumulation and bone loss, 942-948
- Postmenopausal (PM) women, obese androgenicity and obesity association with insulin sensitivity in, 507-512 fluvastatin effects on endothelial function in, via sdLDL reduction, 733-739
- Postmenopausal (PM) women on ERT, exercise effects in on abdominal AT and MS, 1192-1196 with risk for CAD, effects of high-fiber, low-fat diet and exercise on inflammatory and adhesion molecules in, 377-381 *see also* Body composition of PM women, exercise effects on
- Postprandial (PP) blood pressure (BP) in NIDDM, stevioside effects on, 75
- Postprandial (PP) cholesterol (C), plasma, alcohol effects on, in NIDDM, 79
- Postprandial (PP) C-peptide (CP), and effects of OCs on glucoregulatory responses to exercise, 350, 351
- Postprandial (PP) fructose (F), plasma, in NIDDM retinopathy, 583-588
- Postprandial (PP) glucagon (Glc: hyperglycemic-glycogenolytic factor), stevioside effects on, in NIDDM, 75
- Postprandial (PP) glucagon-like peptide-1 (GLP-1), stevioside effects on, in NIDDM, 75
- Postprandial (PP) glucose and effects of OCs on glucoregulatory responses to exercise, 350, 351 in IDDM, H1M2 effects on, 54-58 in IGT first-degree relatives of African American NIDDM subjects, 1553
- Postprandial (PP) hyperglycemia, MNH-01 effects on PP hyperinsulinemia and, 977-983
- Postprandial (PP) hyperinsulinemia, MNH-01 effects on PP hyperglycemia and, 977-983
- Postprandial (PP) incretins, alcohol effects on, in NIDDM, 77-83
- Postprandial (PP) insulin in IGT first-degree relatives of African American NIDDM subjects, 1553 and OC effects on glucoregulatory responses to exercise, 350, 351
- Postprandial (PP) lipemia, exercise effects on effects of alcohol intake on PP incretin levels and, in NIDDM, 77-83 after HF/HC diet, exercise effects on, 1021-1026 with ω -3 PUFA, 1365-1371
- Postprandial (PP) low-density lipoprotein (β lipoprotein; LDL) in sedentary subjects and in exercise, apo E polymorphism- $\dot{V}O_{2\text{max}}$ association and, 111, 113
- Postprandial (PP) plasma cholesterol (C), alcohol effects on, in NIDDM, 79
- Postprandial (PP) plasma fructose (F) in NIDDM retinopathy, 583-588
- Postprandial (PP) triacylglycerols (TAG) in NIDDM, alcohol effects on, 77-83
- Postprandial (PP) triglycerides (TGs), plasma TG self-monitoring to evaluate response of, 620-623
- Postpubertal Asian Indian adolescents, adiponectin, CRP, and IR in, 1336-1341
- Potassium (K) channel blocker inhibitors, and 4AP effects on delayed vasorelaxation by troglitazone, 147-152
- PP, *see entries beginning with term:* Postprandial
- PPAR, *see* Peroxisome proliferator-associated receptor α mRNA; Peroxisome proliferator-associated receptor γ ; Peroxisome proliferator-associated receptor γ 2
- Pramlintide, effects of, on responses of catecholamine, glucagon, and symptoms of hypoglycemia, 1227-1232
- Pravastatin (PRV) effects in mixed hyperlipidemia, effects of S-2E compared with, 680-685 on plasma LDL clearance, 484
- Preadipocytes (adipocyte precursor cells) FPFS-410 effects on transcription factors in 3T3-L1, 1534 from omental and subcutaneous AT of obese subjects, proliferation and differentiation of, compared, 632-637
- Preclinical changes in abdominal aorta of obese children, 1243-1246
- Prediabetic subjects cardiac function in, 1391-1394
- LSF effects on glucose-stimulated insulin secretion in, 290-296
- Preeclampsia, established, IR and inflammation in, 1433-1435
- Pregnancy β_3 -ADR Trp64Arg polymorphism in GDM Taiwanese women, 1136-1139 with established preeclampsia, IR and inflammation in, 1433-1435 3.3-T₂S in, 538-543 uncomplicated, leucine turnover during third trimester of, 545-549
- Premature atherosclerosis, normocholesterolemic and daytime hypertriglyceridemia in subjects with, 49-53
- Premenopausal women non-obese, abdominal and liver AT and metabolic risk in, 1066-1071 sex steroids and plasma Lp in, 187-192
- Pre-pancreatic islet transplantation, effects of, on serum resistin levels in IDDM, 403-404
- Propranolol mRNA (messenger ribonucleic acid), palmitate effects on, 1445-1446
- Prevalence of IR and associated CV disease risk factors in normal weight, overweight, and obese subjects, 495-499

Prevention

- beta-cell mass loss, effects of pioglitazone on insulin secretion and, in obese NIDDM subjects, 488-494
- of NIDDM in IGT first-degree relatives of obese African American NIDDM subjects with GITS, 414-422
- Primary hyperthyroidism, serum PTH relation to vitamin D profile in eucalceemia after parathyroideectomy for, vitamin D profile relation to, 1101-1106
- Primrose oil (PO), evening, effects of, on generation of inflammatory mediators and fatty acid composition in neutrophils, 59-65
- PRL (prolactin) in older NIDDM men with partial androgen deficiency, 668
- Pro, see Proline**
- Pro12Ala polymorphism of PPAR γ (peroxisome proliferator-activated receptor γ)
 - effects of, on dietary fat and physical activity association with fasting insulin level, 11-16
 - effects of interaction between FABP-4 polymorphism and, on insulin secretion and body composition, 303-309
- Pro12Ala polymorphism of PPAR γ 2 (peroxisome proliferator-associated receptor γ 2)
 - associated with adiponectin concentrations in young Japanese men, 1548-1551
 - effects of, on AT distribution in Korean women, 1538-1543
- Progesterone in PCOS, 361-362
- Proinsulin in CHD, IR, 853, 854
- Prolactin (PRL) in older NIDDM men with partial androgen deficiency, 668
- Proliferation, see Cell proliferation**
- Proline (Pro)**
 - dietary, with and without glucose, metabolic response to, 241-246
 - plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 - see also* Hydroxyproline; Pro12Ala polymorphism of PPAR γ
 - Pro12Ala polymorphism of PPAR γ 2
- Propeptide type 1 collagen, aminoterminal, in adrenal insufficiency, 1252
- Propionic acidemia, late-onset, fatal outcome and, 809-810
- Prostaglandin (PG), caffeine effects on alveolar macrophages via its effects on synthesis of cAMP and, 687-692
- Prostaglandin E₁ (PGE₁), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Prostaglandin E₂ (PGE₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Prostaglandin I₂ (PGI₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Protease, IGFs, GHBP, IGFBPs, and IGFBP-3, in lipodystrophic HIV-infected subjects, 1565-1573
- Proteasome, dietary protein restriction effects on production of, in skeletal muscle, 340-347
- Protein**
 - binding, *see* Fatty acid-binding protein-4; Growth hormone-binding protein; Insulin-like growth factor-binding protein(s); Insulin-like growth factor-binding protein 3 protease; Retinoic acid binding protein-1 mRNA; Sterol regulatory element binding protein-1
 - cardiac, effects of galactosamine-induced liver disease and bile duct ligation on synthesis of, 964-968
 - cardiac myocyte, high glucose and insulin effects on synthesis of, 710-715
 - L-carnitine effects on body composition, AT oxidation, and turnover of, in slightly overweight subjects, 1001-1006
 - C-reactive, *see* C-reactive protein
 - dietary, *see* Dietary protein intake

Protein (Continued)

- glargine effects on metabolism of, 1037-1044
- in Korean women, AT distribution and, 1541
- mRNA of steroidogenic acute regulatory, low temperature blocking hCG effects on testosterone production and, but not cAMP production in tumor cells, 955-958
- SM, see Protein in SM**
- total plasma, beer ingestion and sauna bathing effects on, 774
- transfer, see Cholesterol ester transfer protein; Phospholipid transfer protein*
- whole-body, plasma AA concentration and synthesis of, in young men, 388-396
- see also Glycoprotein; Protein kinase; Protein kinase Ba/Akt1 entries beginning with terms: Uncoupling protein and specific proteins*
- Protein-1, see Fatty acid transporter protein-1; Monocyte chemoattractant protein-1; Retinoic acid binding protein-1; mRNA; Sterol regulatory element binding protein-1; Uncoupling protein-1 mRNA; Uncoupling protein-1 -3826A-G polymorphism**
- Protein in SM**
 - effects of epinephrine and ionomycin on IL-6 mRNA and release of, in compared, 1492-1495
 - estimation of breakdown of contractile, with [³H]-3-methylhistidine, 1076-1080
- Protein kinase (PK), HF diet effects on glucose transport in SM stimulated by adenosine monophosphate-activated, 914**
- Protein kinase Ba/Akt1 (PKBa/Akt1), insulin regulation of hepatic apo B production independently of mass or activity of, 228-236**
- Proteinuria**
 - in preeclampsia, 1434
 - see also* Albuminuria
- Prothrombin time in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089**
- PRV, see Pravastatin effects**
- PTH, see Parathyroid hormone**
- PUFA, see Polyunsaturated fatty acids**
- Pulse rate, see Heart rate**
- Pumps, syringe and peristaltic, in metabolic research, accuracy and precision of, compared, 875-878**
- Purine bases, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776**
- Pyruvate, thioctic acid effects on NEFA oxidation and metabolism of, in hepatocytes, 165-173**
- Pyruvate dehydrogenase (PDH), DM effects on, 66-72**
- QT intervals, corrected, associated with carotid artery IMT in NIDDM, 1152-1157**
- Race and ethnicity**
 - adiponectin, *see* Race and ethnicity, adiponectin and of children, *see* Race and ethnicity of children insulin secretion and insulin sensitivity in normal glucose-tolerant LBW Pima Indians, 904-911
 - of kidney transplantation recipients, 615
 - Kuwaiti IDDM adolescents, cardiovascular disease risk factors associated with serum sialic acid in, 638-643
 - lifestyle effects on leptin in Ecuadorian Amazon Shuar women, 1355-1358
 - of NIDDM subjects, *see* Race and ethnicity of NIDDM subjects of obese women, β -adrenergic receptor density in subcutaneous and omental AT and, 247-251
 - polymorphism and, *see* Race and ethnicity, polymorphism and

- Race and ethnicity (*Continued*)
see also Japanese subjects; Korean subjects; Spanish subjects
 Race and ethnicity, adiponectin and
 adiponectin, CRP, and IR in postpubertal Asian Indian
 adolescents, 1336-1341
 adiponectin levels and, 1-3
 and NEFA regulation of adiponectin, 791
 Race and ethnicity, polymorphism and
 β_2 -ADR Arg16Gly polymorphism and, 1184, 1185
 β_3 -ADR Trp64Arg polymorphism in GDM Taiwanese women, 1136-1139
 apo E polymorphism association with blood lipids and $\dot{V}O_{2\max}$ and, in exercise, 110-113
 caloric intake, UCP-3 polymorphism, body composition and, 461
 effects of interaction between FABP-4 and PPAR γ Pro12Ala polymorphism and, 305, 306
 effects of Pro12Ala polymorphism of PPAR γ 2 on AT distribution in Korean women, 1538-1543
 and exercise effects in overweight nondiabetic subjects, 1236
 Race and ethnicity of children
 apo E polymorphism in Vietnamese children, relation of, to plasma lipids and Lp, 1517-1521
 associated with glycoprotein PC-1 K121Q polymorphism but not with IR, 465-468
 high plasma HDL-C level in Spanish children, and low CHD mortality in Spain, 1045-1047
 Kuwaiti IDDM children, and cardiovascular disease risk factors association with serum sialic acid, 638-643
 serum HDL-C or apo A-1 levels associated with ABCA1 gene polymorphism in Japanese school-age children, 182-186
 Race and ethnicity of NIDDM subjects
 and exercise effects in overweight NIDDM subjects, 1236
 non-obese insulin-resistant NIDDM Korean subjects, 142-146
 and Pancreas Tonic effects in NIDDM, 1169
 triple HNF-4 α gene mutations associated with early-onset NIDDM in Filipino family, 959-963
see also First-degree relatives, IGT, of African American NIDDM subjects
 RBCs, *see entries beginning with term:* Erythrocyte
 RCT (reverse cholesterol transport), implications of smoking effects on intravascular remodeling of HDL particles for, 858-862
 Reactive oxygen species (ROS), differential effects of glucose and alcohol on intranuclear nuclear factor- κ B in mononuclear cells and generation of, 330-334
 Rebaudioside A, dose-, glucose-, and calcium-dependent effects of, on insulin secretion, 1378-1381
 Recovery of endothelial function after denudation of carotid arteries, effects of elevated plasma Hcy on, 760-765
 Red blood cells, *see entries beginning with term:* Erythrocyte(s)
 Red wine drinking
 effects of white and, on circulating inflammation-sensitive molecules in men with CAD, 318-323
 lack of acute effects of food intake and, on vascular reactivity, 1081-1086
 REE, *see* Resting energy expenditure
 Relatives, *see* First-degree relatives
 Remethylation of homocysteine, 1480-1483
 Remnant lipoprotein-cholesterol (RLP-C) in NIDDM, metformin effects on, 161
 Renal cholinophosphotransferase (CHPT) mRNA (messenger ribonucleic acid) in NIDDM, 842-846
 Renal cortex
 different glucose level effects on arginase activity and NO production in, 868-874
 Renal cortex (*Continued*)
 water diuresis-induced changes in endothelial function and oxygenation of, in NIDDM and at-risk for NIDDM subjects, 222-227
 Renal disease, *see* Nephropathy
 Renal failure
 HHcy associated with impaired Hcy trans-sulfuration as cause of, 1482
see also Chronic renal failure
 Renal fibronectin insulin resistance (IR), cilostazol effects on, 1405-1410
 Renal glucose, effects of hyperglycemia, glucagon, and epinephrine on release of, in conscious subjects, 933-941
 Renal 11 (beta)-hydroxysteroid dehydrogenase 2 (11-HSD2) mRNA (messenger ribonucleic acid), responsiveness of body weight and, to 11 β -HSD inhibition by glycyrhetic acid, 600-606
 Renal medullary blood flow (MBF), tempol effects on hypertension and hyperinsulinemia based on increase of, 1305-1308
 Renal transplantation, correlation between AT, serum leptin, and food intake during 6-month period following, 614-619
 Renal weight in IR with microalbuminuria, 1407
 RER (respiratory exchange ratio) during exercise at cold temperature, 204, 205
 Resistance
 to obesity, adaptive thermogenesis and, 1417-1423
see also Insulin resistance
 Resistance exercise effects
 on glycemic control in NIDDM women, 284-289
 on insulin-mediated glucose disposal with minimal effect on TNF- α in older hypertensive subjects, 397-402
 Resistin (FIZZ3; ADSF)
 in obese women, effects of moderate weight loss and sibutramine or orlistat on, 432
 serum levels of, in IDDM before and after pancreatic islet transplantation, 403-404
 Respiratory distress, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with sepsis and, 209-214
 Respiratory exchange ratio (RER) during exercise at cold temperature, 204, 205
 Respiratory quotient (RQ) in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
 Resting energy expenditure (REE)
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
 and hyperinsulinemia effects on whole-body protein synthesis, 389 by lipodystrophic subjects, leptin replacement therapy effects on, 515
 Resting heart rate (HR) of young subjects with NIDDM parents, 756
 Resting metabolic rate (RMR) in advanced NIDDM nephropathy, 1395-1398
 Restricted diet, *see* Dietary restriction
 Retinal glucose, effects of acute insulin-induced hypoglycemia and normoglycemic hyperinsulinemia on ocular glucose metabolism and uptake of, 1274-1283
 Retinocytes, correlation between HbA_{1c}, serum haptoglobin, serum bilirubin and, 1498
 Retinoic acid binding protein-1 mRNA (messenger ribonucleic acid), cellular, effects of, on CYP26-mediated catabolism of A11-trans retinoic acid and cell proliferation in head and neck squamous cell carcinoma, 1007-1012
 Retinopathy, *see* Non-insulin-dependent diabetes mellitus retinopathy

- Reverse cholesterol transport (RCT), implications of smoking effects on intravascular remodeling of HDL particles for, 858-862
- Ribonucleic acid, *see* mRNA
- Risk factors
- for endometrial cancer in obese PCOS women, 366
 - metabolic, in non-obese premenopausal women, abdominal and liver AT and, 1066-1071
 - for metabolic syndrome, lifestyle effects on, 1503-1511
 - for NIDDM, and water diuretics-induced changes in renal cortex oxygenation and endothelial function, 222-227
 - see also* Risk factors for CV disease
- Risk factors for CV disease
- associated with serum sialic acid in IDDM Kuwaiti children and adolescents, 638-643
 - for CAD, effects of exercise and high-fiber, low-fat diet on inflammatory and adhesion molecules in PM women on ERT and, 377-381
 - diet, lifestyle, and plasma CRPs associated with, 1436-1442
 - for myocardial infarction in CAD men, 324-329
 - in NIDDM, *see* Risk factors for CV disease in NIDDM
 - in obesity, *see* Risk factors for CV disease in obesity
 - in subclinical hypothyroidism, 1512-1515
- Risk factors for CV disease in NIDDM
- with IGT, contribution of visceral AT and cardiorespiratory fitness to risk factors for CHD, 644-649
 - multiple, effects of metformin on, 159-164
- Risk factors for CV disease in obesity
- in obese PCOS women, 366
 - prevalence of IR and associated, 495-499
- R-LA [R-(+)- α -lipoic acid; thioctic acid], effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- RLP-C (remnant lipoprotein-cholesterol) in NIDDM, metformin effects on, 161
- RMR (resting metabolic rate) in advanced NIDDM nephropathy, 1395-1398
- ROS (reactive oxygen species), differential effects of glucose and alcohol on intranuclear nuclear factor- κ B in mononuclear cells and generation of, 330-334
- Rosiglitazone effects
- on insulin regulation and dyslipidemia in NIDDM, 1121-1125
 - on insulin sensitivity, insulin secretion, and plasma adiponectin in IGT first-degree relatives of African American NIDDM subjects, 1552-1557
 - in obese PCOS women, 371
- Roux-en-Y bypass (RYBG), changes in BMC after ASGB and, for morbid obesity, 918-921
- RQ (respiratory quotient) in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- RYBG (Roux-en-Y bypass), changes in BMC after ASGB and, for morbid obesity, 918-921
- S, *see* Sucrose
- S12911-2 (strontium ranelate), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- SAA (serum amyloid A), aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380
- Safety of Pancreatic Tonic, 1170
- Sarafotoxin, effects of, on AVP₂ mRNA in IMCD, 1180
- SAT, *see* Subcutaneous adipose tissue
- Saturated fatty acid(s) (SFA)
- CV disease risk factors and intake of, 1439
 - effects of, on SPI-induced apo A-1 promoter, 1342-1348
 - skeletal muscle cell and erythrocyte membrane, 573
- Saturated fatty acid(s) (SFA) (*Continued*)
- WPG and, 1312
 - see also* Saturated fatty acid intake
- Saturated fatty acid (SFA) intake
- with MNH-01 formula, 978
 - plasma ADMA in mild hypercholesterolemia and, 1073
 - by prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia and by their first-degree relatives, 51
- Sauna bathing, effects of beer ingestion and, on plasma concentration of purine bases, 772-776
- SCC (squamous cell carcinoma), head and neck, effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-trans retinoic acid and on cell proliferation in, 1007-1012
- SCI, *see* Spinal cord injury
- sdlLDL, *see* Small-dense low-density lipoprotein
- S-2E [(+)-(s)-p-[1-(*p*-*tert*-butylphenyl)-2-oxo-4-pyrrolidinyl] methoxybenzoic acid], effects of PRV and in mixed hyperlipidemia, compared, 680-685
- Sedentary subjects
- apo E polymorphism associated with in blood lipids and $\dot{V}O_{2\max}$ in, 108-116
 - OGTT assessment of plasma nitrate/nitrite in, 673-679
- Selective estrogen receptor modulators (SERMs), effects of, on GH secretion, 563-570
- Self-monitoring of plasma TGs, PP TG response to nutrients evaluated with, 620-623
- Sepsis, circulating ACTH and cortisol concentrations in normal appropriate-for-gestational-age newborns versus newborns with respiratory distress and, 209-214
- Serine (Ser), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- SERMs (selective estrogen receptor modulators), effects of, on GH secretion, 563-570
- Serum adiponectines, effects of moderate weight loss and orlistat or sibutramine treatment on waist circumference of obese women, 430-434
- Serum adiponectin
- associated with HDL-C, TGs, and LDL particle size in young men, 589-593
 - in postpubertal Asian Indian adolescents, 1338-1339
 - relationship between serum soluble leptin receptor, serum leptin, HOMA IR index, lipids, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms and levels of, in Japanese subjects, 879-885
- Serum albumin
- in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
 - food intake, AT and, in 6-month period following kidney transplantation, 614-619
 - in HD subjects, 1014
 - in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum amyloid A (SAA), aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380
- Serum apolipoprotein A-1 (apo A-1) in CAD men, 425
- Serum apolipoprotein A-2 (apo A-2) in CAD men, 425
- Serum apolipoprotein C-2 (apo C-2) in CAD men, 425
- Serum apolipoprotein C-3 (apo C-3)
- in CAD men, 425
 - in IDDM, 1299, 1301
- Serum apolipoprotein E (apo E) in CAD men, 425
- Serum bilirubin

- Serum bilirubin (*Continued*)
 correlation between HbA_{1c}, retinocytes, serum haptoglobin and, 1498
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- Serum Ca (calcium) in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum cholesterol (C)
 effects of ATPCL inhibitors on, 68
 total, in CAD men, 425
- Serum C-peptide (CP; connecting peptide) in IGT first-degree relatives of obese African American NIDDM subjects, 418
- Serum C-reactive protein (CPR), diet and
 aerobic exercise and high-fiber, low-fat diet effects on, in postmenopausal women on ERT and at risk for CAD, 377, 379-380
- AT and, in 6-month period following kidney transplantation, 614-619
- Serum C-reactive protein (CRP)
 diet and, *see* Serum C-reactive protein, diet and
 high-sensitivity, effect of insulin therapy of NIDDM on, 693-699
- in preeclampsia, 1434, 1435
- Serum creatinine
 in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
- in HD subjects, 1014
- in NIDDM nephropathy, *see* Serum creatinine in NIDDM nephropathy
 in primary hyperthyroidism, 1102
- Serum creatinine in NIDDM nephropathy
 in Japanese NIDDM subjects with incipient nephropathy, 1224
 pioglitazone effects on, 1383
- Serum fatty acids (FAs), PP, in NIDDM, alcohol effects on, 79-80
- Serum glucose
 acute effects of nicotine on, in smokers, 578-582
 in obese NIDDM subjects, 408
see also Serum glucose in first-degree relatives
- Serum glucose in first-degree relatives
 in IGT first-degree relatives of obese African American NIDDM subjects, 418
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
- Serum glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD), IR and levels of, 138-139
- Serum haptoglobin, correlation between HbA_{1c}, retinocytes, serum bilirubin and, 1498
- Serum high-density lipoprotein-cholesterol (α lipoprotein-cholesterol; HDL-C)
 apo E genotype and changes in maximal oxygen uptake and, in exercise, 196, 198-200
 effects of levels of, on plasma oxidized LDL-CAD association in men, 423-429
 levels of apo A-1 and, associated with ABCA1 gene polymorphism in Japanese school-age children, 182-186
- Serum high-density lipoprotein₂-cholesterol (α lipoprotein₂-cholesterol; HDL₂-C)
 apo E genotype and changes in, during endurance exercise, 196, 198-200
 effects of levels of, on plasma oxidized LDL-CAD association in men, 425
 in preeclampsia, 1434, 1435
- Serum high-density lipoprotein₃-cholesterol (α lipoprotein₃-cholesterol; HDL₃-C)
 apo E genotype and changes in $\dot{V}O_{2\max}$ and, in endurance exercise, 196, 198-200
 effects of levels of, on plasma oxidized LDL-CAD association in men, 425
- Serum high-sensitivity C-reactive proteins (CRPs) in NIDDM, effects of insulin therapy on, 693-699
- Serum 1,25 hydroxyvitamin D in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum 25-hydroxyvitamin D in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum insulin
 preservation of circadian rhythm of concentration of, during fasting by lean and overweight subjects, 1449-1453
 response of, to IVGTT, of obese NIDDM subjects, 408
see also Serum insulin in first-degree relatives
- Serum insulin in first-degree relatives
 in IGT first-degree relatives of obese African American NIDDM subjects, 418
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
- Serum interleukin-6 (IL-6) in preeclampsia, 1434, 1435
- Serum interleukin-6 receptor (IL-6R), and IR in liver cirrhosis, 923, 924
- Serum leptin
 AT, food intake and, during 6-month period following kidney transplantation, 614-619
 in preeclampsia, 1434, 1435
- Serum soluble leptin receptor, serum adiponectin levels, HOMA IR index, lipids, leptin receptor gene Lys109Arg and Gln223Arg polymorphisms and, in Japanese subjects, 879-885
- in severe lipodystrophy, effects of leptin replacement therapy on, 514, 515
- Serum lipids
 profile of, and interaction of Arg16Gly β_2 -ADR polymorphism with β_3 -ADR Trp64Arg polymorphism, 1184-1191
 regulation of EFAs in, in short-gut subjects on lipid-containing TPN, 273-277
see also specific serum lipids
- Serum lipoprotein(a) [Lp(a)] in CAD men, 425
- Serum lipoprotein lipase (LPL), relation between TG metabolism and concentration of, in hypercholesterolemia, 526-531
- Serum low-density lipoprotein-cholesterol (β lipoprotein-cholesterol; LDL-C) in CAD men, 425
- Serum magnesium (Mg) in adrenal insufficiency, 1252
- Serum Na (sodium), beer ingestion and sauna bathing effects on, 774
- Serum nitric oxide (NO), concentration of TNF soluble receptors, TNF- β and, in overweight and obese women, 1268-1273
- Serum nonesterified fatty acids (NEFAs; free fatty acids), fasting, in obese NIDDM subjects, bezafibrate effects on, 407-408
- Serum osteocalcin in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum paraoxonase (PON1), polymorphism of, correlated with vascular complications, plasma oxidized LDL level and, in NIDDM, 297-302
- Serum parathyroid hormone (PTH) in eucalcemia after parathyroideectomy for primary hyperthyroidism, relation of to vitamin D profile, 1101-1106
- Serum phosphate in adrenal insufficiency, 1252
- Serum phospholipids (PL), regulation of, in short-gut subjects on PL-containing TPN, 273-277
- Serum phosphorus (P)
 in primary hyperthyroidism, 1102

- Serum phosphorus (P) (Continued)**
- in severe lipodystrophy, leptin replacement therapy effects on, 516
- Serum resistin, pre- and post-pancreatic islet transplantation levels of, in IDDM,** 403-404
- Serum sialic acid, cardiovascular disease risk factors associated with, in IDDM Kuwaiti children and adolescents,** 638-643
- Serum sodium (Na), beer ingestion and sauna bathing on urinary excretion of,** 774
- Serum transferrin, food intake, AT and, in 6-month period following kidney transplantation,** 614-619
- Serum triglycerides (TGs)**
- ATPCL inhibitor effects on, 68
 - in CAD men, 425
 - in IDDM, 1301
 - in NIDDM with obesity, bezafibrate effects on, 407-408
 - in postpubertal Asian Indian adolescents, 1338, 1339
 - in preeclampsia, 1434
- Serum tumor necrosis factor (TNF), serum concentration of NO, TNF- β , and soluble receptors of, in overweight and obese women,** 1268-1273
- Serum tumor necrosis factor- α (TNF- α)**
- levels of, in obese adolescents, MS components and, 863-867
 - in preeclampsia, 1434
 - soluble, associated with IR in liver cirrhosis, 922-926
- Serum tumor necrosis factor- β (TNF- β), serum concentrations of NO, TNF soluble receptors and, in overweight and obese women,** 1268, 1273
- Serum urea in HD subjects,** 1014
- Serum uric acid in IDDM, and oxidation of glycated and nonglycated LDLs,** 970
- Severe lipodystrophy, effects of leptin replacement therapy of, on body composition,** 513-519
- Sex**
- of acromegalic subjects, 565
 - β_2 -ADR Arg16Gly polymorphism and, 1184, 1185
 - birth weight and, 1545
 - of CT subjects, 557
 - CV disease risk factors and, 1437, 1440
 - of disabled hospitalized older subjects, HHcy and, 1018
 - of DM subjects, *see Sex of DM subjects*
 - effects of, on HbA_{1c} , 1497
 - of HD subjects, 1014
 - of hypercholesterolemic subjects, *see Sex of hypercholesterolemic subjects*
 - of hypothyroidic subjects, 278
 - of insulin-resistant subjects, *see Sex of insulin-resistant subjects*
 - of insulin-sensitive subjects, 1109
 - of kidney transplantation recipients, 615
 - of LBW Pima Indians with normal glucose tolerance, 906, 908
 - leptin levels and, 1412-1414
 - of lipodystrophic subjects, *see Sex of lipodystrophic subjects*
 - of NIDDM nephropathy subjects, *see Sex of NIDDM nephropathy subjects*
 - of obese subjects, *see Sex of obese subjects*
 - of overweight subjects, *see Sex of overweight subjects*
 - of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
 - and preservation of circadian rhythm of serum insulin concentration at low plasma glucose during fasting by non-obese subjects, 1450
 - of primary hyperthyroidism subjects, 1102
 - and risk for metabolic syndrome, 1508
 - serum LPL concentration and, 527, 528
- Sex (Continued)**
- and WPG effects on normal or mildly elevated plasma cholesterol, 1311
 - see also Men; Sex, diet and; Sex, exercise and; Women*
 - Sex, diet and**
 - and acute effects of red wine drinking and food intake on vascular reactivity and, 1082
 - and CV disease risk factors, 1437, 1440
 - and PP TG response to different nutrients, 621
 - Sex, exercise and**
 - and plasma nitrate/nitrite assessment during OGTT, 675
 - relationship of alcohol, adiposity and, to HDL-C levels and, 704, 706
 - Sex, exercise, $\dot{V}O_{2\max}$ and**
 - apo E genotype and changes in serum lipids and $\dot{V}O_{2\max}$ in endurance exercise, 196-198
 - and apo E polymorphism association with blood lipids and $\dot{V}O_{2\max}$, 110-113
 - Sex of DM subjects**
 - and relation between plasma VEGF, plasma ET-1 concentration, and glycemic control of, 551
 - see also Sex of IDDM subjects; Sex of NIDDM subjects*
 - Sex hormone-binding globulin (SHBG)**
 - in PM women, *see Sex hormone-binding globulin in PM women in preeclampsia,* 1434, 1435
 - in premenopausal women, plasma Lp and, 189
 - Sex hormone-binding globulin (SHBG) in PM women**
 - insulin sensitivity and, 508-510
 - plasma Lp and, 189
 - Sex of hypercholesterolemic subjects**
 - of mildly hypercholesterolemic subjects, 1073
 - serum LPL concentration and, 527, 528
 - Sex of IDDM subjects**
 - and glycemic control effects on F_2 isoprostane level at IDDM onset, 1119
 - oxidation of glycated and nonglycated LDLs and, 970
 - Sex of insulin-resistant subjects**
 - indices of IR and, 1525
 - with LVH, 778, 779
 - obese, with normal FPG or IGT, 1097
 - plasma NEFA regulation and, 1198
 - serum GPI-PLD and, 139
 - Sex of lipodystrophic subjects**
 - with HIV infection, 1567
 - with severe lipodystrophy, 514
 - Sex of NIDDM nephropathy subjects**
 - of Japanese NIDDM subjects with incipient nephropathy, 1224
 - and pioglitazone effects on carotid artery stiffness and intima-media thickness in NIDDM nephropathy, 1383
 - Sex of NIDDM subjects**
 - association of corrected QT intervals with carotid artery IMT, 1153, 1154
 - and in at-risk for NIDDM subjects, 224
 - with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360
 - glyburide and metformin effects on NIDDM and, 1332
 - with IGT, 646
 - and insulin therapy effects on serum high-sensitive CRP, 694, 695
 - Japanese subjects, insulin secretion and insulin sensitivity and, 832
 - with obesity, adiponectin and C-reactive protein and, 1457
 - and Pancreas Tonic effects in, 1169
 - with retinopathy, 585
 - and risk factors for CV disease, 160

- Sex of NIDDM subjects (*Continued*)**
- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
 - see also* Sex of NIDDM nephropathy subjects
- Sex of obese subjects**
- adipocyte precursor cell proliferation and differentiation and, 633, 635
 - adolescents, 864
 - Korean subjects, $-3826A \rightarrow G$ UCP-1 polymorphism effects on level of LDL-C and, 1055
 - with NIDDM, adiponectin, C-reactive protein and, 1457
- Sex of overweight subjects**
- of fasting overweight subjects, preservation of circadian rhythm of serum insulin concentration at low plasma glucose in, 1450
 - of slightly overweight subjects, effects of L-carnitine and, 1002
- Sex steroids**
- plasma Lp and, in women, 187-192
 - see also specific sex steroids*
- SFA, *see* Saturated fatty acid(s)**
- SHBG, *see* Sex hormone-binding globulin**
- Short-gut subjects on lipid-containing total parenteral nutrition, serum lipid EFAD regulation in, 273-277**
- Short-term stored frozen blood samples, HbA_{1c} in, 1497**
- Shuar women, Ecuadorian Amazon, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358**
- S_i, *see* Insulin sensitivity**
- Sialic acid**
- in inflammation of chronic disease, 901, 902
 - serum, cardiovascular disease risk factors associated with, in IEDM Kuwaiti children and adolescents, 638-643
- Sibutramine, effects of moderate weight loss by obese women and, on waist circumference and serum adipocytokines, 430-434**
- Silicone gastric banding, adjustable, changes in BMC after RYBG and, for morbid obesity, 918-921**
- Simvastatin effects**
- on bone mineral density in hypercholesterolemic PM women, 744-748
 - on plasma LDL clearance, 484
- Skeletal muscle (SM)**
- fiber type- and FA composition-dependent effects of HF diet on TAG and FATP-1 content of, 1032-1036
 - of transgenic male subjects, GSK-3 β mRNA in, 1322-1330
 - see also* Glucose transport in SM; Protein in SM; Skeletal muscle, diet effects on; Skeletal muscle cells; Skeletal muscle insulin resistance
- Skeletal muscle (SM), diet effects on**
- dietary protein restriction effects on proteasome production in, 340-347
 - HF diet effects, *see* High-fat diet, effects of, on SM
- Skeletal muscle (SM) cells, lipid composition of, associated with arachidonic acid and insulin sensitivity in men, 571-577**
- Skeletal muscle (SM) insulin resistance (IR), development of, after 1-day hindlimb suspension, 1215-1222**
- Slight overweight, L-carnitine effects on fat oxidation, protein turnover, and body composition in, 1001-1006**
- SM, *see* Skeletal muscle; Skeletal muscle cells**
- Small-dense low-density lipoprotein (sdLDL)**
- carotid atherosclerosis, vascular dementia and, 476-482
 - fluvastatin effects on endothelial function in obese PM women via reduction of, 733-739
- Smoking**
- acute effects of nicotine on serum glucose, insulin, GH, and cortisol, 578-582
 - CAD and, *see* Smoking, CAD and
 - Smoking (*Continued*)**
 - and CV disease risk factors, 1437, 1439
 - by disabled hospitalized older subjects, HHcy and, 1018
 - effects of, on intravascular remodeling of HDL particles for RCT, 858-862
 - FABP-4 and PPAR γ -activated receptor polymorphism interaction effects on, 305, 306
 - growth hormone in, *see* Growth hormone in smokers
 - by hypercholesterolemic PM women, 745
 - in hypothyroidism, 278
 - by insulin-resistant subjects, *see* Smoking by insulin-resistant subjects
 - by NIDDM subjects, *see* Smoking by NIDDM subjects
 - pituitary response to exercise by nondiabetic and IDDM smokers, 1140-1144
 - relationship between obesity, ADMA and, 1574-1579
 - and risk for metabolic syndrome, 1506-1508
 - and UCP-3 polymorphism-body composition association, 460, 461
 - by young subjects with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules and, 756
- Smoking, CAD and**
- by CAD men, as risk for myocardial infarction, 325, 326
 - serum HDL-C level effects on association between plasma oxidized LDLs and, 424-426
- Smoking by insulin-resistant subjects**
- central HPA dysfunction and, 722
 - with CHD, 855
- Smoking by NIDDM subjects**
- with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360
 - with IGT, as risk factor for CHD, 646
 - pituitary response to, 1140-1144
 - serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
- Soccer players, cholesterol efflux in, 1262-1267**
- SOD (superoxide dismutase), erythrocyte, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41**
- Sodium, *see* Urinary excretion, sodium**
- Sodium nitroprusside, glucose transport in SM stimulated by, 914**
- Soluble leptin receptor, relationship between serum leptin, serum adiponectin levels, HOMA IR index, lipids, and leptin receptor gene Lys109Arg and Gln223Arg polymorphisms in Japanese subjects, 879-885**
- Soluble tumor necrosis factor- α (TNF- α), serum, associated with IR in liver cirrhosis, 922-926**
- Soy isoflavone, effects of moderate exercise and, on AT accumulation and bone loss in postmenopausal subjects, 942-948**
- Soybean oil in obesity-inducing HF diet, 783**
- Sp1, SFA effects on apo A-1 promoter induced by, 1342-1348**
- Spanish subjects**
- association of Trp64Arg polymorphism of β_3 -adrenergic receptor associated with increased leptin levels but not with $-3826A \rightarrow G$ polymorphism of UCP-1 gene in, 1411-1416
 - low CHD mortality in Spain and high-plasma HDL-C in Spanish children, 1045-1047
- Spinal cord injury (SCI)**
- acute, circulating leptin as marker of fat mass in, 989-994
 - MS in men with, 1372-1377
- Spironolactone for obese PCOS women, 370**
- Spontaneous hypertension (HTN), intracellular Ca^{2+} chelator effects on IR and on, in subjects on high-fat diet, 269-272**

- Squamous cell carcinoma (SCC), head and neck, effects of cellular CRABP-1 mRNA on CYP2-mediated catabolism of A11-*trans* retinoic acid and on cell proliferation in, 1007-1012
- SR (strontium ranelate), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- SREBP-1 (sterol regulatory element binding protein-1) mRNA (messenger ribonucleic acid), upregulation of lipogenic enzyme and, in white adipose tissue of CRF subjects, 1060-1065
- SSPG, *see* Steady-state plasma glucose in IR
- Stability over time of GHb, RBC survival and, in hematologically stable subjects without DM, 1399-1403
- Starch in HF diet, 1033
- Statins
- in CAD, 319
 - in NIDDM, serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299, 301
 - see also* Atorvastatin; Fluvastatin; Pravastatin effects; Simvastatin effects
- Steady-state plasma glucose (SSPG) in IR
- with associated CV disease risk factors in overweight and normoponderal subjects, 495-498
 - see also* Steady-state plasma glucose in obesity with IR
- Steady-state plasma glucose (SSPG) in obesity with IR
- with associated CV disease risk factors, 495-498
 - effects of moderate weight loss by obese insulin-resistant women on, 280-283
- Stearic acid
- effects of, on SPl-induced apo A-1 promoter, 1343-1345
 - TG content of, in MS, 312
- Steroid(s), *see specific steroids*
- Steroidogenic acute regulatory protein mRNA (messenger ribonucleic acid), low temperature blocking testosterone production and stimulatory effects of hCG on, but not cAMP production in tumor cells, 955-958
- Sterol regulatory element binding protein-1 (SREBP-1) mRNA (messenger ribonucleic acid), upregulation of lipogenic enzyme and, in white adipose tissue of CRF subjects, 1060-1065
- Stevioside (SVS)
- effects of, on glucose transport in insulin-sensitive and insulin-resistant subjects, 101-107
 - effects of, in NIDDM, 73-76
- Stiffness, carotid artery, pioglitazone effects on carotid intima-media thickness and, in NIDDM nephropathy, 1382-1386
- Storch-Young model of Hcy remethylation and TS, 1480-1483
- Streptozotocin-induced diabetes mellitus (STZ-DM)
- effects of oral vanadate with tea extract on mortality and morbidity associated with, 1145-1151
 - high-fat diet-induced fatty liver in, 260-263
 - leptin effects on HPA axis activity, dysphagia, and weight loss in, 1558-1564
 - LSF effects on glucose-stimulated insulin secretion in, 290-296
 - with obesity, effects of *P. yoelli* GPs on glucose homeostasis in, 1048-1053
- Stress
- mental, and lipolysis activation in IR, 1199
 - oxidative, in NIDDM with obesity, pioglitazone protecting beta cells from, 488-494
- Stromal vascular cells from omental and subcutaneous AT of obese subjects, differentiation and proliferation of, compared, 634
- Strontium ranelate (SR; S1291-12), bone matrix mineralization induced by, in MC3T3-E1 osteogenic cells, 532-537
- STZ-DM, *see* Streptozotocin-induced diabetes mellitus
- Subclinical hypothyroidism, CV disease risk factors in, 1512-1515
- Subcutaneous adipose tissue (SAT)
- abdominal, in lipodystrophic HIV-infected subjects, 1567
 - see also* Omental adipose tissue, subcutaneous and, in obese subjects
- Sucrose (S)
- in HF diet, 1033
 - in MHN-01 formula, 978
 - NOS inhibition and pioglitazone effects on insulin action in subjects on high-sucrose diet, 22-27
- Sulfonylurea, effects of Pancreas Tonic and, in NIDDM, compared, 1169
- Sunflower oil in HF diet, 1033
- Superoxide dismutase (SOD), erythrocyte, effects of Cu enzymes in CF before and after Cu supplementation with or without zinc on, 37-41
- Supplementation, *see specific supplements*
- Survival, RBC, stability over time of GHb, glucose and, in hematologically stable subjects without DM, 1399-1403
- SVS, *see* Stevioside
- Swimming, effects of, on hepatic glucose production in response to glucagon, 1027-1031
- Symptoms of hypoglycemia, pramlintide effects on response of catecholamines, glucagon and, 1227-1232
- Synthase
- deficiency in cystathione- β -, betaine effects on, 594-599
 - fatty acid, upregulation of mRNA SREBP-1 and, in WAT of CRF subjects, 1060-1065
 - inducible and endothelial nitric oxide, in early NIDDM nephropathy, 1474
 - nitric oxide, *see* Nitric oxide synthase
 - see also* Glycogen synthase; Glycogen synthase kinase-3 β mRNA
- Syringe pumps, peristaltic and, in metabolic research, accuracy and precision of peristaltic and, compared, 875-878
- Systolic pressure, *see* Blood pressure
- T lymphocytes, activated, CD4 $^{+}$ and CD8 $^{+}$, emergence of growth factor receptors in, 117-122
- T₃, *see* Triiodothyronine in hypothyroidism
- T3T3-L1 preadipocytes, PPFS-410 effects on, in preadipocytes 1534
- T₄, *see* Thyroxine in hypothyroidism
- TAG, *see* Triacylglycerol
- Taiwanese women, GDM and β_1 -ADR Trp64Arg polymorphism in, 1136-1139
- Taurine (Tau), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- TC, *see* Total cholesterol
- Tea extract with oral vanadate, effects of, on morbidity and mortality in STZ-DM, 1145-1151
- Telopeptide, β -carboxy terminal, of type 1 collagen in adrenal insufficiency, 1252
- Temperature
- adaptive thermogenesis and resistance to obesity, 1417-1423
 - cold, *see* Exercise at cold temperature, NEFA oxidation during low, hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production blocked by, in tumor cells, but not cAMP production, 955-958
- Tempol, effects of, on hyperinsulinemia and hypertension based on increase of medullary BF, 1305-1308
- Testosterone
- carotid atherosclerosis, vascular dementia and, 477
 - free, *see* Free testosterone
 - low temperature blocking stimulatory effects of hCG on steroidogenic acute regulatory protein mRNA and production of, but not cAMP production in tumor cells, 955-958

- Testosterone (*Continued*)
 total, *see* Total testosterone
- Tetraacetic acetoxymethyl ester [bis(*o*-aminophenoxyethane-N,N,N',N')], effects of, on IR and spontaneous HTN in subjects on HF diet, 269-272
- 25-Tetrol, plasma, in CTX, 558
- TG(s), *see* Triglyceride(s)
- TGF- β 1 (transforming growth factor- β 1), effects high glucose and insulin on expression of, in cardiac fibroblasts, 712
- TGL (triglyceride lipase), hepatic, endurance exercise effects on, 196, 198-200
- TGZ, *see* Troglitazone
- tHcy (total homocysteine) in subclinical hypothyroidism, 1513
- Thermogenesis
 adaptive, resistance to obesity and, 1417-1423
see also Temperature
- Thiazolidinediones, *see* FPS-410; Non-insulin-dependent diabetes mellitus, pioglitazone effects on; Rosiglitazone effects; Troglitazone
- Thioctic acid [R-(+)- α -lipoic acid], effects of, on pyruvate metabolism and NEFA oxidation in hepatocytes, 165-173
- Third trimester of uncomplicated pregnancy, leucine turnover in, 545-549
- 3826A→G polymorphism of UCP-1 gene, increased leptin level associated with β_2 -ADR Trp64Arg polymorphism but not with, in Spanish subjects, 1411-1416
- Threonine (Thr), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
- Thrombin, effects of, on platelet function in DM, 66-72
- Thromboxane B₂ (TXB₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
- Thyroidal diseases
 3,3'-T₂S in, 538-543
see also specific conditions
- Thyrotropin (TSH) in hypothyroidism
 effects of therapy with, on endothelial function and, 279
 free, in subclinical hypothyroidism, CV disease risk factors and, 1513
- Thyroxine (T₄) in hypothyroidism
 effects of therapy with, on endothelial function, 278-279
 free, in subclinical hypothyroidism, CV disease risk factors and, 1513
- Tissue plasminogen activator (tPA)-antigen in NIDDM and at-risk for NIDDM subjects, 224, 226
- TNF, *see* Tumor necrosis factor
- α (alpha)-Tocopherol (vitamin E)
 CV disease risk factors and intake of, 1439
 and plasma ADMA in mild hypercholesterolemia, 1073
see also: all-rac -Tocopherol
- all-rac* α (alpha)-Tocopherol (vitamin E)
 anti-inflammatory effects of ω -3 PUFAs alone or combined with, 236-240
 in obesity-inducing HF diet, 783
- Total adipose tissue (AT)
 in IR, 722, 723
 in obese NIDDM subjects, bezafibrate effects on, 407
 in PM women, androgenicity and, and insulin sensitivity, 508
- Total bilirubin
 in Korean women, AT distribution and, 1541
 in obese Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
- Total cholesterol (TC)
ABCA1 gene and, *see* Total cholesterol, *ABCA1* gene and β_2 -ADR Arg16Gly polymorphism and, 1184
- Total cholesterol (TC) (*Continued*)
 in atherosclerosis, *see* Total cholesterol in atherosclerosis
 in CAD, *see* Total cholesterol, CAD and
 in disabled hospitalized older subjects, HHcy and, 1018
 in dyslipidemic CRF subjects on HD, 1114
 during estrous cycle, 140
 exercise effects on, *see* Total cholesterol, exercise effects on fat mass and, in acute SCI subjects, 991
 HF/HC diet effects on, 1023
 in hypercholesterolemia, *see* Total cholesterol in hypercholesterolemia
 in hypothyroidism, *see* Total cholesterol in hypothyroidism
 in IDDM, *see* Total cholesterol in IDDM
 in IGT first-degree relatives of African American NIDDM subjects, 1553
 in IR, *see* Total cholesterol in IR
 in Japanese subjects, *see* Total cholesterol in Japanese subjects
 in Korean women, AT distribution and, 1541
 leptin levels and, 1412-1414
 in MS, *see* Total cholesterol in MS
 in NIDDM, *see* Total cholesterol in NIDDM
 in non-obese subjects, *see* Total cholesterol in non-obese subjects
 in obesity, *see* Total cholesterol in obesity
 plasma, *see* Total plasma cholesterol
 plasma LDL clearance and, 484
 plasma vitamin K transport and, 216
 in postpubertal Asian Indian adolescents, 1338
 ω -3 PUFAs and, *see* Total cholesterol, ω -3 PUFAs and in SCI, *see* Total cholesterol in SCI
 serum, *see* Serum cholesterol
 in Vietnamese children with apo E polymorphism, 1519
 in young subjects with NIDDM parents, 756
- Total cholesterol (TC), *ABCA1* gene and
ABCA1 gene expression-fasting glucose relationship in normoglycemic men and, 19
ABCA1 gene polymorphism-TC association in Japanese school-age children and, 183
- Total cholesterol (TC), CAD and
 in PM women on ERT and at risk for CAD, aerobic exercise and high-fiber, low-fat diet effects on, 378
 red and white wine drinking effects on, 320
 serum, in CAD men, 425
- Total cholesterol (TC), exercise effects on
 blood, apo E polymorphism association with $\dot{V}O_{2\max}$ and, in exercising and sedentary subjects, 111-113
 in overweight nondiabetic and NIDDM subjects, 1236
 serum, apo E genotype and changes in, in endurance exercise, 196, 198-200
- Total cholesterol (TC), ω -3 PUFAs and
 in FCHL, 154
 plasma, effects of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol on, 237
 in SCI men with MS, 1373, 1374
 WPG effects on, 1311
- Total cholesterol (TC) in atherosclerosis
 carotid atherosclerosis, vascular dementia and, 477
 in premature atherosclerosis with normocholesterolemia and daytime hypertriglyceridemia, 50
- Total cholesterol (TC) in hypercholesterolemia
 in mild hypercholesterolemia, 1073
 serum LPL concentration and, 527, 528
- Total cholesterol (TC) in hypothyroidism
 and effects of T₄ therapy on endothelial function, 279
 in subclinical hypothyroidism, CV disease risk factors and, 1513

- Total cholesterol (TC) in IDDM
 energy substrate oxidation and, 656
 in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 plasma apo C-3 polymorphisms and, 1299
- Total cholesterol (TC) in IR
 with CHD, 853
 with LVH, candesartan effects on, 779
 plasma NEFA regulation and, 1198
 visceral AT and TG FA content and, 312
see also Total cholesterol in IR with microalbuminuria
- Total cholesterol (TC) in IR with microalbuminuria
 cardiovascular autonomic dysfunction and, 1360, 1362
 and cilostazol effects on microalbuminuria, 1407
 in NIDDM, glycemic control effects on, 354
- Total cholesterol (TC) in Japanese NIDDM subjects
 with incipient nephropathy, 1224
 insulin secretion and insulin sensitivity and, 832
- Total cholesterol (TC) in Japanese subjects
 with beta-cell dysfunction, 950
and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, and lipids, 881-883
see also Total cholesterol in Japanese NIDDM subjects
- Total cholesterol (TC) in MS, 312
 with obesity and chronic renal disease, 1257
 in SCI men, 1373, 1374
- Total cholesterol (TC) in NIDDM
 and association of corrected QT intervals with carotid artery IMT, 1155
 and in at-risk for NIDDM subjects, 224, 226
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362
 and correlation of HbA_{1c} with lipid composition in RBC membrane, 124
 with IGT, 646
 insulin therapy effects on, 694, 697, 698
 in Japanese NIDDM subjects, *see* Total cholesterol in Japanese NIDDM subjects
 metformin effects on, 161
 microalbuminuria and, 354
 in overweight NIDDM subjects, 1236
- Pancreas Tonic effects on, 1169
- serum PON1 polymorphism, vascular complications, plasma oxidized LDL level and, 299
- Total cholesterol (TC) in non-obese subjects
 in non-obese men, and AT as fibrinogen level predictor, 985, 986
 in non-obese premenopausal women, metabolic risk and, 1068-1070
- Total cholesterol (TC) in obese adolescents
 in hyperuricemic Japanese male adolescents, 450, 452
 serum TNF- α and, 864, 865
- Total cholesterol (TC) in obese women
 effects of moderate weight loss and sibutramine or orlistat on, 432
 in obese PM women, fluvastatin effects on, 736
- Total cholesterol (TC) in obesity
 in children, 1244
 in insulin-resistant Japanese subjects, 651
 in Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
 with normal FPG or IGT, effects of weight loss on, 1097
and smoking-ADMA-obesity relationship, 1575, 1576
- Total cholesterol (TC) in obesity (*Continued*)
see also Total cholesterol in obese adolescents; Total cholesterol in obese women
- Total cholesterol (TC) in SCI
 and fat mass in acute SCI subjects, 991
 in SCI men, 1373, 1374
- Total fat mass (FM) of lipodystrophic HIV-infected subjects, 1567
- Total homocysteine (tHcy) in subclinical hypothyroidism, 1513
- Total parenteral nutrition (TPN), lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277
- Total plasma cholesterol (C)
 and anti-inflammatory effects of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol, 237
 HF/HC diet effects on, 819
 in HL deficiency, 522
 in IDDM, oxidation of glycated and nonglycated LDLs and, 970
 in Spanish children, 1046
- Total plasma protein, beer ingestion and sauna bathing effects on, 774
- Total plasma triglycerides (TGs) in IDDM, oxidation of glycated and nonglycated LDLs and, 970
- Total serum cholesterol (C) in CAD men, 425
- Total testosterone
 in older NIDDM men with partial androgen deficiency, 668
 in PM women, insulin sensitivity and, 508-510
- Total triglyceride(s) (TGs)
 plasma, in IDDM, oxidation of glycated and non-glycated LDLs and, 970
 and plasma vitamin K transport, 216
- TPN (total parenteral nutrition), lipid-containing, regulation of serum lipid EFAD in short-gut subjects on, 273-277
- Traditional lifestyle, effects of agricultural lifestyle versus, on leptin in Ecuadorian Amazon Shuar women, 1355-1358
- Training, *see* Exercise
- Transcription factors in 3T3-L1 preadipocytes, FPFS-410 effects on 1534
- Transfer protein, *see* Cholesteryl ester transfer protein; Phospholipid transfer protein
- Transferase
 point mutation of hypoxanthine phosphoribosyl, responsible for hyperuricemia in women, 1500-1502
see also Acyl-coenzyme A:cholesterol acyltransferase; Alanine aminotransferase; Aspartate aminotransferase
- Transferrin (Trf)
 in disabled hospitalized older subjects, HHcy and, 1018
 serum, food intake, AT and, in kidney transplantation recipients, 614-619
- Transforming growth factor- β 1 (TGF- β 1), effects of high glucose and insulin on expression of, in cardiac fibroblasts, 712
- Transgenic subjects, male, glucose intolerance development in, with GSK-3 β overexpression in skeletal muscle, 1322-1330
- Transplantation
 kidney, correlation between AT, serum leptin, and food intake during 6-month period following, 614-619
 pancreatic islet, serum resistin levels in IDDM before and after, 403-404
- Trans-sulfuration (TS) of homocysteine, 1480-1483
- Trf, *see* Transferrin
- Triacylglycerol (TAG)
 in CRF, 1063
 fiber type- and FA composition-dependent effects of HF diet on content of FAP-1 and, in skeletal muscle, 1032-1036
 plasma, during exercise at cold temperature, 204
- PP, in NIDDM, alcohol effects on, 77-83

- Triacylglycerol (TAG) (Continued)**
- WPG effects on, 1311-1312
 - Triglyceride(s) (TG)**
 - ABCA1* gene and, *see* Triglyceride(s), *ABCA1* gene and blood, *see* Blood triglycerides
 - in CAD men, effects of red and white wine drinking on, 319, 320
 - CV disease risk factors and, *see* Triglyceride(s), CV disease risk factors and
 - diet effects on, *see* Triglyceride(s), diet effects on in DM, *see* Triglyceride(s) in DM
 - in dyslipidemic CRF subjects on HD, 1114, 1115
 - erythrocyte membrane, 574
 - during estrous cycle, 140
 - exercise and, *see* Triglyceride(s), exercise and fasting, *see* Fasting triglycerides
 - and fat mass in acute SCI subjects, 991
 - and GSK-3 β in transgenic subjects, 1328
 - in HD subjects, 1014
 - in hypercholesterolemia, *see* Triglyceride(s) in hypercholesterolemia
 - in hypothyroidism, *see* Triglyceride(s) in hypothyroidism
 - in IGT first-degree relatives of African American NIDDM subjects, 1553
 - intramuscular, after 1-day hindlimb suspension, 1217
 - in IR, *see* Triglyceride(s) in IR
 - in Japanese subjects, *see* Triglyceride(s) in Japanese subjects
 - in Korean women, AT distribution and, 1541
 - leptin levels and, 1412-1414
 - MHN-01 effects on concentration of, 981
 - in non-obese subjects, *see* Triglyceride(s) in non-obese subjects
 - in obesity, *see* Triglyceride(s) in obesity
 - in overweight women, serum TNF, TNF- β , NO and, 1269
 - plasma, *see* Plasma triglycerides
 - and plasma LDL clearance, 484
 - in PM women, simvastatin effects on BMD and, 745, 746
 - ω -3 PUFA effects on, *see* Triglyceride(s), ω -3 PUFA effects on serum, *see* Serum triglycerides
 - smoking effects on, 860
 - total, *see* Total triglyceride(s)
 - VAT accumulation and fatty acid content of, associated with MS components, 310-317
 - in young subjects, *see* Triglyceride(s) in young subjects
 - Triglyceride(s) (TG), *ABCA1* gene and**
 - ABCA1* gene expression-fasting glucose relationship in normoglycemic men and, 19
 - ABCA1* gene polymorphism-TG association in Japanese school-age children and, 183, 184
 - Triglyceride(s) (TG), CV disease risk factors and**
 - in Kuwaiti children, 640, 641
 - in overweight and normoponderal subjects, 498
 - in subclinical hypothyroidism, 1513
 - Triglyceride(s) (TG), diet effects on**
 - CV disease risk factors and, 1437, 1438
 - effects of aerobic exercise with high-fiber, low-fat diet in PM women on ERT, 378
 - HF diet effects, 1034
 - HF/HC diet effects, 819, 1023
 - Triglyceride(s) (TG), exercise and**
 - acipimox-induced reduction of, during exercise at cold temperature, 1133
 - blood, apo E polymorphism-VO_{2max} association and, 111-113
 - endurance exercise, 196, 198-200
 - in overweight nondiabetic and NIDDM subjects, 1236
 - in PM women on or not on ERT, 1194
 - Triglyceride(s) (TG), exercise and (Continued)**
 - ω -3 PUFA and exercise effects, 751
 - in soccer players, 1263
 - see also* Triglyceride(s) in exercising PM women on ERT
 - Triglyceride(s) (TG), ω -3 PUFA effects on**
 - with exercise, 751
 - of ω -3 PUFAs alone or combined with *all-rac* α -tocopherol, 154, 155
 - Triglyceride(s) (TG) in DM**
 - in STZ-DM, NO-1886 effects on, 261
 - see also* Triglyceride(s) in IDDM; Triglyceride(s) in NIDDM
 - Triglyceride(s) (TG) in exercising PM women on ERT**
 - on or not on ERT, 1194
 - with risk for CAD, effects of aerobic exercise with high-fiber, low-fat diet, 378
 - Triglyceride(s) (TG) in hypercholesterolemia**
 - in mild hypercholesterolemia, 1073, 1074
 - relation between serum LPL concentration and metabolism of, 526-531
 - Triglyceride(s) (TG) in hypothyroidism**
 - effects of T₄ therapy on, on, 279
 - in subclinical hypothyroidism, CV disease risk factors and, 1513
 - Triglyceride(s) (TG) in IDDM**
 - and glycemic control effects on F₂ isoprostanate level at IDDM onset, 1119
 - in Kuwaiti IDDM children and adolescents, CV disease risk factors and, 640, 641
 - Triglyceride(s) (TG) in IR**
 - with associated CV disease risk factors in overweight and normoponderal subjects, 498
 - central HPA dysfunction and, 722, 724
 - with CHD, 853, 854
 - and cilostazol effects on microalbuminuria, 1407
 - indices of IR and, 1524
 - with LVH, candesartan effects on, 779
 - with microalbuminuria, *see* Triglyceride(s) in microalbuminuric IR
 - plasma NEFA regulation and, 1198
 - serum GPI-PLD and, 139
 - in Vietnamese children with apo E polymorphism, 1519
 - see also* Triglyceride(s) in obesity with IR
 - Triglyceride(s) (TG) in Japanese NIDDM subjects**
 - with incipient nephropathy, 1224
 - insulin sensitivity, insulin secretion and, 832
 - Triglyceride(s) (TG) in Japanese subjects**
 - with beta-cell dysfunction, 950
 - with NIDDM, *see* Triglyceride(s) in Japanese NIDDM subjects and relationship between leptin receptor gene Lys109Arg and Gln223Arg polymorphisms, HOMA IR index, serum soluble leptin receptor, serum leptin, serum adiponectin, 881-883
 - Triglyceride(s) (TG) in microalbuminuric IR**
 - cilostazol effects on, 1407
 - with NIDDM, cardiovascular autonomic dysfunction and, 1360, 1362
 - Triglyceride(s) (TG) in microalbuminuric NIDDM, 354**
 - adiponectin, C-reactive protein and, 1456, 1457
 - cardiovascular autonomic dysfunction, IR and, 1360, 1362
 - Triglyceride(s) (TG) in NIDDM**
 - and association of corrected QT intervals with carotid artery IMT, 1155, 1156
 - and in at-risk for NIDDM subjects, 224, 226
 - fasting, *see* Fasting triglycerides
 - with IGT, 646
 - insulin therapy effects on, 694, 697
 - metformin effects on, 161

- Triglyceride(s) (TG) in NIDDM (*Continued*)
 - with microalbuminuria, *see* Triglyceride(s) in microalbuminuric NIDDM
 - rosiglitazone effects on, 1123
 - Triglyceride(s) (TG) in non-obese subjects
 - in non-obese men, AT as fibrinogen level predictor and, 985, 986
 - in non-obese premenopausal women, metabolic risk and, 1068-1070
 - Triglyceride(s) (TG) in obese women
 - effects of moderate weight loss and sibutramine or orlistat on, 432
 - PM women, fluvastatin effects on, 736
 - Triglyceride(s) (TG) in obesity
 - adolescents, 864, 865
 - Korean subjects, -3826A→G UCP-1 polymorphism effects on level of LDL-C and, 1057
 - with MS and chronic renal disease, 1257
 - with NIDDM, adiponectin and C-reactive protein and, 1456, 1457;
 - see also* Fasting triglycerides in obese NIDDM subjects
 - with normal FPG or IGT effects of weight loss on, 1097
 - in obese children, 1244
 - and smoking-ADMA-obesity relationship, 1575, 1576
 - see also* Triglyceride(s) in obese women; Triglyceride(s) in obesity with IR
 - Triglyceride(s) (TG) in obesity with IR
 - associated CV disease risk factors and, 498
 - in Japanese men, Ob-R polymorphism associated with, 651
 - in treatment-seeking subjects, 436
 - Triglyceride(s) (TG) in young men
 - with hypertensive parents, 470
 - serum adiponectin association with, 589-593
 - Triglyceride(s) (TG) in young subjects
 - with NIDDM parents, 756
 - see also* Triglyceride(s) in young men
 - Triglyceride lipase (TGL), hepatic, endurance exercise effects on, 196, 198-200
 - Triglyceride-rich lipoprotein (TRL), plasma vitamin K transport and, 215-221
 - Triiodothyronine (T₃) in hypothyroidism
 - free, in subclinical hypothyroidism, CV disease risk factors and, 1513
 - T₄ therapy and, 279
 - Triphosphate, *see* Adenosine triphosphate-citrate lyase; Adenosine triphosphate-citrate lyase mRNA
 - Triple mutations of *HNF-4α* gene associated with early-onset NIDDM in Filipino family, 953-963
 - TRL (triglyceride-rich lipoprotein), plasma vitamin K transport and, 215-221
 - Troglitazone (CS-045; TGZ)
 - 4-aminopyridine effects on delayed vasorelaxation by, 147-152
 - for obese PCOS women, 366, 371
 - Trp64Arg polymorphism, *see* β₃-Adrenergic receptor, Trp64Arg polymorphism of
 - Tryptophan (Trp)
 - plasma effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 - see also* β₃-Adrenergic receptor, Trp64Arg polymorphism of
 - TS (trans-sulfuration) of homocysteine, 1480-1483
 - 3,3'-T₂S (3,3'-diiodothyronine sulfate) in thyroidal diseases, nonthyroidal diseases, pregnancy, and fetal/neonatal life, 538-543
 - TSH, *see* Thyrotropin in hypothyroidism
 - Tumor cells, low temperature blocking hCG stimulatory effects on steroidogenic acute regulatory protein mRNA and testosterone production but not cAMP production in tumor cells, 955-958
 - Tumor necrosis factor (TNF)
 - serum, serum concentration of NO, TNF-β, and soluble receptors of, in overweight and obese women, 1268-1273
 - see also* Tumor necrosis factor α; Tumor necrosis factor β; Tumor necrosis factor receptor
 - Tumor necrosis factor α (TNF-α)
 - effects of ω-3 PUFAs alone or with *all-rac* α-tocopherol on, 236-240
 - effects of weight loss by obese subjects with normal FPG or IGT on, 1097
 - in inflammation of chronic disease, 901
 - in NIDDM and in at-risk for NIDDM subjects, 224
 - resistance exercise effects on insulin-mediated glucose disposal with minimal effects on, in older hypertensive subjects, 397-402
 - serum, *see* Serum tumor necrosis factor-α
 - Tumor necrosis factor β (TNF-β), serum concentration of NO and soluble receptors of, in overweight and obese women, 1268-1273
 - Tumor necrosis factor receptor (TNF-R), serum concentration of NO, TNF-β and, in overweight and obese women, 1268-1273
 - TXB₂ (thromboxane B₂), effects of inhibition of, on apo A-1 promoter activity in hepatoma cells, 177
 - Type 1 collagen, β-carboxy terminal telopeptide of, in adrenal insufficiency, 1252
 - Type 1 diabetes mellitus, *see* Insulin-dependent diabetes mellitus
 - Type 2 diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
 - Tyrosine (Tyr), plasma, effects of, on whole-body protein synthesis in hyperinsulinemic young men, 392
 - TZDs (thiazolidinediones), *see* PPFS-410; Non-insulin-dependent diabetes mellitus, pioglitazone effects on; Rosiglitazone effects; Troglitazone
 - UA, *see* Uric acid
 - UACR (urinary albumin to creatinine ratio), glycemic control effects on, in NIDDM, 353-357
 - UCA (ursodeoxycholic acid), effectiveness of, in CTX, 556-562
 - UCP-1 (uncoupling protein-1) -3826A→G polymorphism, effects of, on LDL-C level in Korean obese subjects, 1054-1059
 - UCP-1 mRNA, *see* Uncoupling protein-1 mRNA
 - UCP-2 (uncoupling protein-2) mRNA (messenger ribonucleic acid) in diabesity, CL316,243 effects on, 804
 - UCP-3 (uncoupling protein-3) mRNA (messenger ribonucleic acid) in diabesity, CL316,243 effects on, 802, 804
 - UCP-3 (uncoupling protein-3) polymorphism, food intake and body composition associated with, 458-464
 - UDCA (ursodeoxycholic acid), effectiveness of, in CTX, 556-562
 - Uncomplicated pregnancy, leucine turnover in third trimester of, 545-549
 - Uncoupling protein-1 (UCP-1) mRNA (messenger ribonucleic acid) in AT, effects of restricted diet on, 30-31
 - in diabesity, CL316,243 effects on, 802, 804
 - Uncoupling protein-1 (UCP-1) -3826A→G polymorphism effects of, on LDL-C level in Korean obese subjects, 1054-1059
 - not associated with increased leptin levels in Spanish subjects, 1411-1416
 - Uncoupling protein-2 (UCP-2) mRNA (messenger ribonucleic acid) in diabesity, CL316,243 effects on, 804
 - Uncoupling protein-3 (UCP-3) mRNA (messenger ribonucleic acid) in diabesity, CL316,243 effects on, 802, 804
 - Uncoupling protein-3 (UCP-3) polymorphism, food intake and body composition associated with, 458-464
 - Urate in young subjects with NIDDM parents, 756

- Urea**
 plasma, in DCA-induced hypolactatemia in cirrhotic and noncirrhotic subjects, 1089
 serum, in HD subjects, 1014
- Urea nitrogen, see BUN**
- Uric acid (UA)**
 in IR with LVH, candesartan effects on, 779
 in NIDDM, *see Uric acid in NIDDM*
 plasma, sauna bathing and beer ingestion effects on concentration of, 772-776
 point mutation in HPRT responsible for hyperuricemia in women, 1500-1502
 in preeclampsia, 1434
see also Hyperuricemia
- Uric acid (UA) in NIDDM**
 with cardiovascular autonomic dysfunction, microalbuminuria, and IR, 1360, 1362
 serum, in IDDM, and oxidation of glycated and nonglycated LDLs, 970
- Urinary excretion**
 effects of glycemic control in NIDDM on UACR, 353-357
 of hydroxyproline, deoxypyridinol, pyridinoline, Ca, phosphorus, and creatinine in severe lipodystrophy, leptin replacement therapy effects on, 516
 of plasma purines, beer ingestion and sauna bathing effects on, 773-774
 of serum chloride, beer ingestion and sauna bathing effects on, 774
 of sodium, *see Urinary excretion, sodium*
see also Albuminuria
- Urinary excretion, sodium**
 in hyperinsulinemia with hypertension, 1306
 of serum sodium, beer ingestion and sauna bathing effects on, 774
- Urine volume, beer ingestion and sauna bathing effects on, 774**
- Ursocholic acid (UCA), effectiveness of, in CTX, 556-562**
- Ursodeoxycholic acid (UDCA), effectiveness of, in CTX, 556-562**
- VaD (vascular dementia), sdLDLs, carotid atherosclerosis and, 476-482**
- Valine, *see* Plasma valine**
- Vanadate, oral, with tea extract, effects of, on morbidity and mortality in STZ-DM, 1145-1151**
- Vascular cell(s)**
 stromal, from omental and subcutaneous AT of obese subjects, differentiation and proliferation of, compared, 634
see also Vascular cell adhesion molecule
- Vascular cell adhesion molecule (VCAM)**
 in NIDDM and in at-risk for NIDDM subjects, 224, 226
see also Vascular cell adhesion molecule-1
- Vascular cell adhesion molecule-1 (VCAM-1)**
 CAD and, *see* Vascular cell adhesion molecule-1, CAD and metformin effects on, in NIDDM, 161
- Vascular cell adhesion molecule-1 (VCAM-1), CAD and plasma, effects of red and white wine on, in CAD men, 318-323**
 in postmenopausal women on ERT and at risk for CAD, effects of high-fiber, low-fat diet and exercise on, 377-381
- Vascular complications, correlation between plasma oxidized LDLs, serum PON1 polymorphism and, in NIDDM, 297-302**
- Vascular dementia (VaD), sdLDLs, carotid atherosclerosis and, 476-482**
- Vascular disease**
 cerebral and microvascular, in NIDDM, serum PON1 polymorphism, plasma oxidized LDL level and, 298-300
see also Risk factors for CV disease
- Vascular endothelial growth factor (VEGF), plasma, in DM, relation between concentration of plasma ET, glycemic control and, 550-555**
- Vascular reactivity, absence of acute effects of red wine drinking and food intake on, 1081-1086**
- Vasopressin, *see* Arginine-vasopressin**
- Vasorelaxation, 4AP effects on delayed, by troglitazone, 147-152**
- VAT, *see* Visceral adipose tissue**
- VCAM, *see* Vascular cell adhesion molecule; Vascular cell adhesion molecule-1**
- VEGF (vascular endothelial growth factor), relation between concentration of plasma ET, glycemic control and, in DM, 550-555**
- Venous hyperinsulinemia, effects of portal, on gut glucose absorption in conscious subjects, 1290-1295**
- Ventricular hypertrophy, left, candesartan effects on IR and, 777-781**
- Vertebral bone mineral content (BMC) after RYBG and ASGB for morbid obesity, 920**
- Vertebral bone mineral density (BMD) after RYBG and ASGB for morbid obesity, 920**
- Very-low-density lipoprotein (VLDL)**
 in HL deficiency, 523
 plasma, in PM and premenopausal women, sex steroids and, 189, 190
see also Very-low-density lipoprotein-cholesterol
- Very-low-density lipoprotein-cholesterol (VLDL-C)**
 in dyslipidemic CRF subjects on HD, 1115
 in exercise, *see* Very-low-density lipoprotein-cholesterol in exercise
 in HD subjects, 1014
 in hypercholesterolemia, serum LPL concentration and, 528
 in IDDM, *see* Very-low-density lipoprotein-cholesterol in IDDM plasma, HF/HC diet effects on, 819
 S-2E effects on, in mixed hyperlipidemia, 682-683
- Very-low-density lipoprotein-cholesterol (VLDL-C) in exercise apo E polymorphism association with changes in $\dot{V}O_{2\text{max}}$ and, in sedentary subjects and exercising subjects, 111-113**
 in soccer players, 1264
- Very-low-density lipoprotein-cholesterol (VLDL-C) in IDDM and oxidation of glycated and nonglycated LDLs, 970**
 plasma apo C-3 polymorphisms and, 1299, 1301
- Vietnamese children, relationship of apo E polymorphism to plasma lipids and Lps in, 1517-1521**
- Visceral adipose tissue (VAT)**
 contribution of cardiorespiratory fitness and, to hyperinsulinemia, dyslipidemia, and hypertension in NIDDM with IGT, 644-649
 HF diet effects on, 913, 1033
 in IR with obesity, 436
 TG fatty acid content and accumulation of, associated with MS components, 310-317
- Vitamin(s) in HF diet, 1033**
- Vitamin B₁₂ in subclinical hypothyroidism, 1513**
- Vitamin C (ascorbic acid)**
 CV disease risk factors and intake of, 1439
 and plasma ADMA in mild hypercholesterolemia, 1073
- Vitamin D, relation of serum PTH level to, in eucalcemia after parathyroideectomy for primary hyperthyroidism, 1101-1106**
- Vitamin D₁₂ in disabled hospitalized older subjects, HHcy and, 1018**
- Vitamin E, *see* α -Tocopherol**
- Vitamin K (phylloquinone), transport of plasma, in men consuming deuterium-labeled collard greens, 215-221**
- VLDL, *see* Very-low-density lipoprotein**
- VLDL-C, *see* Very-low-density lipoprotein-cholesterol**

- $\dot{V}O_{2\max}$ (maximum oxygen uptake)
 by non-obese premenopausal women, 1068
 and risk factors for CHD in NIDDM with IGT, 646
see also $\dot{V}O_{2\max}$ during exercise
- $\dot{V}O_{2\max}$ (maximum oxygen uptake) during exercise
 apo E genotype and changes in serum lipids in endurance exercise, 193-202
 apo E polymorphism and changes in blood lipids and, 108-116
 and exercise effects in overweight nondiabetic and NIDDM subjects, 1236
 by nondiabetic and IDDM smokers, 1140-1144
 OC effects on, 350
 by PM women on or not on ERT on, 1194
 ω -3 PUFA and exercise effects on, 750, 1366
 and resistance exercise effects on insulin-mediated glucose disposal in older hypertensive subjects, 399
see also $\dot{V}O_{2\max}$ during exercise at cold temperature
- $\dot{V}O_{2\max}$ (maximum oxygen uptake) during exercise at cold temperature
 acipimox-induced plasma NEFA reduction and, 1133
 and substrate oxidation, 204, 205
- Von Willebrand factor (vWF) antigen in young subjects with NIDDM parents, 756
- Von Willebrand factor (vWF) in NIDDM and at-risk for NIDDM subjects, 224, 226
- Waist circumference (WC)
 and CV disease risk factors, 1437, 1438
 of Ecuadorian Amazon Shur women, 1356
 exercise and, *see* Waist circumference, exercise and insulin therapy of NIDDM effects on, 694, 697
 of MS subjects, 312
 of non-obese subjects, *see* Waist circumference of non-obese subjects
 of obese subjects, *see* Waist circumference of obese subjects
 of postpubertal Asian Indian adolescents, 1338-1340
 of young men with hypertensive parents, 470
- Waist circumference (WC), exercise and alcohol, exercise, and adiposity relation to HDL-C levels and, 704
 exercise effects on NIDDM women's, 285
 exercise effects on PM women's, on or not on ERT on, 1194
 oral contraceptives and, 350
- Waist circumference (WC) of non-obese subjects
 of men, and AT as fibrinogen level predictor, 985, 986
 of premenopausal women, 1068
- Waist circumference (WC) of obese subjects
 of adolescents, 864
see also Waist circumference of obese women
- Waist circumference (WC) of obese women
 effects of moderate weight loss and orlistat or sibutramine treatment on serum adipokines and, 430-434
 fluvastatin effects on, 735, 736
 insulin-resistant women, 281
- Waist-to-hip ratio (WHR)
 adiponectin and, *see* Waist-to-hip ratio, adiponectin and and AT distribution in Korean women, 1539, 1541
 and CV disease risk factors, 1437, 1438
 exercise effects on, *see* Waist-to-hip ratio, exercise effects on of insulin-resistant subjects, 722
 and isotretinoin effects on insulin sensitivity and plasma TGs, 5
 leptin levels and, 1412-1414
of lipodystrophic HIV-infected subjects, 1567
of non-obese men, and AT as fibrinogen level predictor, 985, 986
- Waist-to-hip ratio (WHR) (*Continued*)
 of obese subjects, *see* Waist-to-hip ratio of obese subjects
 of PM women, *see* Waist-to-hip ratio of PM women
 of postpubertal Asian Indian adolescents, 1338-1340
 of prematurely atherosclerotic subjects with normocholesterolemia and daytime hypertriglyceridemia, 50
 or premenopausal women, sex steroids, plasma Lp and, 189
 and smoking effects on intravascular remodeling of HDL particles, 860
of young subjects, *see* Waist-to-hip ratio of young subjects
- Waist-to-hip ratio (WHR), adiponectin and levels of adiponectin, 2
 NEFA regulation of adiponectin and, 791
- Waist-to-hip ratio (WHR), exercise effects on apo E genotype, changes in serum lipids and, 195, 198, 199
 and OC effects on glucoregulatory responses to exercise, 350
 with ω -3 PUFAs, 750, 1366
 in soccer players, 1263
- Waist-to-hip ratio (WHR) of obese subjects
 of obese adolescents, 864
see also Waist-to-hip ratio of obese women
- Waist-to-hip ratio (WHR) of obese women
 PM women, fluvastatin effects on, 735, 736
 sex steroids and plasma Lp and, 189
- Waist-to-hip ratio (WHR) of PM women
 effects of exercise by PM women's on or not on ERT on, 1194
 of obese women, fluvastatin effects on, 735, 736
 sex steroids, plasma Lp and, 189
- Waist-to-hip ratio (WHR) of young subjects
 with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules and, 756
 of young men with hypertensive parents, 470, 473
- WAT, *see* White adipose tissue
- Water diuresis, changes induced by, in renal cortex oxygenation and endothelial function in NIDDM and in at-risk for NIDDM subjects, 222-227
- WC, *see* Waist circumference
- Weight, *see* Body weight; Organ weight; Weight gain; Weight loss
- Weight gain
 fenofibrate effects on white adipose tissue and HF diet-induced, in ovariectomized subjects, 1284-1289
 in GDM, β_3 -ADR Trp64Arg polymorphism and, 1137
- Weight loss
 leptin effects on HPA axis activity, dysphagia and, in STZ-DM, 1558-1564
see also Weight loss by obese subjects
- Weight loss by obese subjects
 due to HF diet-induced obesity, leptin therapy to augment leptin circadian rhythm after, 782-789
 with normal fasting plasma glucose or impaired glucose tolerance, effects of, on insulin release and IR, 1095-1100
see also Weight loss by obese women
- Weight loss by obese women
 moderate, *see* Moderate weight loss by obese women
 with PCOS, 367-368
 and racial differences in -adrenergic receptor density in subcutaneous and omental AT, 247-251
- Wheat germ policosanol (WGP), effects of, on normal and mildly elevated plasma cholesterol, 1309-1314
- White adipose tissue (WAT)
 in CRF, upregulation of lipogenic enzyme and SREBP-1 mRNA in, 1060-1065
 fenofibrate effects on, and HF diet-induced weight gain in ovariectomized subjects, 1284-1289

- White blood cells, WPG effects on, 1312
White wine drinking, effects of red and, on circulating inflammation-sensitive molecules in men with CAD, 318-323
Whole-body glucose, oral glucose metabolism and, in born small-for-gestational-age children and, 847-851
Whole-body insulin resistance (IR), development of, after 1-day hindlimb suspension, 1215-1222
Whole-body protein, plasma AA concentration and synthesis of, in young men, 388-396
WHR, *see* Waist-to-hip ratio
Wine drinking
 effects of white, on circulating inflammation-sensitive molecules in men with CAD, 318-323
 see also Red wine drinking
Women
 Ecuadorian Amazon Shur, effects of agricultural versus traditional lifestyle on leptin in, 1355-1358
 exercising, *see* Women, exercising
 HC diet effects on atherogenic LDL particles in, 823-830
 hyperuricemic, HPRT point mutation in, 1500-1502
 Korean, effects of PPAR γ 2 Pro12Ala polymorphism on AT distribution in, 1538-1543
 obese, *see* Women, obese
 postmenopausal, *see* Postmenopausal women
 pregnant, *see* Pregnancy
 premenopausal, *see* Premenopausal women
 see also Sex and specific conditions
Women, exercising
 NIDDM, effects of resistance exercise on glycemic control in, 284-289
 see also Exercise
Women, obese
Women, obese (*Continued*)
 concentration of serum TNF soluble receptors, TNF- β , and NO in overweight and, 1268-1273
 see also Obesity; Polycystic ovary syndrome, obesity and;
 Postmenopausal women, obese; Weight loss by obese women
WPG (wheat germ policosanol), effects of, on normal and mildly elevated plasma cholesterol, 1309-1314
Xanthine, plasma, sauna bathing and beer ingestion effects on concentration of, 772-776
Xanthomatosis, cerebrotendinous, effectiveness of hydrophilic 7 β -hydroxy bile acids, lovastatin, cholestyramine, and chenodeoxycholic acid in, compared, 556-562
Xylitol in MHN-01 formula, 978
Young men
 with hypertensive parents, insulin secretion, insulin sensitivity, and metabolic profile of, 469-475
 Japanese, Pro12Ala PPAR γ 2 polymorphism associated with adiponectin levels in, 1548-1551
 plasma AA concentration and whole-body protein synthesis in, 388-396
 serum adiponectin association with LDL particle size, HDL-C, and TGs in, 589-593
Young subjects
 with NIDDM parents, LDL susceptibility to oxidation and circulating adhesion molecules in, 755-759
 see also Young men
Zinc (Zn)
 effects of Cu enzymes in CF before and after Cu supplementation with or without, 37-41
 effects of dietary restriction of, on metabolic rate and substrate utilization, 727-732